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The most convenient strategy to systemically deliver drugs is to utilize the oral route of 
administration due to its non-invasiveness, cost-effectiveness and high patient 
compliance. However, when a drug is orally administered it will be exposed to the 
different physiological processes and environments found along the gastrointestinal (GI) 
tract, which will determine its ability of being absorbed and reach the systemic circulation. 
For this reason, a close evaluation of the impact of the GI physiology on drug absorption 
should be carried out when new drugs and formulations are being developed. As a result 
of this, the need for reliable in vitro models able to mimic both the GI processes and 
environment has become ever so evident. In fact, such models have the potential of being 
utilized in the early stages of drug discovery and formulation development and can aid in 
the reduction of the cost-, time- and ethical- related issues usually associated with animal 
testing.  
To answer the above-mentioned need, this work focused on the development of an in 
vitro model that could be employed to study drug permeation in the presence of an 
intestinally relevant environment. The construction of this model was stepwise. Firstly, 
the already established in vitro PVPA (Phospholipid Vesicle-based Permeation Assay) 
barriers were implemented with the addition of a mucus layer to simulate the intestinal 
mucosa, leading to the development of the mucus-PVPA barriers. The mucus-PVPA model 
demonstrated the ability to distinguish between the permeabilities of drugs characterized 
by different physicochemical properties and between different liposomal formulations. 
Secondly, intestinally relevant pH conditions were added to the mucus-PVPA model to 
account for their impact on drug absorption, and a pH-dependent trend was observed 
regarding the permeability and solubility of ionizable drugs. Additionally, commercially 
available simulated intestinal fluids were added to the mucus-PVPA barriers, to increase 
the biorelevance of the model during permeation studies. Further, the assessment of 
drug permeation was coupled with in vitro lipolysis to produce a combined model capable 
of mimicking this intestinal process and to unravel the impact of lipid digestion on the 
permeation of drugs contained in lipid-based formulations. Finally, the combined model 
was modified to permit in vitro lipolysis and permeation to occur simultaneously. Both the 
combined and simultaneous in vitro lipolysis-permeation models demonstrated to predict 
in vivo drug absorption in rats for three fenofibrate-loaded SNEDDSs (Self Nano-
Emulsifying Drug Delivery Systems), underlining their potential use in the assessment of 
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1  Introduction 
 
1.1 Oral drug administration 
 
The administration of drugs via the oral route is regarded as the most convenient strategy 
to systemically deliver drugs, due to its non-invasiveness, low cost and high patient 
compliance [1]. However, the physiological complexity and structure of the 
gastrointestinal (GI) tract can greatly influence the ability of a drug to exert its effect [2]. 
In particular, the impact that the GI tract anatomy and physiology have on drug 
absorption need to be carefully understood and taken into consideration when new drugs 
or formulations are being developed and studied. 
 
1.1.1 Gastrointestinal tract anatomy, physiology and contents 
 
The GI tract comprises a series of connected 
compartments that go from the mouth to the 
anus, it is linked to organs such as the liver, 
gallbladder and pancreas; its overall function is 
the one of mediating the interaction between 
the environment and the body, with the aim of 
maintaining homeostasis [1]. The three main 
sections of the GI tract are the stomach, small 
intestine and large intestine (Figure 1.1). The 
stomach serves as a storage for the content 
ingested through the mouth, and has the 
function of mixing, grinding and digesting this 
content thanks to its muscular layers, its highly 
acidic pH (pH 1.7-3.3) and enzymatic secretions 
[3]. The composition of the content found in the stomach determines the gastric emptying 
time, which is slower in the case of a high-caloric meal [4, 5].  The stomach gradually 
Figure 1.1: The three main portions of the 





empties its content through the pylorus into the small intestine, which has the main 
function of digesting and absorbing nutrients and drugs [3]. In particular, the duodenum, 
the first portion of the small intestine, receives bile, phospholipids and cholesterol from 
the gallbladder, and pancreatic fluids containing lipase and proteases from the pancreas 
[6]. These secretions play a key role in the digestion process. The second section of the 
small intestine, the jejunum, has the primary function of absorbing what has been made 
available after digestion, while the last section (i.e. the ileum) has the role of absorbing 
lipid degradation products and bile salts [3]. The large intestine, also referred to as colon, 
is the distal part of the GI tract, and has the function of absorbing water, vitamins and 
electrolytes, while being able to ferment undigested fibers and collect fecal content [1, 7]. 
 
 The gastrointestinal mucosa 
 
The mucosal structure present through the whole GI tract is a barrier that separates the 
GI luminal content from the blood circulation. The structure of the GI mucosa differs 
according to the specific GI compartment (i.e. stomach, small intestine, colon), leading to 
region-dependent properties (Figure 1.2). As the focus of this work revolves around drug 
absorption, the following discussion will 
mainly be centered on the characteristics 
and processes taking place in the portion 
where absorption is most abundant, i.e. 
the small intestine. The small intestine 
mucosa is composed of four layers: the 
epithelium covered by a mucus layer, the 
basal membrane, the lamina propria and 
the muscularis mucosa which provides 
support and nutrition to the epithelium 
[8]. The absorbing function of the small 
intestine is made efficient by the specific 
conformation of the enterocytes present 
Figure 1.2: The mucosa of the stomach, small 
intestine and colon, composed of epithelial cells 




in the epithelium. In fact, the 
enterocytes in the small 
intestine are characterized by 
the presence of numerous 
protrusions called villi, which 
extend the absorptive surface 
area of the small intestine [9]. 
Other than the enterocytes, 
cells such as mucus-secreting 
goblet cells, M-cells and Paneth 
cells are also present in the 
intestinal epithelium (Figure 1.3) 
[9]. All these cells are linked 
together in a monolayer 
through tight junctions, which 
prevent leakage of unwanted 
material between the luminal and the basal side of the intestinal mucosa while allowing 
the absorption of essential nutrients from the intestinal contents [10]. 
The mucus layer present on top of the intestinal mucosa represents the first barrier for 
absorption, and it is able to selectively prevent unwanted molecules from being absorbed 
by trapping and moving them towards the colon with the help of the migrating motor 
complex [11, 12]. While both the stomach and colon are characterized by an evident 
double-layered mucus (i.e. inner strongly adherent layer plus loosely adherent layer), the 
small intestine mainly presents a single-layered and loosely bound mucus [13]. For 
instance, in the small intestine of rats, the strongly adherent layer can range from 16 to 
29 µm, whereas the loosely adherent one can be 123 to 480 µm thick [14]. In general, the 
mucus layer is composed of water (≈ 90% w/w), glycoproteins (i.e. mucins ≈ 0.2-5% w/v; 
MUC2 prevails in the GI tract), proteins (≈ 0.5% w/v), salts (≈ 0.5-1% w/w), lipids (≈ 1-2% 
w/w), DNA, cells, and cellular debris, and represents both a steric and physicochemical 
barrier to the absorption of unwanted molecules [11, 15]. Currently, 19 mucin genes 
(MUC) have been discovered, and it has been found that MUC2 is mainly secreted in the 
Figure 1.3: The intestinal mucosa, its epithelial cells, the 





intestine, while MUC5 and MUC6 are usually found in the stomach [16].  Mucins play a key 
role in the barrier function of mucus, as their structure (bottle-brush composed of a 
protein backbone to which numerous oligosaccharide attach to) contributes to 
structuring the mucus network, and the glycan domains in the mucin generate its gel-like 
properties [9, 10, 17-19] (Figure 1.3). Furthermore, the highly glycosylated mucin regions, 
which account for 80% of the dry weight of mucins [20, 21], give mucus an overall 
hydrophilic behavior, with a distinctive negative charge caused by the prevalence of sialic 
acid (pKa ≈ 2.6) in the oligosaccharide chain [22]. The sections of the protein backbone 
that are not associated to oligosaccharide chains are characterized by cysteine-rich 
regions, which lead to the establishment of inter-mucin disulfide bonds that create the 
mesh-like network of mucus [23]. The mucus mesh-like structure acts as a size-exclusion 
filter, which leads to steric hindrance to the diffusion of pathogens, while its overall 
hydrophilicity and negative charge produces a physicochemical barrier to molecules that 
are not compatible with such environment [15, 24]. Moreover, the pH of mucus along the 
GI tract changes according to the specific GI compartment, and it has been shown that 
the viscosity of mucus increases at more acidic pH due to a pH-dependent sol-gel 
transition and varies with temperature and salt concentration [25-27]. This pH-dependent 
behavior leads to increased protective properties for the mucus found in the stomach, 
compared to the more permeable mucus found in the small intestine [16, 17].  
 
 The gastrointestinal fluids 
 
The characteristics and composition of the fluids found throughout the GI tract depend 
on the GI compartment (i.e. stomach, small intestine or colon) and on the prandial state 
(i.e. fasted or fed state) [28, 29]. For instance, the stomach is characterized by an acidic pH 
(1.7-3.3), the small intestine pH ranges between 6 and 8 (i.e. 5.6- 7.0 in the duodenum; 6.5-
7.8 in the jejunum), while the pH of the fluids found in the colon is highly variable [5, 8, 28, 
30, 31]. Moreover, after meal intake an increased concentration of bile salts, 
phospholipids, cholesterol, free fatty acids, mono, di and tri-acylglycerides can be 
observed in the small intestine (Table 1.1) [32, 33], together with higher enzymatic activity, 




composition occurring in the fed state determines the formation of various structures, 
such as (mixed) micelles, vesicles of different sizes and lipid droplets, which add a 
lipophilic microenvironment to the fed intestinal fluid that is not found in fasted one [34]. 
 
 
Table 1.1: Fasted human intestinal fluids (FaHIF) and fed human intestinal fluids (FeHIF) 
composition, including bile salts (BS), phospholipids (PL), cholesterol (CH), free fatty acids (FFA), 
monoglycerides (MG), diglycerides (DG) and triglycerides (TG) [33, 35]. 
 














FaHIF  4.4 0.9 0.08 0.64 0.14 - - 




1.1.2 The fate of the drug through the GI tract 
 
Once a drug is orally administered, it will be exposed to the different GI compartments 
and fluids before being absorbed and eventually reach the systemic circulation. In 
particular, when an oral drug formulation is being swallowed, it will first need to 
disassemble and provide the dissolution of the drug in the GI fluids [36, 37]. The specific 
characteristics of the formulation and of the drug itself, together with their interaction 
with the GI compartments and related fluids, will determine the extent of drug dissolution 
(as discussed in Section 1.1.3). As soon as the drug is freely dissolved, it will be available 
for absorption and it will cross the small intestine epithelium via transport mechanisms 
such as passive transcellular diffusion, passive paracellular diffusion, carrier-mediated 
influx transport, active efflux transport and transcytosis (Figure 1.4) [38]. Passive 
transcellular diffusion and carrier-mediated transport occur across the enterocytes, 





On the other hand, efflux transport and 
transcytosis depend on active 
transporters and on the incorporation 
of the drug into vesicles from the 
enterocyte membrane, respectively 
(Figure 1.4) [40, 41]. Out of these five 
drug transport mechanisms, passive 
transcellular diffusion is regarded as 
the predominant one, especially for 
lipophilic drugs [38], whereas passive 
paracellular diffusion is the preferred 
transport route of small hydrophilic 
drugs [42, 43]. However, because of the 
limited surface area available for 
paracellular diffusion (i.e. 0.01 % of the 
overall absorptive intestinal surface 
area) drug absorption resulting from this transport mechanism is limited [44]. Following 
transport, the fraction of drug absorbed (Fa) in the intestinal epithelium is either able to 
reach the portal vein or the lymph, depending on the physicochemical characteristics of 
the drug (Figure 1.4). A percentage of the drug arriving to the liver through the portal vein 
will be metabolized by the hepatic enzymes before being transported to the systemic 
circulation, whereas the amount of drug absorbed in the lymphatic circulation is directly 
able to reach the systemic blood circulation (Figure 1.4) [45]. Once in the systemic 
circulation, the drug will be distributed to the tissues where it will exert its effect. 
 
1.1.3 Factors affecting oral drug absorption 
 
As previously mentioned, the extent to which a drug is able to reach the systemic 
circulation depends on various factors. Such factors include both the characteristics of 
the drug and of the formulation in which the drug is loaded (drug and formulation 
Figure 1.4: Intestinal drug transport mechanisms, 
including 1) passive transcellular diffusion, 2) 
passive paracellular diffusion, 3) carrier-mediated 





characteristics) as well as the GI physiology (physiological factors) [1]. More specifically, 
oral drug absorption is driven by the interaction between the characteristics of the drug 
and formulation and the physiological GI environment. To achieve high drug absorption, 
this interaction should lead to high dissolution (solubility) of the drug in the GI fluids 
together with high drug permeation across the intestinal epithelium. 
 
 The impact of drug and formulation characteristics on drug absorption 
 
The impact of the drug 
physicochemical characteristics in 
attaining high drug absorption has 
been highlighted by the ‘rule of five’ 
introduced by Lipinski [46] and by 
the Biopharmaceutics Classification 
System (BCS), introduced by 
Amidon and colleagues [47]. The 
‘rule of five’ states that that high 
absorption is  occurring when: 
hydrogen bond acceptors are less 
than 10, hydrogen bond donor are 
less than 5, the drug molecular 
weight is lower than 500 Da, and the lipophilicity (described by the logP) is lower than 5 
[46]. On the other hand, the BCS categorizes drugs into four classes (Figure 1.5): class I 
(high solubility and permeability), class II (high permeability but low solubility), class III 
(high solubility but low permeability) and class IV (low solubility and permeability) [47]. For 
highly soluble drugs the highest given dose is soluble in a 250 mL aqueous medium (pH 
1-7.5), whereas for highly permeable drugs 90% or more of the administered drug dose 
is absorbed from the GI tract to the blood stream. Both solubility and permeability are 
tightly connected to the physicochemical characteristics of the drugs, such as the 
dissociation constant pKa, logP, logD and melting point (Figure 1.6). More specifically, the 





pKa determines the charge of an ionizable compound in a specific pH environment. The 
ionized state of the compound will have a positive effect on its solubility, while having a 
negative effect on its passive permeability [48, 49]. This concept has been summarized in 
the pH partitioning theory [50, 51]. Consequently, weak bases are highly soluble at the 
acidic pH of the stomach (i.e. drug ionization > 50%) and their transfer into the small 
intestine, characterized by a more neutral pH, can cause their precipitation [52, 53]. The 
opposite is true for weak acids, which 
are less soluble in the stomach 
compared to the small intestine [54]. 
For such ionizable compounds, 
solubility and permeability display 
opposite trends. In fact, high drug 
ionization (> 50%) causes high 
solubility and low permeability, 
whereas low drug ionization (< 50%) 
leads to the opposite effect [48]. 
Instead, logP (i.e. affinity of the neutral 
drug form for a water-immiscible 
organic phase compared to an 
aqueous one) is directly proportional 
to passive permeability and inversely proportional to drug solubility [55], and it is a 
parameter that makes it possible to assess the affinity of a drug for biological membranes. 
On the other hand, logD (i.e. affinity of the charged drug form for a water-immiscible 
organic phase compared to an aqueous one) determines the distribution of ionizable 
drugs at a specific pH, and it is thus directly related to the pKa of the drug [55]. Drugs with 
logD > 3 are referred to as ‘grease ball’ compounds, and they are characterized by a 
solvation-limited solubility caused by their high lipophilicity [56, 57]. Differently, ‘brick 
dust’ compounds are drugs with high melting point (Tm > 200 °C) and their dissolution is 
energy-limited, as high energy is needed to dissociate these molecules from their solid 
form [36, 49].  




As drug dissolution is the first limiting step contributing to drug absorption, it is important 
to highlight than only the molecularly dissolved free drug is able to permeate the 
intestinal walls. This solubility is not only connected to the physicochemical characteristics 
of the drug, but also to the excipients of the formulation in which the drug is loaded and 
to the GI fluids composition and characteristics [36]. For this reason, the definition of drug 
solubilization has been introduced, referring to the amount of drug solubilized by 
formulation excipients, digestion products and endogenous bile salts and phospholipids 
present in the intestine. The solubilized drug is not molecularly and freely dissolved, as it 
is associated with the colloidal structures present in the GI fluids, and it is therefore not 
able to be directly absorbed (Figure 1.6). However, the solubilized drug can serve as a drug 
reservoir for further drug dissolution, thus being able to directly enhance drug absorption 
[58]. Several techniques have been used to enhance the solubility of poorly water-soluble 
drugs (PWSDs) like the ones in BCS class II, and this has led to the development of enabling 
formulations such as lipid-based formulations (LBFs) [36]. The use of LBFs to enhance 
drug dissolution and drug absorption will be discussed in Section 1.1.4. 
 
 The impact of physiological factors on drug absorption 
 
The physicochemical characteristics described above determine how the drug is able to 
interact with the contents found in the GI tract and with its physiological barriers, and this 
interaction determines the extent of drug absorption. The GI factors that can either aid or 
hamper drug absorption going from a luminal-to-basal direction are i) the dissolution 
properties of the luminal fluids, ii) the interaction and size filtering properties of the 
mucus layer, iii) the permeation pathways of the intestinal epithelium and iv) the 
distribution mechanisms of the drugs to the systemic circulation. Dissolution in the 
luminal fluids is particularly central for PWSDs, as their low aqueous solubility can lead to 
precipitation and thus low absorption [8]. However, for PWSD such as the ones classified 
as BCS class II compounds (i.e. drugs with high permeability but low solubility) the increase 
in the presence of solubilizing agents found in the fed intestinal fluids leads to higher drug 




affects drug solubilization and dissolution for neutral compounds, whereas for weak acid 
and bases the pH is the major driver of drug dissolution [55, 59, 60]. Moreover, the 
composition of the ingested meal can lead to negative, positive or neutral food effects, 
depending on the specific drug and its interaction with the food components [8, 61-63]. 
Proceeding towards the intestinal 
membrane, the likelihood that a drug 
is able to reach the epithelial 
absorption site depends on its 
interaction with the mucus layer [19]. 
In fact, this layer acts as a barrier for 
the diffusion of drugs through two 
main mechanisms: interaction and size 
filtering [24]. The first mechanism 
takes into account a decrease in the 
diffusion of drugs due to electrostatic 
or hydrophobic interactions, hydrogen 
bonds and selective binding 
interactions (Figure 1.7) [15, 21]. For 
instance, lipophilic drugs have affinity 
for the non-glycosylated regions of mucins (i.e. protein backbone, Figure 1.3), thus their 
diffusion through the mucus layer is slowed down more than hydrophilic ones [64-66]. 
On the other hand, positively charged drugs can electrostatically bind the negatively 
charged mucins, and this interaction can cause their retention in the mucus layer and 
slow down their diffusion through it (Figure 1.7) [25, 67]. However, even though the 
absorption of lipophilic drugs is negatively affected by the mucus layer, their nature 
makes them more likely to passively cross the intestinal epithelium because of their high 
affinity for biological membranes [55, 68]. Additionally, gel-forming mucins are capable of 
forming a mesh-like structure that is able to impede the diffusion of large molecules 
(Figure 1.7) [69], while the overall high viscosity of mucus layer can retard drug diffusion 
[27]. The active and passive permeation pathways described in Section 1.1.2 can also 
determine the extent of drug absorption, and they can vary across the GI tract [8].  
Figure 1.7: Interaction and size filtering processes 





Finally, drug lipophilicity can 
determine the way by which the 
drug will reach the systemic 
circulation. In fact, drugs with logP 
higher than 5 are assembled into 
triglyceride-rich lipoproteins inside 
the enterocyte (Figure 1.8) [45, 70]. 
This drug-lipoprotein aggregate is 
able to reach the mesenteric 
lymphatic system, which is 
connected to the systemic 
circulation. Instead, drugs with logP 
lower than 5 reach the systemic 
circulation through uptake into the 
portal vein, thus having to be 
exposed to the first-pass 
metabolism of the liver before 
reaching the systemic blood stream 
(Figure 1.8) [45, 70]. 
 
1.1.4 Oral delivery of PWSDs and related formulation strategies 
 
In the past decade, the amount of newly discovered drugs characterized by high (logP > 
5) to moderately high (logP > 3) lipophilicity has steadily increased, accounting for 70 % of 
the new drug candidates [71].  These compounds are referred to as PWSDs, and they can 
be affiliated to BCS class II or IV. These drugs are characterized by solubility-limited 
absorption, as their low solubility in aqueous environments leads to precipitation and 
thus low bioavailability [72]. Moreover, the dissolution of these compounds in the GI fluids 
can depend on inter- and intraindividual factors such as the GI physiology, fasted or fasted 
state and composition of the ingested meal [73]. For BCS class IV compounds, the low 
membrane permeability that accompanies their low solubility makes them poor 
Figure 1.8: Drug absorption via the portal vein and 
the lymph. Lymphatic drug transport is facilitated by 
FA and MG, which are re-assembled in TG and 





candidates for formulation development, whereas the extent of oral absorption of BCS 
class II compounds can be altered by loading them into enabling formulations [74]. 
To answer for the low solubility and variable bioavailability of BCS class II drugs, liposomal 
formulations and LBFs such as self-nanoemulsifying drug delivery systems (SNEDDSs) 
have been introduced as two formulation strategies [75, 76], producing a high number of 
FDA approved drug products for this BCS class [77].  
Liposomes are mainly constituted by phospholipids, which are amphiphilic molecules 
able to arrange upon hydration into a vesicular structure characterized by a phospholipid 
bilayer surrounding an aqueous core [78]. The lipophilic nature of the phospholipid 
bilayer allows loading of lipophilic drugs, while the aqueous core can accommodate drugs 
with a more hydrophilic nature, allowing liposomes to be carriers for drugs with different 
physicochemical properties [76, 79]. Additionally, the liposomal surface can be modified 
to confer characteristics such as mucoadhesion and mucopenetration, which can be 
exploited to improve the oral delivery of drugs by the interaction with or diffusion through 
the GI mucus layer, respectively [80]. Even though the oral delivery of drugs loaded into 
liposomes is considered as one of the strategies for the delivery PWSDs, it suffers from 
the drawback connected to the instability of these drug delivery systems in the presence 
of gastric acids, bile salts and digestive enzymes [79]. Therefore, these formulations have 
been either modified to improve their stability in the GI environment, or they have been 
used for oromucosal drug delivery, which does not cause large instability issues and is 
able to bypass the first-pass metabolism in the liver [81]. 
On the other hand, LBFs such as SNEDDSs are composed of oils, surfactants and co-
solvents and they are able to spontaneously form nano-emulsions once dispersed in a 
water phase (i.e. oil-in-water emulsions) [82]. The oral delivery of such LBFs has proved to 
enhance bioavailability of PWSDs by inducing drug solubilization (i.e. increase in amount 
of drug associated with micelles and other colloidal structures), drug supersaturation (i.e. 
increase in free drug compared to the drug equilibrium solubility), precipitation inhibition 
and by enhancing lymphatic transport [36, 45, 83-86]. Additionally, it has shown to reduce 
the effect of the prandial state and GI physiology on drug absorption [73, 87]. LBFs can be 
divided into four groups according to their composition, following the lipid formulation 




Table 1.2: Types of LBFs according to the lipid formulation classification system (LFCS) [74]. 
 
 Content of formulation (%) 
Excipients Type I Type II Type IIIA Type IIIB Type IV 
Oil 100 40 - 80 40 - 80 < 20 - 
Water-insoluble surfactants - 20 - 60 - - 0 – 20 
Water-soluble surfactants - - 20 - 40 20 - 50 30 - 80 





The extent to which the drug is able to be absorbed is therefore closely linked to the 
interaction between the LBF and the GI physiology. In fact, the colloidal structures formed 
between the LBF components, their digested portions, endogenous phospholipids, bile 





salts and cholesterol are the determining factors affecting the solubilization of the drug 
and its absorption [70, 75]. For instance, the presence of lipids in the LBF will lead to the 
secretion of lipases from the gastric mucosa and the pancreas, as well as bile from the 
gallbladder, leading to lipid digestion (i.e. lipolysis) [70, 88, 89]. As a result of this, the drug 
previously solubilized in the LBF will now be found i) partitioned in the colloidal structures 
(micelles, vesicles, emulsion droplets) formed upon lipolysis, ii) free in a meta-stable 
supersaturated solution and iii) precipitated in its crystalline or amorphous form (Figure 
1.9) [36, 90, 91]. Because of their impact on drug absorption, the lipolysis-triggered 
changes affecting drug solubilization and dissolution have to be carefully taken into 
account for LBFs. As previously mentioned, it is the amount of drug free in solution the 
portion that is able to be absorbed (Figure 1.6). Therefore, in the case of LBFs the amount 
of supersaturated drug (i.e. free drug present at a concentration higher than its 
equilibrium solubility) will be the driving force for drug permeation across the intestinal 
epithelium, while the amount 
contained in the colloidal 
structures will represent a 
reservoir of solubilized drug that 
will eventually partition in the 
supersaturated solution (Figure 
1.10) [91, 92]. Even though 
supersaturation induced by LBFs 
can be beneficial to enhance the 
bioavailability of PWSDs, its 
thermodynamic instability can lead 
to drug precipitation [93]. In fact, 
drugs tend to precipitate from the supersaturated state until equilibrium solubility is 
reached, leading to the loss of the enhanced absorption offered by LBF [94]. However, 
drug precipitation following supersaturation can be inhibited by the presence of the 
absorptive sink [95, 96]. In fact, the amount of free drug continuously removed by the 
permeation across the intestinal epithelium can create an alternative to precipitation and 
change the precipitation kinetics by relieving the thermodynamic instability caused by 
Figure 1.10: LBF-mediated supersaturation and 




drug supersaturation [94, 96]. In addition, the intestinal mucus layer has also shown to 
stabilize the drug in its supersaturated state, thus aiding in promoting an increase in the 
bioavailability of drugs contained in LBFs [97, 98]. Finally, LBFs have shown to promote 
lymphatic drug transport of highly lipophilic drugs (log P > 5). In fact, the fatty acids and 
monoglycerides resulting from the intestinal lipolysis of LBFs can enter the enterocytes, 
form triglycerides and can be assembled into lipoproteins (Figure 1.8) [83, 99]. The newly 
synthetized lipoprotein are then able to incorporate lipophilic drugs and access the 
mesenteric lymphatic system, thus stimulating lymphatic drug transport and avoiding the 
first-pass metabolism [45, 70, 83]. 
 
 
1.2 In vitro assessment of drug absorption and formulation performance 
 
During the early stages of drug discovery and formulation development, the use of in vitro 
models has become increasingly common, due to their cost and time effectiveness and 
due to the avoidance of the ethical concerns related to animal testing. In fact, in vitro 
models help in the replacement, refinement and reduction of animal research (three Rs 
concept) [100], and are useful in evaluating the performance of oral drug formulations 
before preclinical and clinical stages [101, 102]. Moreover, the complexity and 
physiological relevance of in vitro models can be tailored to the specific application, thus 
enabling both the exclusive simulation of one specific rate-limiting process affecting drug 
performance (i.e. more simplistic models) and also the replication of more complex 
systems [90]. In general, when assessing oral drug absorption, in vitro models can offer 
the simulation of i) the GI fluids composition and dissolution properties, and/or ii) of the 
intestinal permeation membrane through which the drug is being absorbed. Moreover, 
because of the increased number of discovered PWSDs, and because of the relevance of 
LBFs for the administration of such drugs, the lipolysis-triggered processes affecting drug 
absorption can also be accounted for in the chosen in vitro model. Thus, to unravel the GI 
absorption-related processes and to predict in vivo oral drug absorption, in vitro 
dissolution methods, lipolysis systems and permeation models can be singularly utilized 




1.2.1 Simulated intestinal fluids 
 
The evaluation of drug solubility and permeability has been carried out with the use of 
simple aqueous buffers for several decades; however, in the past years it has become 
ever so evident that for drugs such as PWSDs the use of such buffers can lead to a false 
estimation of their in vivo performance [61]. Yet, this problem is not shared by drugs 
having physicochemical characteristics differing from the ones of PWSDs. For this reason, 
Markopoulos and colleagues proposed the separation of simulated intestinal media in 
four levels of biorelevance, where level 0 comprises a buffer where only luminal pH is 
simulated, whereas level 3 simulates luminal pH, osmolarity, buffer capacity, bile, lipids 
and protein components, together with the digestive processes [103]. The choice of one 
of the four levels of biorelevance depends on the physicochemical properties of the drug 
being studied and on the research question being formulated [104]. For example, the 
solubility of ionizable compounds is strictly connected to the pH of the medium, especially 
for drugs that change their state of ionization in the selected pH environment. On the 
other hand, for neutral compounds and molecules that do not change their ionization in 
the chosen pH interval the presence of bile salts and phospholipids is the main driving 
factor affecting drug solubilization (Figure 1.11) [60].  
 
 
Figure 1.11: Influence of pH, bile salt and phospholipids on the solubility of neutral and 




Additionally, solubilization and permeation of PWSDs can largely vary according to the 
prandial state of luminal fluids (i.e. fasted or fed state). Therefore, the performance of 
such drugs should be tested in the presence of fasted and fed state intestinal fluids. 
Furthermore, if these drugs are being loaded into LBFs, the effect of gastric and intestinal 
digesting enzymes should also be taken into account when evaluating LBFs properties 
[104]. 
To answer the need for fluids mimicking human fasted and fed intestinal fluids (HIFs) for 
in vitro studies, different simulated intestinal fluids (SIFs) have been developed and some 
are now commercially available on the market (biorelevant.com) (Table 1.3) [105-107]. The 
main difference between fasted and fed state SIFs is the concentration of bile salts and 
phospholipids, as the fed state SIFs contain a higher amount of these components (Table 
1.3). The presence of bile salts and phospholipids in the SIFs can provide the formation of 
colloidal structures corresponding to those of HIFs, thus enabling the study of drug 
solubilization, supersaturation and absorption in a biorelevant manner [108]. However, 
the simulation of fed state HIFs is still regarded as challenging because of the high inter 
and intraindividual variability of such conditions. Moreover, because of the lack of large 
lipid droplets and colloidal structures in the currently available FeSSIFs, it has been found 
that these SIFs are not able to predict in vivo drug solubilization to a high extent [34, 59, 
107]. On the other hand, fasted state SIFs have shown to better mimic the properties and 
solubilizing effects of fasted HIFs, probably due to the lower media complexity and 
variability compared fed state fluids [32]. 
 
Table 1.3: Commercially available fasted and fed state simulated intestinal fluids (FaSSIF and 
FeSSIF, respectively; biorelevant.com) and their characteristics. 
 FaSSIF – V1 FaSSIF – V2 FeSSIF – V1 FeSSIF – V2 
pH 6.5 6.5 5.0 5.8 
Buffer type Phosphate Maleic acid Acetate Maleic acid 
Bile salts (mM) 3 3 15 10 
Phospholipids (mM) 0.75 0.20 3.75 2.00 
Monoglycerides (mM) - - - 5 





1.2.2 In vitro lipolysis models 
 
Dissolution, supersaturation, precipitation and solubilization of orally administered drugs 
do not only depend on the composition of the GI fluids, but also on the digestion 
processes occurring in the gastric and intestinal compartment. In particular, lipid 
digestion (i.e. lipolysis) is especially important when evaluating absorption of PWSDs 
contained in LBFs. To anticipate the effect of lipid digestion on the performance of LBFs, 
an in vitro lipolysis model has been introduced by Zangenberg and colleagues in 2001 
[109]. This in vitro model consists of a thermostated lipolysis vessel in which SIFs and LBF 
can be mixed, stirred and kept at a constant physiological temperature (Figure 1.12) [109, 
110].  
 
The lipolysis vessel is connected to a pH-stat apparatus, which is able to keep the pH in 
the SIFs constant. Upon addition of digesting enzymes (i.e. lipases) to the lipolysis 
medium, the digestible excipients of the LBF will be hydrolyzed, leading to a release of 
Figure 1.12: In vitro lipolysis apparatus, LBF, colloidal structures in the SIF and the effect of 




free fatty acids. In return, the release of free fatty acids in the SIF will cause a drop in pH, 
which will be neutralized by the pH-stat apparatus by the addition of sodium hydroxide 
(NaOH) (Figure 1.12). Additionally, the lipolysis inhibition caused by the release of free 
fatty acids in the lipolysis medium will be prevented by the addition of calcium either 
continuously through the lipolysis experiment or as an initial bolus (Figure 1.12) [111, 
112]. In general, in vitro lipolysis models can simulate both the digesting processes 
occurring in the stomach and in the small intestine, however most of them typically focus 
on intestinal lipolysis, as most of lipid digestion occurs in the small intestine [113]. 
For the specific simulation of intestinal lipolysis, porcine pancreatic extract is typically 
used, as it has proved to reliably substitute human pancreatic enzymes [114, 115], and its 
activity depends on the pH in the SIF (e.g. optimum lipase activity at pH 6.5-8) [116]. In 
order for the fatty acids resulting from the lipolysis process to be titrated by the addition 
of NaOH, they need to be ionized. Therefore, since the pKa of the long chain fatty acids in 
the SIF is approximately 6.5 [117], the targeted pH 
condition for in vitro lipolysis is usually 6.5 (Figure 
1.12) [118]. Notably, the buffering capacity of the 
buffer used for preparation of the SIF needs to be 
low enough to ensure the pH drop following fatty 
acid liberation [119]. Therefore, this in vitro model 
allows the determination of the degree of LBF 
lipolysis thanks to the evaluation of the amount of 
NaOH used to neutralize the pH decrease. 
Moreover, the in vitro lipolysis model allows the 
determination of drug distribution upon LBF 
digestion [88, 90], as the drug can be found 
distributed in the lipolysis medium into three 
distinct phases: the oil phase consisting of 
undigested LBF, the aqueous phase containing colloidal structures formed upon lipolysis 
and the pellet phase containing precipitated drug, fatty acid calcium soaps and digestive 
enzymes (Figure 1.13) [118]. The physical separation of the three phases can be obtained 
by centrifugation, thus allowing the quantification of the drug in each phase. The fraction 
Figure 1.13: Phases formed upon 
centrifugation after in vitro lipolysis, 




of the free drug found in the aqueous phase represents the amount of drug available for 
absorption, whereas the amount of drug found in the colloidal structures in the aqueous 
phase and the amount solubilized in the oil phase can serve as a drug-solubilizing 
reservoir [91]. One of the shortcomings of the in vitro lipolysis model is related to the fact 
that it is not able to easily separate the amount of drug free for absorption from the one 
solubilized by the colloidal structures in the aqueous phase, and this can lead to an 
overestimation of the amount of drug free to be absorbed [120]. Even though very useful 
for the determination of the degree of LBF lipolysis, the in vitro lipolysis model described 
above is characterized by one limitation: the dependence of the experiment from a costly 
pH-stat titration apparatus.  Therefore, with the aim of developing a pH-stat titration 
independent in vitro lipolysis model, Mosgaard and colleagues introduced the high 
throughput lipolysis model (i.e. the HTP in vitro intestinal lipolysis model) [121, 122]. This 
model relies on the use of a high buffer capacity intestinal medium, able to directly 
neutralize the pH drop caused by the formation of free fatty acids upon LBF lipolysis. This 
in vitro model proved to be equivalent to the pH-stat lipolysis model, leading to higher 
time- and cost-effectiveness [122]. 
 
1.2.3 Cell free in vitro permeation tools 
 
After its dissolution in the GI fluids, the drug will be available for absorption in its free 
form, and will reach the blood circulation after its permeation through the intestinal 
epithelium. Consequently, in the prediction of in vivo oral drug absorption the assessment 
of in vitro drug permeation is regarded as crucial. For this reason, several in vitro cell-free 
permeation tools have been developed over the past decades. These models can be 
utilized to evaluate passive drug transport, which is the absorption pathway shared by 
most of the currently commercially available drugs [123]. Cell-free permeation tools can 
be divided into two classes: biomimetic barriers (constructed by phospholipids) and non-
biomimetic ones (composed of dialysis membranes) (Figure 1.14) [42]. Both classes 
enable the assessment of apparent drug permeability (Papp), which can be calculated after 













A · (Cd − Ca)
 
where Q represents the cumulative amount of drug found in the acceptor compartment 
as a function of time t (nmol/s), A is the surface area of the in vitro barrier (cm2), and Cd 
and Ca are the drug concentrations in the donor and acceptor compartment, respectively 
(nmol/mL) (see Figure 1.14 for acceptor and donor). Since the in vitro permeation 
experiment is usually carried out under sink conditions (i.e. the concentration in the 
acceptor compartment never exceeds 10% of the drug concentration in the donor 
compartment), Ca can be considered low enough to be neglected. Thus, the equation can 











One of the first in vitro permeation barriers developed is the PAMPA (Parallel Artificial 
Membrane Permeation Assay), which was introduced in 1998 by the Roche team [124] 
Figure 1.14: In vitro permeability setup, composed of a donor and acceptor compartment, 
separated by a permeation membrane. The main cell-free permeation membranes: PAMPA, 




(Figure 1.14). PAMPA barriers consist of a filter support soaked with an organic solvent in 
which phospholipids are dissolved, and allow the assessment of passive transcellular 
diffusion (Figure 1.4). The nature of the filter support, the composition of the 
phospholipids and the pH in the donor and acceptor compartment has been tailored to 
simulate different tissues in the human body, leading to different PAMPA barriers [125-
132]. 
The PVPA (Phospholipid Vesicle-based Permeation Assay) was introduced shortly after the 
PAMPA at the University of Tromsø in 2006 [133]. The PVPA barriers consist of a filter 
support in which liposomes with different size distributions are immobilized (Figure 1.15). 
The construction of such biomimetic barriers is based on the fact that liposomes are able 
to simulate the phospholipid bilayers of cells present in different biological barriers [134-
136]; therefore, by immobilizing liposomes in and on top of a membrane filter by 
centrifugation and freeze-thawing, it is possible to simulate the architecture of several 
human membranes by changing the composition of the liposomes [137-142]. In 
particular, liposomes with a diameter below the pore size of the membrane filter are 
deposited inside the filter, whereas liposomes with higher diameter are placed on top. 
 
 
                 
The first PVPA barriers (original PVPA) mainly consisted of phosphatidylcholine (80 % PC, 
egg phospholipids), a type of lipid present both in the intestinal epithelium and other 
Figure 1.15: Structure of the PVPA barriers, composed of small unilamellar and large 




biological membranes [137]. To improve the simulation of the intestinal epithelium, the 
composition of the PVPA barriers was modified by combining phosphatidylcholine with 
phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and cholesterol, 
leading to the development of the PVPAbiomimetic. The functionality of the PVPA barriers is 
assessed by i) studying the permeability of a highly hydrophilic fluorescent marker (i.e. 
calcein) and by ii) measuring the electrical resistance across the barriers. Intact barriers 
lead on one hand to low calcein permeability, and on the other hand to high electrical 
resistance [133].  The functionality of the PVPA barriers has been assessed in the presence 
of different SIFs, GI relevant pH, co-solvents and tensides, highlighting the potential of 
such in vitro model for different applications [136-138, 143].  
Another biomimetic barrier is the PermeaPad® developed at the University of Southern 
Denmark in 2015 [144]. This barrier consists of phospholipids placed between two 
support sheets, where the phospholipids are able to swell and form a tight phospholipid 
layer once in contact with water. These barriers have been developed to be mounted on 
a side-by-side diffusion cell, on a Franz cell diffusion apparatus or to be used in a 96-well 
plate [145-148]. 
Finally, the AMI (Artificial Membrane Insert)-system has recently been developed as a non-
biomimetic barrier at KU Leuven in 2018 [149]. This system consists of a regenerated 
cellulose membrane mounted between two support rings, and has proven to be a useful 
and cost-effective tool for estimation of passive diffusion [149]. 
All the cell-free permeation membranes described above have been tested in their 
capability of distinguishing between drugs with different physicochemical properties, and 
have been used to evaluate the impact of several formulation strategies on drug 
permeation. Moreover, they proved to be predictive of the fraction of drug absorbed in 
humans and/or of drug permeation obtained from cell-based permeation membranes, 
such as the ‘golden standard’ Caco-2 (human colorectal adenocarcinoma cell line) 
permeation model [42, 124, 133, 144, 150]. Furthermore, the functionality of most of 
these models has been tested in the presence of GI relevant pH and SIFs to better 
simulate the GI physiology. Even though in vitro permeation barriers are considerably 




often been ignoring the impact that the intestinal mucus layer has on drug absorption. 
Mucus is in fact the first barrier to drug absorption, and should therefore be carefully 
considered when drug permeation is being assessed [80]. 
 
1.2.4 Mucus models and sources 
 
The in vivo assessment of the net influence of mucus on drug transport and absorption is 
regarded as a complex process to study, since a distinction between the effect of mucus 
and the one of other physiological factor is problematic. For this reason, several mucus 
alternatives have been developed to be 
able to study the impact of mucus on 
drug absorption. Ex vivo mucus 
samples can be obtained both from 
animal and humans (Figure 1.16), but 
the reliability of such samples is 
relatively limited due to the animal-to-
animal, human-to-animal and disease-
state variability [22]. On the other 
hand, different mucus-producing in 
vitro cell models have been developed to 
study the impact that mucus has on drug 
permeation. One example of such models is the mucus-secreting Caco-2 HT29-MTX co-
culture [151]. Even though very useful for the determination of drug permeation in the 
presence of mucus, the production of these cell-based mucus-secreting models can be 
costly both in terms of time and resources [152]. Therefore, because of the limitations 
connected to ex vivo mucus samples and mucus-producing cell cultures, purified mucins 
from bovine submaxillary gland or from porcine stomach have been largely used for 
mucus-drug/formulation interaction and permeation studies (Figure 1.16) [80, 153-159]. 
Mucins dispersions can be added on top of cell-based [62] or artificial barriers [90] to 
mimic the in vivo environment of intestinal mucosa and to assess the impact of the 
Figure 1.16: Composition of ex vivo mucus and in 




presence of the mucus layer on drug permeability. However, the low cross-linking capacity 
of purified mucins can lead to an under-simulation of the mesh-like structure of mucus, 
thus not being able to completely encompass the viscoelastic characteristics of GI mucus 
[27, 160, 161]. Therefore, because of the need for a biosimilar and easily accessible mucus 
source, the biosimilar mucus model was introduced by Boegh and colleagues [21, 160, 
162]. This model was able to closely mimic the composition and rheology of in vivo mucus 
thanks to the combination of mucins with other components such as bovine serum 
albumin, cholesterol, phospholipids and gel-forming polymers, and was found to be a 
barrier especially to the permeation of lipophilic molecules [21, 160]. Even though the 
biosimilar mucus model has been largely utilized in combination with Caco-2 cell lines to 
study drug permeation [21, 160, 162], its use in combination with cell-free in vitro 
permeation has not been explored in detail, pointing out the lack of a completely artificial 
GI mucosa-mimicking model. 
 
1.2.5 Combined lipolysis – permeation in vitro models 
 
The potential of in vitro lipolysis models to predict in vivo performance of LBFs has been 
evaluated by relating the amount of drug found in the aqueous phase in vitro with the 
outputs of in vivo pharmacokinetics studies (e.g. maximum plasma concentration, area 
under the curve (AUC)). However, in a large number of cases, a lack of a rank order in vivo-
in vitro correlation (IVIVC) was observed [163-170], pointing at the inability of the in vitro 
lipolysis model to predict in vivo drug absorption. The lack of IVIVC has been linked to the 
false assumption that high in vitro drug solubilization is associated to high drug 
bioavailability [90]. In fact, the drug found in the aqueous phase during in vitro lipolysis 
exists in an equilibrium between i) its free fraction (i.e. amount available for absorption) 
and ii) the fraction solubilized by the colloidal structures formed upon lipolysis (Figure 
1.13), and the in vitro lipolysis setup is not able to distinguish between these two. As a 
result of this, it is not possible to determine the amount of drug freely available for 
absorption [90]. Additionally, the absence of an absorptive sink can lead to an incorrect 




lipolysis model the amount of drug available for absorption is not able to escape the 
digesting environment via a permeation barrier, leading to higher drug supersaturation 
and precipitation in vitro compared to the in vivo scenario [171]. 
To overcome the shortcomings associated with the in vitro lipolysis model, this in vitro 
method has been associated both with ex vivo, in situ and in vitro cell-based and cell-free 
permeation barriers [73, 90, 120, 146, 171-176]. The first combined in vitro lipolysis-
permeation models were designed so that, after lipolysis, the digested contents could be 
transferred to a separate permeation setup, whereas more recent combined models have 
been able to provide the simultaneous assessment of lipolysis and permeation (Figure 
1.17). Overall, the in vitro lipolysis-permeation combination led to a better prediction of in 
vivo drug absorption [73, 90, 120, 146, 171, 174, 175]. In particular, the use of cell-free 
barriers such as the ones described in Section 1.2.3 has been found to be particularly 
beneficial from a time and cost perspective [73, 90, 146]. The improved IVIVC obtained 
with the use of such combined models highlighted the importance of the simultaneous 





Even though the mentioned combined models provided essential insight into the 
mechanisms driving drug absorption, for the most part they lacked the presence of a 




mucus layer lining the permeation barrier, especially in the case of cell-free barriers. 
Therefore, because of the impact that mucus has on drug dissolution and permeation, 
and because of the convenience of cell-free permeation membranes, it would be crucial 










2 Aims of the thesis 
 
The overall aim of this work was to develop a mucus-comprising in vitro permeation model 
able to mimic the environment of the intestinal mucosa to study drug permeation and 
predict in vivo drug absorption. 
 
To achieve this, the specific aims have been the following: 
 
- Inclusion of an artificial mucus layer on top of the PVPA in vitro permeability barriers 
(Paper I).  
 
- Validation of the mucus-PVPA barriers in terms of their integrity and ability to 
discriminate between the permeabilities of drugs with different physicochemical 
properties and between different liposomal formulations (Paper I). 
 
- Evaluation of the impact of intestinally relevant pH on drug permeability using the 
mucus-PVPA barriers (Paper II). 
 
- Determination of the functionality of the mucus-PVPA barriers in the presence of 
fasted and fed state simulated intestinal fluids (Paper II). 
 
- Combination of the mucus-PVPA permeation barriers with an in vitro lipolysis model 
to predict in vivo drug absorption from lipid-based formulations (Paper III). 
 
- Development of a simultaneous lipolysis-permeation in vitro model able to correlate 
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3 Summary of papers 
 
3.1 Paper I 
 
The aim of Paper I was to include an artificial mucus layer on top of the PVPA in vitro 
permeability barriers to develop a mucus-comprising model mimicking the environment 
of the intestinal mucosa able to distinguish between drugs with different physicochemical 
properties and between different liposomal formulations. 
 
 
A buffered dispersion of mucin type III from porcine stomach was used to simulate the 
mucus layer, and the integrity of the PVPA barriers was tested in the presence of mucin 
dispersions with different concentrations (10, 20 and 40 mg/mL) by evaluating the 
permeability of a highly hydrophilic fluorescent marker (i.e. calcein) and the electrical 
resistance across the barriers at the end of the permeation experiment. Both calcein Papp 
and electrical resistance did not vary in the presence and absence of the tested mucin 
dispersions, suggesting that the barriers maintained their integrity in such conditions. The 
maintained structural functionality of the barriers was also confirmed by confocal laser 
Figure 3.1: Overview of the experimental setup for Paper I 
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scanning microscopy (CLSM) and by the assessment of lipids loss in the presence and 
absence of mucin dispersions. 
The viscosity assessment of the different mucin dispersions revealed that viscosity 
increased with increasing mucin concentration, pointing out at the Newtonian character 
of the analyzed dispersions. Because of the similarity in terms of viscosity and impact on 
barrier integrity for all the prepared mucin dispersions, mucin 10 mg/mL was chosen for 
further permeation studies. Moreover, the choice of the thickness of the mucin dispersion 
applied on top of the barriers was made by comparing the permeability of naproxen in 
the presence of different mucin dispersion volumes (mucin 10 mg/mL). 50 µL of mucin 
dispersion was chosen as the standard volume to be used in further permeation studies 
to allow a complete and uniform coverage of the barriers since drug permeation did not 
vary in the presence of different mucin volumes (20-50 µL). 
The permeation of five model compounds was tested in the presence and absence of 
mucin 10 mg/mL to study the impact of mucin on drug permeation and to evaluate if the 
barriers were able to discriminate between drugs with different physicochemical 
properties. The Papp of the analyzed drugs confirmed the ability of both the PVPA and the 
mucus-PVPA barriers to distinguish drugs with different characteristics, and the presence 
of mucin on top of the barriers led to a decrease in drug permeability. 
The permeation of three compounds from solution, plain, chitosan-coated and PEGylated 
liposomes was studied to evaluate if the mucus-PVPA barriers were able to differentiate 
between different formulations. The obtained results showed that formulations with 
positive zeta potential (i.e. chitosan-coated liposomes) led to lower drug permeation 
compared to negatively charged ones, suggesting that the mucus-PVPA model had the 
potential to discriminate mucopenetrating from mucoadhesive liposomes. 
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3.2 Paper II 
 
The aim of Paper II was to implement the donor compartment of the mucus-PVPA barriers 
with intestinally relevant pH conditions and fed/fasted state SIFs to provide a drug 
permeation tool able to mirror the human intestinal environment. 
 
 
The integrity of the mucus-PVPA barriers was evaluated by the assessment of calcein 
(highly hydrophilic marker) Papp and of the electrical resistance across the barriers in the 
presence of different pH conditions (i.e. pH 5.5, 6.2 and 7.4) and of commercially available 
fasted and fed state SIFs (namely, FaSSIF and FeSSIF version V1 and V2). The results 
obtained showed that the barriers were stable in all the tested pH conditions and in the 
presence of fed state SIFs (FeSSIF V1 and V2), whereas their integrity was impaired in the 
presence of fasted state SIFs (FaSSIF V1 and V2). These findings were confirmed by the 
analysis of lipids lost from the PVPA barriers in the presence of the different SIFs. The 
permeability of a more lipophilic drug in the presence of FaSSIFs and FeSSIFs was also 
tested. Even though in the presence of the fasted media the electrical resistance 
suggested barrier impairment, the permeability of the chosen compound did not 
significantly increase compared to the fed ones. Moreover, for the lipophilic compound, 
Figure 3.2: Overview of the experimental setup for Paper II 
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the presence of the mucin dispersion on top of the PVPA barriers led to a decrease in 
permeability, which was not observed in the case of calcein. 
The rheology of the mucin dispersion used on top of the PVPA barriers (i.e. mucin 10 
mg/mL) was tested at pH 5.5, 6.2 and 7.4, and the results displayed a non-Newtonian 
(shear-thinning) behavior for the mucin dispersion at pH 5.5 and a Newtonian character 
at pH 6.2 and 7.4. 
Five model compounds were chosen to cover both acidic and basic features in order to 
test their pH-dependent solubility and permeability. The solubility of acidic compounds 
was found to be higher with a pH increase due to a higher degree of ionization at pH 
higher of their isoelectric point. Conversely, the permeability of these compounds 
decreased with a pH increase, whereas the Papp of a basic compound increased with the 
pH. The described pH-dependent trend was especially visible in the absence of the mucin 
dispersion on top of the PVPA barriers.  
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3.3 Paper III 
 
The aim of Paper III was to couple the mucus-PVPA barriers, used to determine drug 
permeation, with in vitro intestinal lipolysis. This was done to determine whether drug 
solubilization upon lipolysis of three fenofibrate-containing SNEDDSs would impact drug 
permeation, and how drug solubilization and permeation would correlate with in vivo drug 




In this study, biosimilar mucus was utilized as the mucus-simulating source instead of 
mucin 10 mg/mL. This choice was made to account for most of the components found in 
intestinal mucus, not only mucins. Firstly, the functionality of the PVPA barriers was tested 
in the presence of biosimilar mucus, SNEDDS, digesting enzymes (i.e. pancreatin from 
porcine pancreas) and combinations of the three. The results obtained showed that the 
PVPA barriers were particularly stable in the presence of biosimilar mucus when SNEDDSs 
were placed on top of the barriers, thus this layer was present for all further permeation 
experiments. 
SNEDDSs digestion was carried out using the in vitro intestinal lipolysis model, and the 
ability of three different fenofibrate-loaded SNEDDSs of solubilizing fenofibrate during in 
Figure 3.3: Overview of the experimental setup for Paper III 
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vitro lipolysis was evaluated. The data obtained demonstrated that the SNEDDSs wherein 
the drug was originally present in solubilized form in the formulation (both below and 
above its  equilibrium solubility in the SNEDDS) led to high drug solubilization upon in vitro 
lipolysis, while the SNEDDS where the drug was originally present in suspension caused 
lower drug solubilization. The drug solubilization results obtained by utilizing in vitro 
lipolysis failed to correlate with in vivo absorption data (i.e. AUC) published in the literature 
for the same SNEDDSs. 
The permeation of free fenofibrate across the mucus-PVPA barriers before and after in 
vitro lipolysis of the three different SNEDDSs was studied. The concentration of the drug 
in the donor compartment of the mucus-PVPA barriers was the same for all three 
formulations to enable the comparison between drug permeation promoted by the three 
different SNEDDSs. The results obtained highlighted that drug permeation was highest in 
the case of the SNEDDS where fenofibrate was solubilized in the formulation above its 
equilibrium solubility. This permeation resulted higher than the one connected to the 
SNEDDS where the drug was solubilized below its equilibrium solubility. The lowest drug 
permeation was linked to the SNEDDS where the drug was present both solubilized and 
also in suspension.  
The AUCs resulting from the mass transfer of free fenofibrate across the mucus-PVPA 
barriers over time for the three SNEDDSs were compared to in vivo AUCs obtained from 
the plasma drug concentration curve in rats found in the literature for the same 
fenofibrate-loaded SNEDDSs. The Level D correlation between the in vitro results obtained 
in this study and the in vivo data was excellent (R2 > 0.9), demonstrating the ability of the 
combined in vitro lipolysis―mucus-PVPA permeation model to predict in vivo drug 
absorption for the chosen formulations. 
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3.4 Paper IV 
 
The aim of Paper IV was to add the high throughput (HTP) in vitro lipolysis model (i.e. a 
pH-stat-independent lipolysis model) on top of the mucus-PVPA barriers to allow the 
construction of a system where in vitro lipolysis of fenofibrate-loaded SNEDDSs and 
fenofibrate permeation could take place simultaneously. 
 
 
The same three SNEDDSs evaluated in Paper III were studied to compare the results 
obtained by the use of the combined in vitro lipolysis―mucus-PVPA permeation model 
with the ones obtained with the developed simultaneous model. The high buffer capacity 
of the HTP intestinal medium allowed to keep the pH constant during in vitro lipolysis of 
SNEDDSs, ensuring the optimal pH condition for the activity of the lipase used in the 
study. The distribution of fenofibrate in the aqueous and pellet phase formed upon in 
vitro lipolysis was in accordance with the data presented in Paper III and with already 
published data regarding the same SNEDDSs. This evidence highlighted the ability of the 
developed model to produce results in line with the conventional in vitro lipolysis model, 
while being independent from a pH-stat apparatus. As previously shown in Paper III, the 
Figure 3.4: Overview of the experimental setup for Paper IV 
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fenofibrate solubilization results collected in this study failed to correlate with in vivo 
absorption data (i.e. AUC) published in the literature for the same SNEDDSs. 
The permeation of fenofibrate was studied both in the absence and presence of 
simultaneous in vitro lipolysis, and in both cases the SNEDDS that led to the highest drug 
permeation potential was the one where fenofibrate was solubilized in the formulation 
above its equilibrium solubility. However, a difference in formulation ranking regarding 
fenofibrate permeation was found when comparing the remaining two SNEDDSs in the 
absence and presence of lipolysis. In fact, when lipolysis was not occurring, the SNEDDS 
where the drug was present suspended at a supersaturated concentration led to higher 
drug permeation compared to SNEDDS where the drug was solubilized below its 
equilibrium solubility. On the contrary, upon lipolysis, the mentioned two SNEDDSs led to 
the same drug permeation. The change in SNEDDSs ranking found in this study was also 
observed in an in vivo study where fenofibrate absorption from the same SNEDDSs was 
studied both when lipolysis was occurring and when this process was inhibited by the 
addition of the lipase inhibitor orlistat. 
The Level D correlation between the AUCs resulting from the mass transfer of free 
fenofibrate across the mucus-PVPA barriers over time for the three SNEDDSs and the in 
vivo AUCs obtained from the plasma drug concentration curve in rats found in the 
literature for the same SNEDDSs resulted to be excellent (R2 > 0.98). Moreover, the in vitro 
results correctly predicted the change in formulations ranking taking place in vivo when 
lipolysis was occurring compared to when it was inhibited by the presence of orlistat. 
Overall, this study proves the suitability of the developed model in predicting drug 
absorption in vivo for the chosen fenofibrate-loaded SNEDDSs. Moreover, the model 
demonstrates to be especially relevant because of its ability to simultaneously assess in 
vitro lipolysis and permeation and because of its independence from a pH-stat apparatus.
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4 Results and discussion 
 
The need for an in vitro model able to predict oral drug absorption and simulate the 
intestinal environment has become ever so evident in the past decades [42, 102]. To 
answer the above-mentioned need, this thesis focused on the development of an in vitro 
model that could be employed to study drug permeation in the presence of an intestinally 
relevant environment. The construction of the model was stepwise. Firstly, the already 
established PVPA barriers were implemented with the addition of a mucus layer to 
simulate the intestinal mucosa, leading to the development of the mucus-PVPA barriers 
(Paper I). Secondly, intestinally relevant pH conditions and simulated intestinal fluids were 
added to the mucus-PVPA model to account for their impact on drug absorption (Paper 
II). Further, the assessment of drug permeation was coupled with in vitro lipolysis to 
produce a combined model capable of mimicking this intestinal process and to unravel 
the impact of lipid digestion on the permeation of drugs contained in LBFs (Paper III). 
Finally, the combined model was modified to permit in vitro permeation and lipolysis to 
occur simultaneously (Paper IV). 
 
4.1 From a naked to a mucus-covered in vitro permeation barrier – simulation of 
the intestinal mucosa (Paper I-II) 
 
To simulate the mucus layer covering the intestinal epithelium, Paper I and II focused on 
the preparation and characterization of a mucin dispersion which was utilized to evaluate 
the impact of this mucus component on drug permeation. 
 
4.1.1 Simulation of the intestinal mucus 
 
The mucin dispersions employed in Paper I and II to simulate the intestinal mucus were 
composed of mucin from porcine stomach type III in a buffered solution. The rationale 
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for the exclusion of the other mucus components (i.e. proteins, lipids, DNA and cellular 
debris) from this mucus model was that the focus of the two studies was to specifically 
evaluate the impact of mucin on drug permeation. The sole inclusion of mucin is 
particularly relevant as this component is known to be playing a key role in the barrier 
function of the mucus layer, contributing to its the gel-like properties [10, 17-19] and 
preventing the diffusion of exogenous particles thanks to its size and interaction filtering 
properties [15, 24]. The choice of mucin from porcine stomach type III was made because 
this commercially available product proved to resemble human mucins [25], and its 
preparation avoids the degradation that typically occurs in the case of mucin from porcine 
stomach type II, which can alter the gel-forming properties of this glycoprotein [27]. As 
both mucin concentration and mucus pH vary along the intestine [102], the viscosity of 
different mucin dispersions was tested to characterize the mucus model prior to its 
addition on top of the PVPA barriers. In particular, the viscosity of mucin 10 mg/mL pH 
5.5/6.2/7.4, mucin 20 mg/mL pH 7.4 and mucin 40 mg/mL pH 7.4 was studied in Paper I 
and II, and it is depicted in Figure 4.1.  
As can be observed in Figure 4.1, an increase in mucin concentration corresponded to an 
increase in viscosity, which is to be expected due to the higher gel-forming potential at 
higher mucin concentration [157, 177]. Moreover, the mucin dispersions at pH 7.4 and 6.2 
exhibited a rather Newtonian character (i.e. constant viscosity at increasing shear rates), 
whereas the mucin dispersion at pH 5.5 displayed a non-Newtonian nature (i.e. shear-
thinning behavior), which better corresponds to the shear-thinning behavior of the mucus 
found in vivo [160, 178]. This pH-dependent shift in mucin rheology and increase in 
viscosity is thought to be due to a sol-gel transition occurring when the pH goes from a 
neutral to a more acidic one. In particular, at neutral pH the ionization of the acidic groups 
in the mucin glycosylated side chains (e.g. sialic acid) is able to produce electrostatic 
interactions, which lead to the formation of a random coil. Instead, when the pH 
decreases to a more acidic one, mucins exhibit an extended rod-like conformation due to 
the unfolding and exposure of their protein core (i.e. hydrophobic region), which leads to 
non-covalent crosslinking within the mucin structure and provides stabilization of water 
molecules and formation of a viscous gel [16, 27].  






Moreover, the resemblance of mucin from porcine stomach type III to human mucus has 
been confirmed in the study by Teubl and colleagues [69], where it was found that in both 
cases the gel structure resulted into a network of parallel and crossing mucins. Because 
of the resemblance between human mucus and the mucin dispersion utilized in Paper I 
and II, this mucus model was used on top of the PVPA barriers to simulate the 
environment of the intestinal mucosa. 
 
4.1.2 PVPA barrier integrity in the presence of mucus 
 
Prior to the assessment of drug permeation, the integrity of the PVPA barriers was 
evaluated in the presence of the mucin dispersions mentioned in Section 4.1.1. The 
integrity of the PVPA barriers is typically evaluated by studying the permeability (Papp) of 
the highly hydrophilic fluorescent marker calcein (CAL), together with the measurement 
of the electrical resistance across the barriers at the end of the permeation experiment 
[133]. Barriers that lead to CAL Papp below 0.06 · 10-6 cm/s and to electrical resistance 
Figure 4.1: Viscosity of mucin dispersions at different mucin concentration (10, 20 
and 40 mg/mL) and pH (5.5, 6.2 and 7.4). 
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above 290 Ω · cm2 are considered intact (Figure 4.2, dotted lines) [133-136]. An increase in 
CAL Papp above the mentioned limit is thought to be associated to the formation of excess 
aqueous pores in the PVPA barriers, causing higher permeation for hydrophilic molecules 




The results collected in Paper I and II regarding CAL Papp and electrical resistance across 
the barriers prove that the PVPA barriers were able to maintain their integrity in the 
presence of different i) pH conditions (i.e. pH 5.5, 6.2 and 7.4) and ii) mucin dispersions 
(mucin 10, 20, 40 mg/mL) (Figure 4.2). The quantification of phospholipids lost by the PVPA 
barriers in the presence and absence of the different mucin dispersions also suggested 
that the barriers were intact in all tested conditions. Moreover, confocal laser scanning 
microscopy (CLSM) analyses showed that no significant aqueous channels were formed 
in the presence of the utilized mucin dispersions. These findings are of crucial importance, 
Figure 4.2: Calcein Papp and electrical resistance across the PVPA barriers 
in the presence and absence of mucin (10, 20 and 40 mg/mL) at pH 5.5, 6.2 
and 7.4. The results are indicated as mean ± SD (n = 6). 
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as they confirm the possibility of safely utilizing the model for the screening of drug 
permeability in the mentioned intestinally relevant conditions. Furthermore, the 
mentioned results suggest that it is possible to compare the results obtained in the 
presence and absence of the mucus model. On another note, the presence of the mucin 
dispersions on top of the PVPA barriers did not cause significant changes in CAL Papp 
compared to their absence, suggesting that CAL was able to freely diffuse through this 
layer (Figure 4.2). These findings could be related to the fact that hydrophilic compounds, 
such as CAL, usually exhibit low affinity for mucus and they are able to reach the 
permeation membrane without being highly affected by its presence [160]. 
 
4.1.3 Selection of the mucus model used for permeability studies 
 
The permeability of compounds with different physicochemical properties (i.e. atenolol 
ATN, ibuprofen IBP, indomethacin IND and naproxen NPR) was studied in the presence of 
different mucin dispersions (i.e. mucin 10, 20 and 40 mg/mL, pH 7.4) to determine if a 
difference in drug Papp would be observed at varying mucin concentrations, and to define 
which mucin dispersion would be used in further studies. 
As can be observed in Figure 4.3, a consistent trend in drug Papp with increasing mucin 
concentrations could not be observed. In particular, even though a significant decrease in 
Papp could be observed for all the tested drugs in the presence of the mucin dispersions, 
the permeability decrease was not proportional to the mucin concentration. Therefore, 
the increase in mucin viscosity with increasing mucin concentration described in Section 
4.1.1 did not seem to significantly impact drug permeation. Because of this, and because 
the aim of the study (Paper I) was to identify a simple mucus model, mucin 10 mg/mL was 
chosen as the preferred dispersion for further permeation experiments. When designing 
the preferred mucus model to use on top of permeation barriers, it is important to 
cautiously consider not only its composition (e.g. components and their concentration), 
but also the volume to utilize. To this regard, it has been reported that the mucus layer in 
the intestine and colon ranges from 50 to 450 µm [66] and that this can vary according to 
the prandial state [21]. Therefore, different mucin 10 mg/mL volumes (20, 22, 25 and 50 
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µL) were placed on top of the PVPA barriers, leading to various thicknesses (580-1450 µm, 
right Y-axis Figure 4.3), to assess their impact on the permeability of NPR. The chosen 
volumes had to both permit the complete coverage of the PVPA barriers and the 
simulation of in vivo mucus thickness. As can be observed in Figure 4.3a, NPR Papp 
significantly decreased in the presence of all the different mucus volumes compared to 
its absence; however, a change in permeability was not observed between the tested 
volumes. Due to the absence of statistical difference in NPR Papp in the presence of 
different mucin dispersion volumes, 50 µL was chosen as the preferred volume for further 
studies even though it led to high thickness, as it allows a homogeneous coverage of the 




Figure 4.3: Papp of ATN, IBP, IND and NPR in the presence and absence of different mucin 
dispersions (10, 20 and 40 mL), and Papp of NPR in the presence of different volumes of mucin 10 
mg/mL on top of the PVPA barriers (Figure 4.3a). The results are indicated as mean ± SD (n = 3). 
* Statistically significant difference (p < 0.05) in drug Papp between the absence and presence of 
mucin dispersions. 
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4.2 Use of the mucus-PVPA barriers to distinguish between different drugs and 
formulations (Paper I and II) 
 
Once the mucus-PVPA model was established (Section 4.1.1-4.1.3), it was used to 
determine how the presence of the hydrophilic mucus layer would affect the permeability 
of drugs with different physicochemical characteristics (Table 4.1) both from solution and 
from different liposomal formulations. 
 
Table 4.1: Physicochemical characteristics of the compounds studied in Paper I and II. 
Compound  MW (g/mol) pKa Log P Log D7.4d BCS class 
CAL  622.55 1.8/9.2a -1.71b - - 
ATN  266.34 9.54b 0.16d -1.03 III 
IBP  206.29 4.45b 3.97d 0.81 II 
IND  357.80 4.42c 4.27d 0.77 II 
MTP  267.36 9.56b 1.88d 0.16 I 
MTR  171.16 2.62e -0.02d 0.14 I 
NPR  230.26 4.15b 3.18d 1.70 II 
   
                          a [133]; b [137]; c [138]; d [179] 
 
4.2.1 Assessment of drug permeability from solutions (Paper I and II) 
 
As can be observed in Figure 4.4, drug permeability varied both according to the 
physicochemical characteristics of the drug and to the presence or absence of mucus. In 
particular, drugs with low Log D7.4 (Table 4.1) generally displayed lower permeation 
potential (e.g. ATN) compared to drugs characterized by a more lipophilic nature (e.g. 
NPR). Moreover, when the Log D7.4 of two different drugs was comparable (e.g. IND-IBP 
and MTP-MTR), physicochemical properties such as the drug molecular weight (MW) 
seemed to influence drug permeation.  In fact, it was found that smaller molecules led to 
higher Papp compared to larger ones. Furthermore, the Papp results were found to be in 
accordance with the fraction absorbed in humans (Fa %). For instance, the fraction 
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absorbed in humans for ATN (Papp 1.15 ˑ 10-6 cm/s; Fa % 55; [137]) resulted to be much 





Additionally, the presence of mucin 10 mg/mL led to a decrease in Papp for all of the 
analyzed drugs, and this decrease varied according to the specific drug. To this regard, it 
has been previously demonstrated that the mucus layer can impair the diffusion and 
sequential permeation of both hydrophilic and lipophilic drugs thanks to hydrophobic, 
electrostatic and hydrogen bond mediated interactions, and that this impairment is in fact 
drug-specific [21, 24, 67, 180]. 
Thus, the described findings confirm i) the capability of the (mucus-)PVPA barriers to 
discriminate between different drugs and ii) the fact that drug permeability is compound-
specific and depends on the environment to which the drug is presented. 
Figure 4.4: Papp of ATN, IBP, IND, MTP, MTR and NPR in the presence and 
absence of mucin 10 mL (pH 7.4). The results are indicated as mean ± SD (n = 3). 
* Statistically significant difference (p < 0.05) in drug Papp between the absence 
and presence of mucin dispersions. 
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4.2.2 Assessment of drug permeability from liposomal formulations (Paper I) 
 
To successfully deliver drugs through the oral route of administration it is necessary to 
design an appropriate drug delivery system able to i) incorporate the drug, ii) carry it to 
the targeted site and iii) release it to allow its absorption. One of the delivery strategies 
utilized to enable oral drug absorption is the one based on drug loading into 
mucoadhesive or mucopenetrating formulations. In fact, mucoadhesive systems are able 
to prolong the resident time of the formulation at the mucosal site, improving the delivery 
of drugs to the mucosal membrane, whereas mucopenetrating systems easily cross the 
mucus layer, directly presenting the drug to the epithelial site [80].  Liposomal 
formulations are a type of drug delivery system that has been investigated for such 
purposes. The advantages of these delivery systems are mainly related to the fact that 
they can incorporate both hydrophilic and lipophilic drug (in their aqueous core and 
phospholipid bilayer, respectively) and to their potential mucoadhesive and 
mucopenetrating properties obtained through their surface modification [181-185]. 
Liposomes have been used both for oromucosal drug delivery [81] and for GI delivery of 
drugs [181], even though in the second case the acidic and digesting environment of the 
GI tract can be an obstacle for the optimal performance of such delivery systems. 
Therefore, since in vitro permeability models should be used to study the potential of such 
delivery systems, the mucus-PVPA barriers were utilized to assess the permeability of 
drugs loaded into different liposomal formulations. The liposomal formulations were 
chosen as model mucoadhesive/mucopenetrating systems. Specifically, MTR, IND or NPR 
were loaded into plain, chitosan-coated and PEGylated liposomes to assess the effect of 
the different formulations on drug permeation. These liposomal formulations were 
chosen as chitosan-coated liposomes are known for their mucoadhesive properties [21], 
whereas PEGylated liposomes are known for their mucopenetrating potential [186-188]. 
Liposomal diameter, polydispersity index (PdI), zeta potential and drug entrapment 
efficiency (EE %) of the prepared liposomes are summarized in Table 4.2. As can be 
observed in Table 4.2, the three types of liposomal formulations (i.e. plain, chitosan coated 
and PEGylated) exhibited differences in diameter and zeta potential not only according to 
their surface modification, but especially to the drug incorporated. For instance, the 
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chitosan-coating resulted in an increase in zeta potential compared to plain liposomes, 
but this did not result into a positive zeta potential for all the investigated formulations. 
Moreover, the drug entrapment efficiency was also found to be drug-dependent (Table 
4.2). The dependence of the described liposomal characteristics from the incorporated 
drug is supposedly related the location of the drug inside the liposome (i.e. aqueous core 
for hydrophilic drugs, phospholipid bilayer for lipophilic drugs) [182-185, 189, 190]. 
 
Table 4.2: Size, zeta potential and drug entrapment efficiency of the prepared liposomes. The 











MTR plain  202.52 ± 2.24 0.52 -2.13 ± 1.34 2.82 ± 0.14 
MTR coated  162.27 ± 8.44 0.63 1.91 ± 0.24 2.78 ± 0.01 
MTR PEGylated 105.40 ± 5.11 0.20 -4.38 ± 0.519 2.58 ± 0.20 
IND plain  140.85 ± 5.87 0.27 -24.75 ± 0.35 83.30 ± 3.88 
IND coated  134.15 ± 18.74 0.30 -18.68 ± 1.53 73.87 ± 4.03 
IND PEGylated 96.22 ± 5.11 0.23 -10.60 ± 0.34 77.81* 
NPR plain 146.30 ± 13.15 0.28 -2.32 ± 1.20 26.15 ± 2.19 
NPR coated  138.10 ± 4.38 0.38 0.19 ± 0.50 37.43 ± 5.79 
NPR PEGylated  128.00 ± 6.36 0.18 -10.89 ± 2.13 23.58 ± 0.31 
  *One batch was prepared  
 
The characterization of the prepared liposomes is crucial to understand the impact of 
these formulations on drug permeation, especially in the presence of the negatively 
charged and hydrophilic mucus layer. In fact, it has been proved that positively charged 
particles are able to interact with the mucus layer, highly negatively charged ones are 
repulsed by it, whereas slightly negative or neutral particles are usually interacting with 
this layer to a low extent, leading to their free diffusion through it [81]. Thus, only 
positively and highly negatively charged particles lead to a slowed down diffusion through 
mucus, possibly causing lower drug permeation [17, 25, 191]. The lower drug permeation 
caused by the positive zeta potential related to the chitosan coating can be seen for both 
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MTR and NPR in Figure 4.5. In fact, it can be observed that, in the presence of mucin 10 
mg/mL, MTR and NPR permeation was significantly lower in the case of chitosan-coated 
liposomes compared to plain and/or PEGylated liposomes (Figure 4.5). On the other hand, 
all liposomes containing IND exhibited a negative zeta potential, thus not causing a 
difference in drug permeation between the different formulations. However, it should be 
noted that the extent of drug permeation across a barrier does not depend exclusively on 
the interaction between the formulation and the mucus layer, but also on factors such as 
i) the release of the drug from the formulation, ii) the diffusion of the free drug through 
the mucus layer, iii) the drug permeation potential across the specific barrier, and most 
importantly iv) on the equilibrium of the drug between the formulation and the medium 
in which it is found. 
 
 
Figure 4.5: Papp of MTR, IND, and NPR in the presence and absence of mucin 10 
mL (pH 7.4) from solution and different liposomal formulations. The results are 
indicated as mean ± SD (n = 3). *Statistically significant difference (p < 0.05) in 
drug Papp between plain/PEGylated liposomes and chitosan-coated ones. 
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4.3 Simulation of the intestinal environment on top of the mucus-PVPA barriers 
(Paper II) 
 
Drug absorption in the intestine can vary according to the environment to which the drug 
is exposed. For instance, acidic drugs are better absorbed at acidic pH, while the opposite 
is true for basic drugs [54], and it has also been demonstrated that lipophilic drugs are 
better absorbed in a fed state compared to a fasted one [8]. Thus, it is crucial that an in 
vitro model designed to predict drug absorption is able to mimic the characteristics of the 
intestinal environment. For this reason, the mucus-PVPA barriers were used to assess 
drug permeation at intestinally relevant pH and in the presence of fasted and fed state 
SIFs.  
 
4.3.1 Solubility-permeability interplay in the presence and absence of mucus 
 
As previously mentioned, drug solubility and permeability directly affect drug absorption 
in the GI tract. This is especially true in the case of ionizable compounds, as they depend 
on the pH that the drug is presented to [54]. To this regard, previous findings have 
emphasized the importance of determining the solubility-permeability trade-off for 
(novel) drugs [192, 193]. Therefore, in Paper II the use of an intestinal medium which 
exclusively simulated the intestinal pH made it possible to infer if a pH-dependent trend 
could be observed in terms of drug solubility and permeability. Five model drugs were 
chosen to cover different physicochemical characteristics (Table 4.1), and their solubility 
and permeability (both in the presence and absence of mucin 10 mg/mL) was tested at 
pH 5.5, 6.2 and 7.4. The medium used corresponded to level 0 in the biorelevance levels 
proposed by Markopoulos and colleagues [103] (Section 1.2.1).  
As can be observed in Figure 4.6, for acidic drugs such as IBP, IND and NPR, characterized 
by a pKa around 3-4, the solubility increased with an increase in pH, while their 
permeability had the opposite trend (decreasing Papp at increasing pH). The same trend 
was not visible for MTR (pKa 2.62), since both its solubility and permeability did not 
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significantly change with the pH. The different pH-dependent trend between MTR and 
IBP/IND/NPR can be ascribed to the fact that for MTR the pH conditions tested were far 
from its isoelectric point.  In the case of the basic drug MTP, the solubility decreased with 
the increase in pH, while MTP Papp increased within the pH range tested.  
 
 
Figure 4.6: pH-dependent solubility (black diamond) and Papp in the presence (white triangle) 
and absence (white circle) of mucin 10 mg/mL for IBP, IND, NPR, MTP and MTR. The results are 
indicated as mean ± SD (n = 6). 
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The observed trends are in line with the pH partition hypothesis, which affirms that 
ionizable compounds display higher solubility when their ionized form is the predominant 
one, while their permeability is higher when the drugs are in their unionized form [51]. 
These trends are furthermore in accordance with other in vitro and in silico studies [48, 
55, 194-196]. Additionally, a general decrease in drug Papp could be observed in the 
presence of mucin 10 mg/mL, and the influence of pH was less evident in the presence of 
this layer on top of the PVPA barriers (Figure 4.6). The decrease in the pH-effect on drug 
permeability in the presence of the mucus layer could be connected to the fact that 
mucins themselves exhibit a pH-dependent ionization, especially associated to their 
abundance in acidic functional groups (i.e. sialic acid) [81]. As observed in Figure 4.1, 
changes in pH can affect the rheological properties of mucin, and this can impact the 
diffusion and permeation of drugs. Therefore, the collected results suggest that drug 
permeability in the presence of such layer does not only depend on the drug ionization, 
but also on the pH-dependent behavior of mucin. Even though the results depicted thus 
far highlight the importance of simulating the intestinal mucus and the pH condition in 
this GI compartment, other components present in the intestinal fluids (e.g. bile salts, 
dietary lipids, lipid digestion products etc.) are as essential when studying drug 
permeation, particularly in the case of PWSDs. Therefore, the impact of fasted and fed 
state SIFs on drug permeation was assessed with the use of the mucus-PVPA barriers. 
 
4.3.2 Use of fasted and fed state SIFs with the mucus-PVPA barriers 
 
The composition of the intraluminal fluids found in the small intestine can vary according 
to the prandial state (i.e. fasted or fed state), and these differences can affect the 
absorption of drugs [29]. For this reason, different version of fasted and fed state SIFs 
(namely, FaSSIF and FeSSIF) have been developed and have proved to be useful for the 
determination of drug solubility and permeability in several studies [143, 145, 149]. 
Because of their usefulness, the commercially available FaSSIF and FeSSIF were utilized in 
the mucus-PVPA setup to evaluate their compatibility with the PVPA barriers and their 
potential use in drug permeability studies. 
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 Mucus-PVPA barriers integrity in the presence of simulated fluids 
 
The compatibility of two versions (V1 and V2) of FaSSIF and FeSSIF with the (mucus-)PVPA 
barriers was determined by calculating CAL permeability and by measuring the electrical 
resistance across the barriers in the presence of the chosen SIFs. As can be observed in 
Figure 4.7, the presence of fasted state SIFs on top of the PVPA barriers led to CAL Papp 
above and electrical resistance below the standard limit both in the presence and absence 
of mucin 10 mg/mL, suggesting a certain level of barrier impairment. On the other hand, 
fed state SIFs did not cause an increase in CAL Papp nor decrease of electrical resistance 




The discussed results were confirmed when the release of barrier phospholipids to the 
donor compartment of the PVPA barriers was determined in the presence of the different 
Figure 4.7: Calcein Papp and electrical resistance across the PVPA barriers after addition of 
FaSSIF or FeSSIF (V1 or V2) in the donor compartment of the PVPA barriers in the presence 
and absence of mucin 10 mg/mL. The results are indicated as mean ± SD (n = 6). 
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SIFs. In fact, it was found that fasted state SIFs caused significantly higher phospholipid 
loss compared to the negative control (i.e. phospholipid loss in the presence of PBS pH 
7.4 on top of the PVPA barriers) (Figure 4.8). On the other hand, fed state SIFs did not lead 
to higher phospholipid loss compared to the same control. Even though the fasted state 
SIFs led to higher barrier impairment compared to fed ones, they did not cause complete 
barrier disruption as in the case of Triton 0.5% (positive control), confirming the ability of 
the barriers to withstand their presence to a certain degree. 
 
 
The different impact on the functionality of the PVPA barriers in the presence of the fasted 
compared to fed state SIFs could be ascribed to their different composition. In fact, the 
two types of SIFs differ both in terms of their buffer composition (FaB and FeB) and of the 
bile salts and lecithin concentrations (Table 4.3). The results depicted in Figure 4.8 show 
that the fasted buffer V1 alone was able to cause significant increase in phospholipid loss, 
whereas the same could not be observed for V2. On the other hand, the phospholipid loss 
caused by V1 and V2 fasted state SIFs could results from the interactions between the 
micelles formed in such media and the PVPA barriers. The composition of fasted 
Figure 4.8: Phospholipids lost in the donor compartment of the PVPA barriers in the presence of 
PBS pH 7.4 (negative control) Triton X-100 0.5% (positive control), fasted and fed state buffers 
(FaB and FeB respectively) and fasted and fed state SIFs (FaSSIF and FeSSIF, respectively). The 
results are indicated as mean ± SD (n = 6). *Statistically significant difference (p < 0.05) in 
phospholipids loss compared to PBS pH 7.4. 
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compared to fed state SIFs can cause the formation of different vesicular structures, 
which can in turn have a different effect on the integrity of the barriers. To this regard, 
Riethorst and colleagues have demonstrated how the micellar/vesicular structures 
formed in fasted and fed state SIFs can differ according to their bile salts/lecithin 
concentration [33]. Specifically, fasted state SIF showed to be characterized by both small 
and medium sized micelles (10-50 nm), fed state SIF V1 mainly contained medium micelles 
(20-50 nm), and fed state SIF V2 showed high abundance of larger structures (50-200 nm) 
[33]. The mentioned differences in vesicular size could be the reason for the 
incompatibility of the fasted state SIFs with the PVPA barriers. 
 
Table 4.3: Composition of fasted and fed buffers (FaB/FeB) and SIFs for both version 1 (V1) and 
version 2 (V2) media. 



















- 3.00 - 3.00 - 15.00 - 10.00 
Lecithin (mM) - 0.75 - 0.20 - 3.75 - 2.00 
Glycerol monooleate 
(mM) 
- - - - - - - 5.00 
Sodium oleate (mM) - - - - - - - 0.80 




28.40 28.40 - - - - - - 
Sodium chloride (mM) 106 106 68.60 68.60 203 203 126 126 
Sodium hydroxide 
(mM) 
8.70 8.70 101 101 101 101 82.00 82.00 
Glacial acetic acid 
(mM) 
- - - - 144 144 - - 
pH 6.5 6.5 6.5 6.5 5.0 5.0 5.8 5.8 
Osmolarity 
(mOsm/kg) 
 270  180  670  390 
Buffer capacity 
(mM/dpH) 
 12  10  76  25 
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 Drug permeability with fasted and fed state SIFs 
 
The permeability of one BCS class II drug (IBP) was tested in the presence of both fasted 
and fed state SIFs to determine whether the different media would lead to differences in 
drug permeability. 
Firstly, Figure 4.9 displays that the electrical resistance across the barriers in the presence 
of the fasted state SIFs was below the acceptable limit, in line with the results depicted in 
Figure 4.7. Even though these results indicated a certain level of barrier impairment, IBP 
permeability did not seem to drastically change in the presence of fasted state SIFs 
compared to the control (PBS pH 6.2) as it was observed in the case of CAL Papp (Section 
4.3.2.1). These findings suggest that the changes in the structure of the barriers in the 
presence of fasted state SIF could be related to an increase in aqueous pores, which can 
impact the permeation of hydrophilic compounds (i.e. CAL) to a higher extent compared 
to more lipophilic ones (i.e. IBP) [133]. In the case of fed state SIFs, the electrical resistance 
across the barriers measured at the end of the permeation experiment indicated correct 
barrier functionality (Figure 4.9). Because of the electrical resistance differences in the 
fasted compared to the fed conditions, a comparison of IBP permeability could not be 
carried out. Moreover, minor differences in drug Papp could be observed with the fed state 
SIFs compared to the control (PBS pH 5.5), whereas a significant decrease in IBP 
permeability was observed in all fed conditions in the presence of mucin 10 mg/mL 
compared to its absence (Figure 4.9). The same decrease in Papp in the presence of mucin 
10 mg/mL was not observed in the case of CAL (Figure 4.7), highlighting the fact that this 
additional layer was able to particularly affect the permeability of a more lipophilic 
compound. This evidence stresses the importance of the inclusion of a mucus layer on 
top of permeation membranes especially when evaluating the absorption potential of 
lipophilic drugs. Moreover, when it comes to lipophilic drugs which exhibit a high affinity 
for the colloidal structures found in the intestinal fluids, other processes (e.g. enzymatic 
degradation) can affect drug solubilization and permeation [33].  





4.4 Combination of in vitro intestinal lipolysis with in vitro drug permeation 
(Paper III) 
 
Loading of drugs into LBFs is one of the commonly used strategies for the oral delivery of 
PWSDs. LBFs are able to increase drug bioavailability thanks to their drug solubilization 
and supersaturation effect, their inhibition of drug precipitation and enhancement of 
lymphatic transport [36, 45, 83, 84, 86]. However, because of their lipid nature, the 
performance of LBFs can be affected by physiological processes such as the digestion (i.e. 
lipolysis) occurring in the small intestine. This, together with the variability in affinity 
between PWSDs and the colloidal structures found in the intestinal fluids, can have a 
substantial impact on drug absorption and should be considered carefully. Therefore, 
Paper III focused on the combination of the mucus-PVPA permeation model with the in 
vitro intestinal lipolysis model previously developed by Zangenberg [109]. In particular, 
Figure 4.9: IBP permeability from PBS solutions (controls) and from fasted and fed state 
SIFs (FaSSIF and FeSSIF, respectively). The results are indicated as mean ± SD (n = 6). 
*Statistically significant difference (p < 0.05) in IBP Papp between the presence and absence 
of mucin 10 mg/mL on top of the PVPA barriers. 
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three SNEDDSs (namely super-SNEDDS solution, SNEDDS, super-SNEDDS suspension) 
containing the PWSD fenofibrate were the chosen LBFs in this study. Prior to the in vitro 
permeation study, the compatibility of the PVPA barriers with the digesting environment 
was studied. Additionally, this study utilized biosimilar mucus as the mucus-simulating 
source to not only account for mucins (as in Paper I and II), but to also consider the other 
components present in intestinal mucus.  
 
4.4.1 Mucus-PVPA barrier integrity in the presence of a digesting environment 
 
The compatibility of the PVPA barriers with biosimilar mucus, fasted intestinal medium, 
SNEDDS and digesting SNEDDS was evaluated in the previously mentioned manner 
(assessment of CAL Papp and measurement of electrical resistance across the barriers). 
Since the commercially available FaSSIF negatively impacted the PVPA barrier 
functionality, another fasted state intestinal medium was chosen for this study 
(composition: bile bovine 2.95 mM; calcium chloride 1.40 mM; maleic acid 2.00 mM; 
sodium chloride 146.80 mM; S-PC 0.26 mM; Tris 2.00 mM; pH 6.5). The fasted medium 
was chosen to exclusively assess the impact on drug solubilization and permeation of the 
lipid digestion products originating from the lipolysis of SNEDDS. 
As can be observed in Figure 4.10, the barriers maintained their integrity in all the tested 
conditions except one, namely the presence of SNEDDS on top of mucus-naked barriers. 
In fact, in this case, CAL permeability was significantly (p < 0.05) above the upper Papp limit 
and below the lower electrical resistance limit. However, the presence of biosimilar mucus 
on top of the barriers seemed to shield them from the impairing events connected to the 
presence of SNEDDS (Figure 4.10). Interestingly, the same trend could not be observed 
when digesting SNEDDS were added on top of the barriers. In fact, digesting SNEDDS did 
not cause an increase in CAL Papp/decrease in electrical resistance in the absence of 
biosimilar mucus. However, since the presence of biosimilar mucus proved to protect the 
barriers from SNEDDS, this layer was used in all further permeation experiments. The 
difference in barrier compatibility between SNEDDS and digesting SNEDDS could be 
connected to the different structures formed in these two conditions. In fact, SNEDDS 
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prior to lipolysis usually display a rather homogeneous and distinctive structure (i.e. nano-
emulsion droplets), while after the addition of lipases they tend to form different colloidal 




Figure 4.10: A) Calcein Papp and electrical resistance across the PVPA barriers in the presence and 
absence of biosimilar mucus BM, fasted medium, SNEDDS and digesting SNEDDS. The results are 
indicated as mean ± SD (n = 12). The permeability experiments were performed in the presence of 
PBS pH in the acceptor side of the PVPA barriers. B) Pictorial representation of the experimental 
conditions used in the study. 
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Table 4.4: Equilibrium solubility of fenofibrate in different acceptor media, together with CAL 
permeability and electrical resistance across the PVPA barriers in the presence of such media. The 
results are indicated as mean ± SD (n = 3). 
 
Acceptor medium Equilibrium solubility of 
fenofibrate (nmol/mL) 




Control (PBS pH 7.4) 0.48 ± 0.03 0.059 ± 0.013 727.43 ± 143.51 
DMSO 10 mg/mL 0.59 ± 0.08 0.050 ± 0.010 577.00 ± 50.60 
DMSO 40 mg/mL 0.82 ± 0.01 a 0.030 ± 0.001  702.70 ± 158.70 
BSA 1% w/v 14.19 ± 0.13 a 0.210 ± 0.030 b 60.60 ± 7.30 c 
BSA 4% w/v 58.02 ± 0.49 a 0.450 ± 0.030 b 44.90 ± 6.30 c 
Tween 20 5 mg/mL 116.71 ± 5.73 a 0.370 ± 0.030 b 116.70 ± 7.30 c 
a Statistically significant difference (p < 0.05) in drug equilibrium solubility compared to the control 
b CAL Papp above to the acceptable upper limit (0.06 · 10-6 cm/s) 
c Electrical resistance across the PVPA barriers below the acceptable lower limit (290 Ω · cm2) 
 
Due to the poor aqueous solubility of fenofibrate, different PVPA acceptor media were 
evaluated to promote higher drug transfer across the barriers and thereby allow a better 
quantification of the permeated drug. Table 4.4 displays the studied media and the 
connected drug solubility. Moreover, the compatibility of the barriers with the same 
media was evaluated by calculating CAL Papp and measuring the electrical resistance 
across the PVPA barriers. According to the results obtained, DMSO 40 mg/mL was chosen 
as the medium to be used in further permeation studies since it was the only one which 
both provided higher fenofibrate solubility compared to the control (PBS pH 7.4) and did 
not impair the functionality of the barriers (Table 4.4). The other studied solutions (i.e. BSA 
1 and 4% w/v, Tween 20 5 mg/mL) were not suitable as acceptor medium due to their 
barrier impairment effects (Table 4.4). Thus, DMSO 40 mg/mL was used as the acceptor 
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4.4.2 In vitro intestinal lipolysis of fenofibrate-loaded SNEDDSs 
 
Three fenofibrate-loaded SNEDDSs were prepared in this study in order to obtain i) 
SNEDDS where the drug was solubilized in the formulation below its equilibrium solubility 
(75% of the drug equilibrium solubility in the SNEDDS preconcentrate), ii) super-SNEDDS 
solution where fenofibrate was solubilized above its equilibrium solubility (150% of the 
drug equilibrium solubility in the SNEDDS preconcentrate) and iii) super-SNEDDS 
suspension where the drug was present both solubilized in the formulation and 
suspended in it (150% of the drug equilibrium solubility in the SNEDDS preconcentrate). 
The ability of the three SNEDDSs to maintain the drug solubilized upon in vitro lipolysis 
was evaluated. In particular, the distribution of fenofibrate between the aqueous and 
pellet phase forming after addition of pancreatin from porcine pancreas (i.e. lipolysis 
initiator) was assessed. To allow for comparison, the lipolysis experiments were carried 
out so that the amount of fenofibrate in the lipolysis vessel would be the same for the 
three formulations; as a result of this, the amount of SNEDDS preconcentrate (i.e. the 
mixture of oil, surfactant, co-surfactant and co-solvent) in the lipolysis vessel varied 
according to the tested formulation. For instance, SNEDDS contained fenofibrate 
corresponding to 75% of the drug equilibrium solubility in the SNEDDS preconcentrate, 
and it had to be added in a double amount in the lipolysis vessel compared to super-
SNEDDS solution and suspension (both containing fenofibrate corresponding to 150% of 
the drug equilibrium solubility in the SNEDDS preconcentrate). 
As shown in Figure 4.11, super-SNEDDS suspension led to the highest degree of drug 
precipitation, which significantly increased overtime, while super-SNEDDS solution had a 
lower amount of drug found in the pellet phase and SNEDDS produced little to no 
precipitation. The ability of SNEDDS to better maintain the drug solubilized in the aqueous 
phase compared to the super-SNEDDSs is most likely connected to the fact that double 
the amount of SNEDDS was added to reach the same fenofibrate amount in the lipolysis 
vessel as the one of the super-SNEDDSs; this led to the presence of double the amount of 
SNEDDS preconcentrate in the medium and to a higher drug solubilization effect. 
Moreover, not only the amount of SNEDDS preconcentrate, but also the nature of the 
loaded drug proved to be important. In fact, in the case where fenofibrate was present 
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both solubilized and suspended in the formulation (i.e. super-SNEDDS suspension) a 
higher degree of drug precipitation was observed.  
 
 
The results discussed thus far are in accordance with previously published data from 
Michaelsen and colleagues [168], where the ranking of the same three SNEDDSs in terms 
of drug plasma concentration after in vitro intestinal lipolysis was in line with the one 
presented above. In the mentioned study, the amount of drug in the aqueous phase upon 
Figure 4.11: Relative amount (%) of fenofibrate found in the aqueous (blue) and pellet (purple) 
phase before initiation (0 min) and after 30 minutes of in vitro lipolysis for SNEDDS, super-
SNEDDS solution and super-SNEDDS suspension. The results are indicated as mean ± SD (n = 4). 
Pictorial representation of the drug distribution in the aqueous and pellet phase (bottom). 
*Statistically significant (p < 0.05) difference between 0 and 30 minutes of in vitro lipolysis. 
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lipolysis of the three SNEDDSs was compared to the amount absorbed in vivo after oral 
dosing in rats, and a lack of IVIVC was found [168]. These results negated the hypothesis 
that the amount of drug in the intestinal lumen (represented by the amount of drug in 
the aqueous phase in the lipolysis vessel) corresponds to the amount able to reach to the 
blood stream. In fact, as can be observed in the pictorial representation in Figure 4.11, the 
drug is found in the aqueous phase both free in solution (i.e. available for absorption) but 
also associated to the colloidal structures forming after lipolysis of SNEDDSs and present 
in the intestinal medium (i.e. not available for absorption)[120, 174]. The more the 
colloidal structures, the more of the PWSD will be likely to be solubilized in them, the 
higher the chance that data obtained using the in vitro lipolysis leads to an overestimation 
of the drug available for absorption (e.g. SNEDDS in Figure 4.11, left side).  Regarding this 
matter, it is known that colloidal structures have a finite capacity to solubilize a specific 
drug [92]. Thus, in the case of SNEDDS, a higher amount of SNEDDS preconcentrate leads 
to the formation of more colloidal structures, which have a higher drug solubilization 
capacity compared to super-SNEDDS solution, since half the amount of colloidal 
structures are present in the lipolysis medium. 
 
 
Figure 4.12: Correlation between amount of fenofibrate in the aqueous phase after lipolysis of 
SNEDDS (black square), super-SNEDDS solution (grey circle) and super-SNEDDS suspension (white 
triangle) and in vivo AUC in rats after oral administration of the same SNEDDSs obtained from 
Michaelsen and colleagues [168]. 
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Since the analysis of the amount of drug present in the aqueous phase does not 
specifically give information on the amount of free drug available for absorption, a 
permeation step is necessary to separate this fraction from the one associated with the 
above-mentioned colloidal structures. The non-correspondence between the in vivo data 
and the in vitro drug solubilization results (i.e. fenofibrate found in the aqueous phase) 
was also observed when the data obtained in the present study was compared to the in 
vivo one collected by Michaelsen and colleagues [168]. In fact, a poor correlation was 
found between the two (R2 = 0.397) (Figure 4.12). 
 
4.4.3 Permeation of fenofibrate using the mucus-PVPA barriers  
 
Samples obtained from the in vitro lipolysis experiments (i.e. after initiation of lipolysis 
with the addition of pancreatin from porcine pancreas) were transferred on top of the 
mucus-PVPA barriers to evaluate the permeation of free fenofibrate from the three 
SNEDDSs in the presence of lipolysis. The PVPA barriers integrity was assessed in parallel 
to the evaluation of fenofibrate permeation by calculating CAL Papp and measuring the 
electrical resistance across the barriers, as previously described. The results obtained 
(data not shown) indicated barrier integrity in all fenofibrate permeation experiments.  
As shown in Figure 4.13, super-SNEDDS solution provided the highest permeation of 
fenofibrate, while SNEDDS led to lower drug permeation and super-SNEDDS suspension 
caused the lowest transfer of the drug across the mucus-PVPA barriers. Thus, the ranking 
in terms of drug permeation was: super-SNEDDS solution > SNEDDS > super-SNEDDS 
suspension. The discrepancy between the ranking described here and the one discussed 
in Section 4.4.2 (i.e. SNEDDS > super-SNEDDS solution > super-SNEDDS suspension) 
highlights how the quantification of drug in the aqueous phase of the lipolysis medium 
does not give enough information on the amount of drug available for absorption. For 
example, the drug distribution results for SNEDDS indicated that all of the drug was in the 
aqueous phase and thus theoretically available for absorption (Figure 4.11). However, this 
hypothesis was not confirmed by the permeation data obtained for the same formulation, 
which exhibited lower drug permeation compared to super-SNEDDS solution (Figure 
4.13). 






As previously discussed, the factor that should be more carefully considered is the 
amount of SNEDDS preconcentrate present during the lipolysis and permeation 
experiments, and how this can affect the amount of drug available for permeation. In the 
case of SNEDDS, it is evident that the double amount of SNEDDS preconcentrate caused 
high drug solubilization (in vitro lipolysis data, Figure 4.11) compared to super-SNEDDS 
solution, and this led to a lower amount of drug available for permeation since most of 
Figure 4.13: A) Cumulative amount of fenofibrate permeated from SNEDDS (black square), super-
SNEDDS solution (grey circle) and super-SNEDDS suspension (white triangle) when samples after 
initiation of lipolysis were transferred on top of the mucus-PVPA barriers. The results are indicated 
as mean ± SD (n = 6). B) Pictorial representation of the permeation experiment. 
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the drug is thought to be associated to the colloidal structures formed in the lipolysis 
medium, as confirmed by the permeation data (Figure 4.13). On the contrary, super-
SNEDDS solution led to higher drug transfer across the mucus-PVPA barriers compared 
to SNEDDS, probably because this formulation enables more drug to be freely solubilized 
and available for permeation thanks to the lower content of SNEDDS preconcentrate. In 
fact, it can be hypothesized that the lower solubilization capacity of the colloidal structures 
formed from super-SNEDDS solution can provide a better supersaturation potential 
compared to the more numerous ones formed from SNEDDS. Thus, super-SNEDDS 
solution has the potential to provide drug supersaturation, which is known to be linked 
to increased drug absorption [85, 197, 198]. Moreover, not only the amount of SNEDDS 
preconcentrate, but also the nature of the drug found in the formulation seemed to affect 
drug permeation. In fact, the presence of fenofibrate both solubilized and suspended in 
super-SNEDDS suspension led to the highest drug precipitation (Figure 4.11) and, as a 
result of this, lowest drug permeation. On the other hand, the presence of fenofibrate in 
a supersaturated and solubilized state (i.e. super-SNEDDS solution) caused the highest 
drug transfer across the mucus-PVPA barriers. Regarding this matter, it is known that the 
drug solubilized in the colloidal structures and in the formulation can serve as a reservoir, 
and this amount can replenish the permeated drug and lead to higher drug absorption 
[199].   Contrarily, the amount of drug precipitated in the case of super-SNEDDS 
suspension has a lower potential for re-dissolution, leading to lower drug permeation. 
 
4.4.4 Correlation of in vivo absorption with in vitro permeation data 
 
The in vitro AUC obtained from the permeation data described in Section 4.4.3 was plotted 
against the AUC calculated from the in vivo plasma drug concentration curve in rats found 
by Michaelsen and colleagues [168] for the same fenofibrate-loaded SNEDDSs. As shown 
in Figure 4.14, the correlation of the in vitro (AUC in vitro permeation) with the in vivo data (AUC 
in vivo absorption) led to an excellent level D correlation after initiation of in vitro lipolysis (R2 > 
0.99), proving the ability of the developed combined in vitro lipolysis―mucus-PVPA 
permeation model to predict in vivo drug absorption for the chosen SNEDDSs. This 
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evidence demonstrates that the use of drug permeation data is essential in the prediction 




Overall, Paper III enabled the construction of an in vitro model where the physiologically 
relevant processes affecting drug absorption were taken into account (i.e. lipolysis and 
permeation) and where the physiology of the intestinal environment and membrane were 
closely mimicked (i.e. intestinal fluids, mucus layer, biomimetic barrier). The combination 
of these factors made it possible to obtain an excellent IVIVC. Nevertheless, even though 
this model proved to be very useful, it failed to capture the simultaneous occurrence of 
lipolysis and permeation, as it relied on the combination of two separate tools. Therefore, 




Figure 4.14: Correlation between amount of fenofibrate permeated across the mucus-PVPA 
barriers after lipolysis initiation for SNEDDS (black square), super-SNEDDS solution (grey circle) 
and super-SNEDDS suspension (white triangle) and in vivo AUC in rats after oral administration of 
the same SNEDDSs obtained from Michaelsen and colleagues [168]. 
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4.5 Simultaneous in vitro lipolysis-permeation (Paper IV) 
 
Formulation digestion and drug permeation both contribute to in vivo drug bioavailability, 
and they both influence one-another in a dynamic manner [36, 45, 83, 86]. Therefore, it is 
of crucial importance to construct in vitro models that are not only able to assess both 
processes, but that also allow them to occur at the same time to account for their dynamic 
interaction.   
      
For this reason, Paper IV focused on the addition of a pH-stat-titrator independent in vitro 
lipolysis model (i.e. the HTP in vitro intestinal lipolysis model) on top of the mucus-PVPA 
barriers (Figure 4.15), allowing for in vitro lipolysis of the three fenofibrate-loaded 
SNEDDSs utilized in Paper IV and drug permeation to occur simultaneously. To test the 
predictive potential of the results obtained with such model in terms of in vivo drug 
absorption, in vitro data was compared to in vivo data in rats for the same SNEDDSs, as 
already mentioned for Paper III. 
 
Figure 4.15: Pictorial representation of the experimental setup used for Paper IV, where HTP in 
vitro lipolysis was added on top of the mucus-PVPA barriers to allow SNEDDSs lipolysis and drug 
permeation to occur simultaneously.  
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4.5.1 Functionality of the HTP in vitro intestinal lipolysis model 
 
The ability of the HTP model of being independent from a pH-stat apparatus is based on 
the fact that the buffer used for the preparation of the intestinal medium in the HTP in 
vitro lipolysis is characterized by a high buffering capacity, which is capable of directly 
neutralizing the pH drop caused by the formation of free fatty acids upon SNEDDSs 
lipolysis. This in vitro model has previously demonstrated to be equivalent to the pH-stat 
lipolysis model, leading to higher time and cost-effectiveness [122], and this was also 
confirmed by the results obtained in Paper IV. In fact, the pH of the intestinal medium in 
which the SNEDDSs were digested was kept around 6.48 ± 0.03 for the whole duration of 
the lipolysis-permeation experiment, in accordance with the results from Mosgaard and 
colleagues [122]. Furthermore, the evaluation of fenofibrate distribution after in vitro 
lipolysis of super-SNEDDS solution, SNEDDS and super-SNEDDS suspension was 
evaluated for a total of 30 minutes to evaluate which formulation would provide the best 
drug solubilization potential and whether these results would be in line with previously 
published data [168] and with the results obtained in Paper III. In addition, fenofibrate 
distribution was assessed both when lipolysis was absent (i.e. sole dispersion of SNEDDS 
in the HTP intestinal medium) and present (i.e. addition of pancreatin from porcine 
pancreas) to study the impact of this process on drug solubilization. Due to the small 
volume in the donor compartment and to difficulties in sampling on top of the mucus-
PVPA barriers, the in vitro lipolysis experiments were carried out in a separate lipolysis 
vessel. As already mentioned in Section 4.4.2, the concentration of fenofibrate in the 
lipolysis vessel and on top of the mucus-PVPA barriers was the same for all three SNEDDSs 
to allow for comparison between the formulations. As shown in Figure 4.16, SNEDDS was 
able to best maintain the drug solubilized in the aqueous phase, whereas for super-
SNEDDS solution and super-SNEDDS suspension drug precipitation was more evident 
both in the absence (Figure 4.16A) and presence (Figure 4.16B) of lipolysis. Interestingly, 
drug precipitation overtime (0-30 minutes) was more evident in the presence of lipolysis 
for super-SNEDDS solution compared to super-SNEDDS suspension (Figure 4.16B), 
presumably due to the instability of the supersaturated system provided by the super-
SNEDDS solution. The described increase in drug precipitation overtime was not visible 
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when lipolysis was not taking place (i.e. sole dispersion of super-SNEDDS solution and 




The fact that drug precipitation significantly increased in the presence of lipolysis 
compared to its absence can be ascribed to the fact that the addition of pancreatin causes 
the formation of colloidal structures, such as micelles and vesicles, which solubilize 
fenofibrate to a different extent compared to the undigested SNEDDSs droplets [121]. To 
this regard, the diameter of SNEDDSs was measured by dynamic light scattering (DLS) in 
Figure 4.16: Relative amount (%) of fenofibrate found in the aqueous (blue) and pellet (green) 
phase overtime A) in the absence (i.e. sole dispersion) and B) presence of in vitro lipolysis for 
SNEDDS, super-SNEDDS solution and super-SNEDDS suspension. The results are indicated as 
mean ± SD (n = 3). Pictorial representation of the drug distribution in the aqueous and pellet 
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Paper IV, and it was found that undigested SNEDDS had a distinct size (50.89 ± 1.09 nm, 
polydispersity index 0.38), whereas the diameter of digested SNEDDS was not definable 
due to high polydispersity (polydispersity index > 0.8), giving an indication of the structural 
differences between the two species. The results described thus-far are in accordance 
both i) with the data described by Michaelsen and colleagues [168], where fenofibrate 
distribution for the same SNEDDSs was evaluated both when lipolysis was inhibited by 
the addition of the pancreatic lipase inhibitor orlistat and in the presence of lipolysis, and 
ii)  with the results described in Paper III. Thus, the data collected in Paper IV confirm the 
equivalence between the HTP lipolysis model and the pH-stat lipolysis model. 
 
 Prediction of in vivo absorption data with the HTP in vitro lipolysis model 
 
According to the results displayed in Figure 4.16, SNEDDS is the formulation able to 
provide most of the drug solubilized in the aqueous phase both in the presence and 
absence of lipolysis, possibly leading to higher drug absorption compared to super-
SNEDDS solution and suspension. However, when plotting the AUCs resulting from the 
amount of fenofibrate found in the aqueous phase overtime for the three SNEDDSs 
against the AUCs resulting from the in vivo plasma exposure of the same SNEDDSs in rats 
(from Michaelsen et al., 2019, [168]) (Figure 4.17), it is evident that drug solubilization data 
failed to predict in vivo drug absorption. The discrepancy between the in vivo and in vitro 
data depicted in Figure 4.17 can be attributed both i) to the fact that in vitro drug 
solubilization experiments produce an overestimation of the amount of drug free for 
absorption and ii) to the absence of an absorptive sink in the in vitro lipolysis experimental 
setup, as already discussed in Section 4.4.2. Specifically, the overestimation of the drug 
available for absorption is connected to the fact that in vitro dispersion/lipolysis 
experiments are not able to distinguish between the fraction of drug actually available for 
permeation (i.e. free drug) and the portion associated to the colloidal structures formed 
upon in vitro dispersion/lipolysis, concomitantly present in the aqueous phase [168]. 
Additionally, it has been proven that precipitation kinetics can be different in the presence 
of an absorption barrier compared to its absence [94, 200].  In fact, in the presence of an 
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absorptive sink the drug has the chance of being removed from the digesting 
compartment, preventing the system from reaching a critical degree of supersaturation, 




4.5.2 Effect of lipolysis on drug permeation and prediction of in vivo drug 
absorption 
 
To evaluate whether the type of formulation and/or the presence of lipolysis would 
influence drug permeation, the transfer of fenofibrate from the donor to the acceptor 
compartment of the mucus-PVPA barriers was determined both in the absence (i.e. sole 
dispersion) and the presence of HTP in vitro lipolysis on top of the barriers for SNEDDS, 
super-SNEDDS solution and super-SNEDDS suspension. To ensure the maintained 
integrity of the barriers through the permeation experiments, an in-line quantification of 
CAL permeability was carried out, and at the end of the permeation experiment the 
electrical resistance across the PVPA barriers was measured. The results obtained in all 
permeation experiments confirmed the correct functionality of the barriers (i.e. CAL 
permeability < 0.06 · 10-6 cm/s; electrical resistance > 290 Ohm · cm2).  
Figure 4.17: Correlation A) in the absence (- lipolysis) and B) presence of lipolysis (+lipolysis) between 
AUCs resulting from the amount of fenofibrate found in vitro in the aqueous phase overtime and 
AUCs resulting from the in vivo plasma curve in rats (from Michaelsen et al., 2019, [168]) for SNEDDS 
(black square), super-SNEDDS solution (grey circle) and super-SNEDDS suspension (white triangle). 
 
 





As shown in Figure 4.18, both the type of formulation and the presence of HTP in vitro 
lipolysis on top of the mucus-PVPA barriers had an impact on the permeation of 
fenofibrate. In particular, super-SNEDDS solution exhibited the highest drug permeation, 
whereas super-SNEDDS suspension and SNEDDS led to lower fenofibrate transfer across 
Figure 4.18: Cumulative amount of fenofibrate permeated from SNEDDS (black square), super-
SNEDDS solution (grey circle) and super-SNEDDS suspension (white triangle) A) in the absence 
and B) presence of HTP in vitro lipolysis on top of the mucus-PVPA barriers. The results are 
indicated as mean ± SD (n = 12). * Statistically significant (p < 0.05) difference between super-
SNEDDS solution and SNEDDS/super-SNEDDS suspension. ** Statistically significant (p < 0.05) 
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the barriers in both the absence and presence of lipolysis. Moreover, super-SNEDDS 
suspension led to significantly higher drug permeation than SNEDDS in the absence of 
lipolysis (Figure 4.18A), while this difference was not visible in the presence of the 
digesting process (Figure 4.18B). The change in fenofibrate mass transfer for SNEDDS and 
super-SNEDDS suspension in the absence compared to the presence of lipolysis can be 
attributed to the different drug solubilization profiles resulting from these two conditions. 
Specifically, in the case of SNEDDS, the presence of lipolysis led to higher drug 
permeation. This was most likely due to the fact that the digesting action of pancreatin 
provides the liberation of fenofibrate from the SNEDDS droplets, causing an increase in 
the fraction of drug free and thus available for permeation. This confirms the hypothesis 
that drug absorption is able to increase only when high drug solubilization is caused by 
an increase in the fraction of drug free in solution [97]. On the other hand, for super-
SNEDDS suspension the presence of lipolysis caused a decrease in drug permeation, 
which can be ascribed to the increased drug precipitation discussed in Section 4.5.1 and 
connected to an increase in the thermodynamic instability of the system [95]. The same 
change in drug permeation observed for SNEDDS and super-SNEDDS suspension was 
described in the study by Michaelsen and colleagues [168], where the three SNEDDSs 
were administered to rats both when lipolysis was occurring and when it was inhibited by 
the use of orlistat (i.e. pancreatic lipase inhibitor). As a result of this, the correlation 
between the in vitro permeation data obtained in Paper IV with in vivo data from 
Michaelsen and colleagues in rats was found to be excellent (R2 > 0.98) both in the absence 
(R2 = 0.988) and presence of lipolysis (R2 = 0.991) (Figure 4.19).  
The excellent correlation with in vivo data can be due both to the correct simulation of the 
intestinal lipolysis and permeation processes, and to the reproduction of the physiological 
structures present in this environment, such as the mucus layer and the permeation 
membrane. In particular, since it has been suggested that mucus plays an important role 
in the stabilization of drug supersaturation when SNEDDSs are orally administered, and 
since this stabilization was found to be drug-specific [98], the inclusion of this layer in an 
in vitro permeation model should be regarded as essential. 
 





Overall, the in vitro model constructed in Paper IV and the results obtained in such study 
highlight the complexity of the processes affecting the performance of SNEDDSs, 
emphasizing that the real driving mechanism of drug absorption is the dynamic 
interaction between drug solubilization, supersaturation and permeation. Even though 
the experiments were carried out only for one type of formulation and one drug, the 
model described in Paper IV shows the potential to be used as a valuable tool for the 





Figure 4.19: Correlation A) in the absence (- lipolysis) and B) presence of lipolysis (+lipolysis) 
between AUCs resulting from the fenofibrate mass transfer across the mucus-PVPA barriers and 
AUCs resulting from the in vivo plasma curve in rats (from Michaelsen et al., 2019, [168]) for SNEDDS 
(black square), super-SNEDDS solution (grey circle) and super-SNEDDS suspension (white triangle). 
 
 










The development of a mucus-comprising in vitro permeability model able to mimic the 
environment of the intestinal mucosa was achieved in the presented work, enabling the 
prediction of in vivo drug absorption. 
In particular, the PVPA barriers proved their correct functionality in the presence of both 
simple (mucin 10 mg/mL) and complex (biosimilar mucus) mucus models, and the 
developed mucus-PVPA model proved its ability to discriminate between the 
permeabilities of drugs with different physicochemical properties and between different 
liposomal formulations. The presence of the mucus layer on top of the PVPA barriers led 
to changes in drug permeability which were related to its interaction with the specific 
drug/formulation. 
Additionally, the pH environment found in the small intestine was simulated on top of the 
barriers, and the permeability results obtained exhibited a distinctive pH-dependent 
trend for ionizable drugs. To increase its biorelevance, the mucus-PVPA model was 
upgraded with the addition of commercially available fasted and fed state simulated 
intestinal fluids, and the barriers proved to be particularly stable in the presence of fed 
state fluids.  
Finally, the addition of the digestive environment affecting the oral administration of drug 
contained in lipid-based formulations was added to the mucus-PVPA model, allowing the 
assessment of the performance of three fenofibrate-loaded SNEDDSs. Initially, the in vitro 
intestinal lipolysis was combined with the mucus-PVPA barriers, and this combined model 
proved to predict in vivo drug absorption data in rats obtained from the literature for the 
same formulations. Subsequently, the addition of a pH-stat-titrator independent in vitro 
lipolysis model (i.e. the HTP in vitro lipolysis model) on top of the mucus-PVPA barriers 
enabled in vitro lipolysis and drug permeation to occur simultaneously. This final lipolysis-
permeation model predicted in vivo drug absorption for the three fenofibrate-loaded 
SNEDDSs to the same extent as the combined model, demonstrating the applicability for 











To validate the prediction potential of the simultaneous in vitro lipolysis-permeation 
model in terms of in vivo drug absorption, a plethora of different lipid-based formulations 
containing drugs with different physicochemical characteristics should be studied with 
the developed model and compared to in vivo data. 
Furthermore, an improved quantification of the amount of drug solubilized in the 
aqueous phase in the donor compartment of the mucus-PVPA barriers should be 
implemented, with a special focus on the distinction between the portion of free drug and 
the one associated with colloidal structures. 
The use of the previously developed PVPAbiomimetic barriers instead of the original PVPA 
could allow the evaluation of the impact of mucus on the permeation of drug contained 
in lipid-based formulations, avoiding the barrier impairment events observed when 
SNEDDSs were applied on top of PVPA barriers in the absence of mucus. 
Once a significant number of drug and formulations have been tested with the 
simultaneous in vitro lipolysis-permeation model and the prediction potential of such 
model has been demonstrated, in silico modelling could be implemented by combining 
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A B S T R A C T
The mucus layer covering all mucosal surfaces in our body is the first barrier encountered by drugs before their
potential absorption through epithelial tissues, and could thus affect the drugs’ permeability and their effec-
tiveness. Therefore, it is of key importance to have in vitro permeability models that can mimic this specific
environment. For this purpose, the novel mucus phospholipid vesicle-based permeation assay (mucus-PVPA) has
been developed and used for permeability screening of drugs and formulations. The model proved to be stable
under the chosen conditions and demonstrated the ability to discriminate between compounds with different
chemical structures and properties. Overall, a decrease in drug permeability was found in the presence of mucus
on top of the PVPA barriers, as expected. Moreover, mucoadhesive (chitosan-coated) and mucopenetrating
(PEGylated) liposomes were investigated in the newly developed model. The mucus-PVPA was able to distin-
guish between the different liposomal formulations, confirming the penetration potential of the tested for-
mulations and the related drug permeability. The mucus-PVPA model appears to be a promising in vitro tool able
to mimic the environment of mucosal tissues, and could therefore be used for further drug permeability
screening and formulation development.
1. Introduction
The mucus layer covering mucosal epithelia is the first barrier en-
countered by many drugs and formulations when entering the body.
This layer could thus potentially limit the effectiveness of most drug
delivery systems (Groo and Lagarce, 2014). Mucus is found on many
epithelial surfaces such as the gastrointestinal tract (GI), the respiratory
tract, the eye and the female genital tract; its composition, structure
and thickness differ according to the different locations in the body
(Friedl et al., 2013; Leal et al., 2017; Sigurdsson et al., 2013). The main
components of mucus are water, glycoproteins (i.e. mucins), free pro-
teins, salts and lipids (Groo and Lagarce, 2014). An important role is
played by mucins, negatively charged glycoproteins (polypeptide
backbone with oligosaccharide side chains), which are secreted by
mucosal glands and goblet cells (Leal et al., 2017; Sigurdsson et al.,
2013). The structure of the mucin gel can hinder the diffusion of drugs
(Boegh and Nielsen, 2015) by two main mechanisms, namely the in-
teraction and size filtering (Olmsted et al., 2001).
Transmucosal drug delivery gained increasing attention in the past
two decades. Various strategies have been proposed to improve the
mucosal permeability of drugs, including mucoadhesive and mucope-
netrating systems, such as liposomes (Leal et al., 2017). Therefore, to
properly tackle the screening of new drugs and optimization of novel
mucosal formulations, it is of key importance to exploit in vitro tools
comprising mucus to better understand its impact on drug permeation
and absorption and to better predict the fate of a drug in vivo. Many
models have been developed to study the effect of the sole mucus layer
on drug permeability, without the presence of an artificial membrane.
Some of them comprise the use of native mucus and some others exploit
the use of commercially available mucins in different types of media
(Khanvilkar et al., 2001; Legen and Kristl, 2001; Matthes et al., 1992).
However, it has to be noted that the removal of mucus from its phy-
siological environment can modify its characteristics (e.g. gel-forming
properties) (Kocevar-Nared et al., 1997). Therefore, it becomes chal-
lenging to produce a model able to mimic physiological mucus, and the
differences between native and reconstituted mucus can lead to varia-
tions in the resulting drug permeability. On the other hand, to date,
several in vitro cell-based (Caco-2 model, Artusson et al., 2001) and
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artificial models (PVPA model, Flaten et al., 2006b; PAMPA model,
Kansy et al., 1998; Permeapad™, di Cagno et al., 2015; AMI-system,
Berben et al., 2017) have been developed for the screening of new drugs
and formulations. Some of those models also include the mucus layer,
such as mucus-producing cell systems (i.e. Caco2/HT29-MTX co-cul-
ture) and cell-based mucosal models with artificial mucus (Boegh et al.,
2014; Lechanteur et al., 2017). Unfortunately, the robustness and re-
producibility of these mucus-including models are not yet well defined.
Therefore, the lack of a reliable artificial in vitro model comprising
mucus remains a considerable limitation for permeability studies tar-
geting the mucosal administration route.
Among the non-cell-based models, the phospholipid vesicle-based
permeation assay (PVPA) has been developed in our group and estab-
lished in the past decade as a predictive and reliable artificial model for
the screening of drugs and optimization of formulations (Flaten et al.,
2006b; Flaten et al., 2011; Kanzer et al., 2010; Naderkhani et al.,
2014a,b). So far, this model has not taken into account the crucial in-
fluence of mucus on the permeation of drugs. Therefore, in this study,
the effect of mucus on drug permeability was assessed and the novel
mucus-PVPA developed and validated. The permeability of five model
drugs (atenolol, ibuprofen, indomethacin, metronidazole and na-
proxen) was investigated. The drugs were chosen to cover a range of
relevant physicochemical properties to challenge the mucus-PVPA’s
ability to distinguish between drugs with different physicochemical
characteristics. Moreover, since nanoparticulate formulations have de-
monstrated great efficacy in in vitro and in vivo experiments (Chen et al.,
2013; Netsomboom and Bernkop-Schnürch, 2016), a focus was put on
the permeation of three selected drugs (indomethacin, metronidazole
and naproxen) from mucoadhesive (chitosan-coated) and mucopene-
trating (PEGylated) liposomal formulations, to better understand the
influence of the mucus layer on the diffusion of the nanocarriers and
permeability of the drugs contained in such delivery systems.
2. Materials and methods
2.1. Materials
Lipoid egg phospholipids E80 (80% phosphatidylcholine), Lipoid
soybean lecithin S100 (> 94% phosphatidylcholine) and Lipoid PE
18:0/18:0 (PEG 2000) were obtained from Lipoid GmbH
(Ludwigshafen, Germany). Acetic acid (≥99.8%), ammonium mo-
lybdate, atenolol, calcein, chitosan (low molecular weight, Brookfield
viscosity 20,000 cps, degree of deacetylation 92%), chloroform, ethanol
(96%, v/v), Fiske-Subbarow reducer, hydrochloric acid, ibuprofen, in-
domethacin, methanol CHROMASOLV®, metronidazole, mucin from
porcine stomach type III (bound sialic acid 0.5–1.5%, partially pur-
ified), naproxen, phosphorus standard solution, potassium phosphate
monobasic, sodium chloride, sodium hydroxide and sodium phosphate
dibasic dodecahydrate were products of Sigma-Aldrich, Chemie GmbH
(Steinheim, Germany). Hydrogen peroxide 30% and titriplex® III were
purchased from Merck KGaA (Darmstadt, Germany). Acetonitrile for
HPLC (gradient grade) was obtained from VWR chemicals (Fontenay-
sous-Bois, France) and sulfuric acid was purchased from May&Baker
LTD (Dagenham, England). All chemicals employed were of analytical
grade.
Plates and Transwell filter inserts (d=6.5mm) were products of
Corning Inc. (Corning, New York). The nitrocellulose membrane filters
(0.65 μm DAWP) were obtained from Millipore (Billerica,
Massachusetts) and the Nucleopore track-etch membrane filters (0.4
and 0.8 μm pore size) were purchased from Whatman (part of GE
Healthcare, Oslo, Norway).
2.2. PVPA barriers preparation
The PVPA barriers were prepared by depositing egg-phospholipid
liposomes on top of cellulose ester filters by centrifugation followed by
a freeze-thaw cycle according to the method previously described
(Naderkhani et al., 2014a).
2.3. Mucus barrier
Different concentrations of mucin (10, 20 and 40mg/mL) were used
as a model for the mucus layer. These suspensions were obtained by the
hydration of mucin from porcine stomach type III with phosphate
buffer saline (PBS) pH 7.40. The viscosity of the mucus was measured at
room temperature on HAAKE ViskoTester 7 plus (Thermo, Hafrsfjord,
Norway) using spindle TL5. In the in vitro permeability studies, the
mucin suspension was directly pipetted on top of the PVPA barriers
before the addition of the drugs or formulation to be tested. The drug
solutions/formulations were carefully added on top of the mucus layer
in the donor compartment in order to prevent mixing of the two layers.
The division of the two layers was visibly distinct.
2.4. In vitro permeability study using the mucus-PVPA
The permeability of different drugs/marker (calcein, CAL; atenolol,
ATN; ibuprofen, IBP; indomethacin, IND; naproxen, NPR; me-
tronidazole, MTR; Table 1) was investigated at room temperature
(23–25 °C) in the presence and absence of mucus following the proce-
dure previously described (Naderkhani et al., 2014a). In the experi-
ments performed in the presence of mucus, 50 μL of mucin 10mg/mL
were added, if not stated otherwise, before the careful addition of drug/
marker. To maintain sink conditions, the inserts were moved to a new
acceptor compartment at certain time intervals for 5 h. After ended
experiment, the electrical resistance was measured to confirm the in-
tegrity of the barriers and the samples collected as previouslu described
(Flaten et al., 2006a,b; Naderkhani et al., 2014a,b)The fluorescent
marker calcein was used to monitor the barriers’ integrity during the
study (Flaten et al., 2006b) and was quantified spectrofluorometrically
on POLARstar Galaxy fluorometer (Fluostar, BMG Labtechnologies,
Table 1
Overview of the model drugs/marker included in this study.
Compound Abbreviation pKa Log P Log D7.4d Charge at pH 7.4b Detection method Wavelength (nm) St.curve (nmol/mL)
Calcein CAL 1.8/9.2a −1.71b – Fluorimeter Ex.: 485 0.10−2.25
Em.: 520
Atenolol. ATN 9.54c 0.16d −1.03 + UV 274 0.20–80.45
Ibuprofen IBP 4.45c 3.97d 0.81 – UV 220 10–150
Indomethacin IND 4.42c 4.27d 0.77 – HPLC-UV 254 0.016−320
Metronidazole MTR 2.62e −0.02d 0.14 0 UV 320 30–200
Naproxen NPR 4.18c 3.18d 1.70 – UV 270 0.8–84
a Flaten et al., 2006b.
b Naderkhani et al., 2014b.
c Avdeef, 2003.
d Benet et al., 2011.
e Rediguieri et al., 2011.
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Offenburg, Germany) at excitation and emission wavelengths of 485
and 520 nm, respectively. The quantification of indomethacin was
carried out by HPLC using a Waters X-select™ CSH ™ C18 (2.5 μm,
3.0×75mm) XP column preceded by a Waters X-select™ CSH ™ C18
(3.5 μm, 3.0× 20mm) guard cartridge on a Waters e2795 Separation
Module connected to a Waters 2489 UV/Visible Detector (Waters,
Milford, Massachusetts, USA) at a wavelength of 254 nm. The mobile
phase consisted of acetonitrile and MilliQ water (60:40, v/v) with 0.1%
glacial acetic acid and the flow rate was set at 0.5 mL/min (retention
time 2.8 min). Atenolol, ibuprofen, metronidazole and naproxen were
quantified spectrophotometrically on SpectraMax 190 Microplate
reader (Molecular Devices Corporation, California, USA) at wave-
lengths of 274, 220, 320 and 270 nm, respectively.
For each compound the experiment was performed at least in tri-
plicates (6 inserts for each parallel) and the apparent permeability
coefficient (Papp) was calculated with the equation derived from Fick’s











where dQ/dt is the slope at the steady-state conditions (nmol/s), A re-
presents the surface area of the PVPA barriers (cm2) and Cd is the
concentration of the compound in the donor compartment (nmol/mL).
As earlier described by our group (Flaten et al., 2006a,b), the con-
centrations of the drugs investigated in the study were chosen in order
to reach a concentration in the acceptor compartment that was below
the solubility limits and thus to obtain sink conditions.
2.4.1. The effect of temperature, mucus volume and mucin concentration on
the permeability of drugs
The permeability of different drugs/marker (Table 1) was measured
in the absence and presence of mucus at 37 °C and compared to the one
obtained at room temperature (23–25 °C) to evaluate possible changes
in permeability due to elevated temperature. Different concentrations
of mucin (10, 20 and 40mg/mL) were tested to estimate their effect on
the permeability of the tested compounds. Moreover, different volumes
of mucus (mucin 10mg/mL; mucus volume range: 20–50 μL) were
deposited on top of the PVPA barriers, and the permeability of na-
proxen was measured to assess if the different mucus’ volumes would
have any effect on the drug’s permeability.
2.5. PVPA barriers – mucus interaction
2.5.1. Phospholipid assay
To determine any changes in the barriers’ integrity caused by the
addition of mucus on top of the PVPA barriers, the amount of phos-
pholipids released after the addition of the mucus layer was measured
by the modified phosphorus assay (Bartlett, 1959) as previously de-
scribed by us (Naderkhani et al., 2015).
2.5.2. 2.5.2. In vitro mucus binding test
The binding potential of the egg-phospholipid liposomes to mucus
was evaluated to determine its interaction with the PVPA barriers. The
study was conducted as previously described (Jøraholmen et al., 2017).
The experiment was carried out in triplicate and the binding efficiency
of mucus to the liposomes was calculated according to Jøraholmen and
colleagues (2017).
2.6. Preparation of liposomal formulations
Three different types of liposomal formulations containing either
indomethacin (IND), metronidazole (MTR) or naproxen (NPR) were
prepared to study the effect of the formulation on drug permeability.
Plain liposomes were obtained using the film hydration technique,
according to the method described by Berginc and colleagues (Berginc
et al., 2014). The liposome dispersion was sonicated for 1min using a
Sonics high intensity ultrasonic processor (Sonics & Materials Inc.,
Newtown, Connecticut) (amplitude setting of 500W/20 kHz processor
40%) to produce a smaller and more homogeneous size distribution.
The sonicated liposome dispersion was stored in the refrigerator for at
least 2 h prior to further use.
Chitosan-coated liposomes were prepared from plain liposomes in
the absence of unentrapped drug as previously described (Jøraholmen
et al., 2014; Naderkhani et al., 2014a). After storage in refrigerator
(4–8 °C) overnight, the pH was measured and adjusted to 7.40.
PEGylated liposomes were prepared using Lipoid S100 (200mg),
PEG 2000 (36.3mg) and the drug (IND, MTR or NPR; 20mg), following
the method described by Jøraholmen and colleagues (Jøraholmen et al.,
2017).
2.7. Characterization of liposomal formulations
2.7.1. Entrapment efficiency and recovery
The encapsulated drug (IND, MTR or NPR) in the different lipo-
somal formulations was separated from the unentrapped drug by dia-
lysis using a dialysis tubing with a MWCO 12–14,000 Da (Medicell
International Ltd., London, UK). The liposomal dispersions (4.2 mL)
were dialyzed against a medium (PBS, pH 7.40) for 6 h at room tem-
perature. The volume of PBS was adjusted to assure the solubility of the
drugs. Aliquots of the dialyzed liposomes were dissolved in MeOH to
free the drug contained in the liposomes and compared with the
amount of drug in the medium (unentrapped drug) to calculate the
entrapment efficiency for the specific drug. Drugs were quantified as
previously described in Section 2.4.
2.7.2. Size analysis and zeta potential measurements
The diameter of the dialyzed liposomes containing different drugs
was determined using a Malvern Zetasizer Nano ZS (Malvern, Oxford,
UK). Two samples for each batch of liposomes were analysed and the
diameters calculated from the mean of three measurements for each
sample. The liposome dispersions were diluted 1:50 (v/v) in PBS pH
7.40 for plain and PEGylated liposomes, and PBS pH 7.40 and acetic
acid 0.1% (1:1 v/v) for the chitosan-coated ones, in order to dilute the
formulations in their own preparation media. The polydispersity index
(PI) of each batch was measured to assess the population’s homo-
geneity.
All liposomal formulations (plain, chitosan-coated and PEGylated)
were diluted 1:10 (v/v) in freshly filtered water (0.2 μm filters) to de-
termine the zeta potential using a Malvern Zetasizer Nano ZS (Malvern,
Oxford, UK). The disposable folded capillary cells (DTS1070) were
cleaned before the loading of the sample using ethanol and filtered
water. Two samples for each batch of formulations were measured in
three parallels at room temperature.
2.8. Statistical analysis
Statistical analysis was done using GraphPad Prism 7.0 software.
Student’s t-test was used to detect significant differences between two
sets of data (p < 0.05). Comparisons between three or more groups
were performed using one-way ANOVA and significance (p < 0.05)
was found out using the Bonferroni multiple comparison post hoc test.
3. Results and discussion
Mucosal tissues, found at various locations in the body, can provide
access to both local and systemic drug administration, and are an in-
teresting barrier considering transmucosal delivery (Leal et al., 2017).
Moreover, mucosal administration is seen as one of the most con-
venient, easy and cost-effective routes (Lechanteur et al., 2017). How-
ever, the mucus layer covering all mucosal tissues represents a barrier
that drugs must overcome to reach deeper epithelia or become ab-
sorbed. Therefore, it is of key importance to develop reliable in vitro
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tools able to evaluate the effect of mucus on drug permeability.
3.1. The effect of mucus on the PVPA barriers
The mucus-PVPA model is expected to provide fast and reliable
means to predict/optimize the permeation of drugs once in contact with
mucosal surfaces. Unpurified mucin type III from porcine stomach was
employed, since this type of mucin has already been exploited in several
other studies (Berben et al., 2017; Griffiths et al., 2010; Jøraholmen
et al., 2017); the molecular weight and structure of pig mucins resemble
human mucins (Groo and Lagarce, 2014). Moreover, its preparation
avoids the degradation that occurs with purified mucin type II; the
degradation often leads to a different mesh structure and related dif-
ferent rheological properties compared to native mucus (Groo and
Lagarce, 2014). To assess whether the mucus-PVPA can provide reliable
evidences on drug permeability, the integrity and functionality of the
barriers were investigated. The permeability of the hydrophilic marker
calcein in the presence of mucus served as a model. Moreover, the effect
of different mucus layer thicknesses on the permeability of a model
drug as well as characterization of the interaction between mucus and
the PVPA barriers were evaluated.
3.1.1. Permeability of a highly hydrophilic marker
The permeability of the hydrophilic marker calcein was investigated
in the presence of different mucin concentrations to study their effect
on permeability. This fluorescent marker provides information on po-
tential aqueous pathways in the PVPA barrier (Flaten et al., 2006b).
Fig. 1 shows that there was no significant change in calcein’s Papp in the
absence or presence of different concentrations of mucin. Considering
mucus’ overall hydrophilicity and negative charge, more hydrophilic
compounds have exhibited lower affinity for mucus compared to hy-
drophobic ones (Boegh et al., 2014). In our case, considering calcein
chemical properties (Table 1), it was not expected that its permeability
should be affected to a great extent by the presence of the mucus layer.
Therefore, the lack of changes in permeability in the presence of mucus
indicates that calcein is free to diffuse through the mucus layer and to
permeate through the PVPA barriers without any considerable inter-
action with this hydrophilic layer. Moreover, as previously stated, no
increase in calcein permeability suggests that the barriers are able to
maintain their integrity in the presence of mucus. Furthermore, the
electrical resistance remained constant in all of the tested conditions
(Fig. 1), also indicating no significant changes in the barriers' integrity.
These findings are of significant importance especially when compared
to the already established cell-based in vitromodels including the mucus
layer such as the Caco-2/HT29-MTX (Hilgendorf et al., 2000). The
major drawback of the Caco-2/HT29-MTX model is related to the de-
crease in transepithelial electrical resistance (TEER) produced by the
introduction of the mucus-producing HT29-MTX goblet cells (Schimpel
et al., 2014). In fact, the presence of these cells lead to a leakier Caco-2
cell monolayer, thus suggesting an uncertain relevance in comparison
of the permeability between the presence and absence of mucus
(Lechanteur et al., 2017). On the contrary, in our case, the addition of
mucus on top of the barriers did not cause any change in electrical
resistance, enabling us to compare values obtained with and without
the addition of the mucus layer.
3.1.2. Characterization of the interaction between mucus and the PVPA
barrier
To assess possible disintegration events taking place in the barrier
when exposed to mucus, the release of phospholipids from the PVPA
barriers into the donor chamber in the presence of mucus (mucin 10
and 40mg/mL) was quantified and compared to the release in the
presence of PBS pH 7.40 on top of the barriers (control). Results showed
that the ratios between the PC released in the presence of 10 and
40mg/mL and the control were 0.95 ± 0.16 and 1.03 ± 0.09 re-
spectively, indicated that no significant difference in phospholipid re-
lease was found in the presence and absence of mucus. This evidence is
in agreement with previous reports on the robustness of the original
PVPA barriers (Flaten et al., 2008) and confirms the maintenance of the
barriers’ integrity and their low degree of interaction with mucus.
To further test the potential interaction between the liposomes in
the PVPA barriers and mucus, a mucin binding test was performed. The
results obtained (data not shown) confirmed a lack in binding between
the two components, especially evident for liposomes with bigger dia-
meter size, comparable to the liposome size on top of the PVPA barrier.
This evidence highlights, once again, the lack of changes produced in
the PVPA barriers by the mucus layer.
The lack of structural changes in the barriers was also suggested by
studies performed using the confocal laser scanning microscopy (CLSM)
(results in Supplementary). The PVPA barriers were investigated to
visually examine if the mucus layer would interfere with the barrier’s
integrity. The micrographs of the cross-sectioned PVPA barriers showed
that no aqueous channels were present throughout the barriers, thus
confirming the intact integrity of the barriers for all the tested condi-
tions, and that calcein was mainly present in the donor side of the PVPA
barrier. These findings are in agreement with previous reports from
confocal studies on the PVPA barrier integrity (Flaten et al., 2006a;
Fischer et al., 2012).
3.1.3. Viscosity, composition and structure of the mucus layer
Since mucin is the major determinant in mucus rheology
(Sigurdsson et al., 2013), the viscosity measurements were performed
to study the effect of different mucin concentrations (Fig. 2). The tested
suspensions exhibited a Newtonian character, with lower viscosity of
mucin in concentration of 10mg/mL compared to the mucin in higher
concentrations. The increase in viscosity with increasing mucin con-
centrations correlates well with the gel-forming effect of mucin
(Grießinger et al., 2015; Dawson et al., 2004). Although the in vivo
mucus layer has been reported to be of non-Newtonian character (vis-
coelastic with shear-thinning properties), studies have reported that the
hydrated mucin type III from porcine stomach exhibits a Newtonian
behaviour (Mackie et al., 2017; Boegh and Nielsen, 2015). Moreover, a
comparison between the viscosity of human saliva and porcine gastric
mucin was proposed by and Park and colleagues (Park et al., 2007).
Both human saliva and animal mucin suspensions exhibited similar
viscosities with increasing shear rates. Furthermore, an increase in
viscosity was found with increasing mucin concentrations, as also found
in our analyses.
As previously stated, the composition and concentration of mucin
vary in the body depending on the location and function of the mucosal
tissue. However, mucin accounts for generally not more than 5% of the
Fig. 1. Papp values for calcein and electrical resistance of the PVPA barriers in the pre-
sence and absence (control) of different concentrations of mucin (10, 20, 40mg/mL). The
results are indicated as mean ± SD (n= 3).
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mucus components (Griffiths et al., 2010). Even though the differences
in viscosity have to be taken into account when developing a new
model, they are only one of the factors affecting the diffusion of drugs
through the mucus (Shaw et al., 2005). For these reasons, mucin in
concentration of 10mg/mL was used as a model for mucus in the
permeability experiments in this study.
The mucus-simulating media used in this study was prepared using
solely unpurified mucin from porcine stomach type III. Constituents
such as lipids, proteins and DNA were not added to keep the mucus-
simulating layer as simple as possible and be a general model for
mucus, since the content of the other components can vary according to
the different site, different species and the specific physiopathological
condition (Lieleg et al., 2010). Our aim was to investigate if the pre-
sence of sole mucin would affect the permeation of the drugs through
the PVPA barriers, and we concluded that it did. However, as reported
by Larhed and colleagues (Larhed et al., 1998), other components can
significantly hinder the diffusion of drugs through the mucus layer. In
particular, the authors found that lipids had a major role in reducing
the diffusion of drugs in native pig intestinal mucus. Moreover, it has to
be kept in mind that a model mucus system made only out of mucin
cannot be considered entirely equivalent to natural mucus, most likely
due to the changes in physico-chemical properties caused by the mucin
isolation procedures (Kocevar-Nared et al., 1997).
With regards to mucus structure, scanning electron microscopy
images of mucin from porcine stomach type III have been obtained by
Teubl and colleagues (Teubl et al., 2013). The authors suggested a
structural similarity between mucin from porcine stomach and human
salivary mucin fibres. The mucus mesh size was also determined for
both samples (pore size up to 0.9 μm for porcine gastric and 0.8 μm for
human mucin). These results can be compared to the ones by Bajka and
colleagues (Bajka et al., 2015), who have investigated ex vivo porcine
mucus and who have estimated the main pore diameter of the mucin
sheets to be around 200 nm. The different results obtained in these two
studies could be traced back to the different sample preparation
methods and different sample origin (Huckaby and Lai, 2017). These
considerations can give us an estimation on how the mucus layer on the
PVPA barriers may look like compared to both human and animal
mucus and on how particles/formulations could diffuse through this
layer, together with the pore size of the mucin mesh. However, it has to
be taken into consideration the fact that the structure and composition
of the mucus layer differs according to different animal species and
different sites of the body (Huckaby and Lai, 2017) and that the mucus-
PVPA model so far is aimed to be established as an artificial model for
mucosal tissues in general.
3.1.4. Permeability study: the effect of the mucus layer thicknesses
To assess possible changes in drug permeability related to different
mucus layer thicknesses on top of the PVPA barriers, the permeability
of naproxen was measured in the presence of different volumes of
mucus (mucin 10mg/mL). The thickness of the mucus layer has been
reported to be around 600 μm in the human stomach and 50–450 μm in
the intestine and colon (Fig. 3, black arrow), although this might vary
depending on fasted and fed state (Boegh and Nielsen, 2015; Shaw
et al., 2005). Also the thickness in the respiratory tract, in the female
reproductive tract and the ocular mucus layer varies according to the
specific site (Huckaby and Lai, 2017; Khanvilkar et al., 2001). For the
naproxen permeability experiment, 20, 22, 25 and 50 μL of mucus,
respectively, were added on top of the barriers and the thickness of the
layer (Fig. 3, shaded area) was calculated from the surface area of the
filter support. Results showed that there was a significant difference in
naproxen's Papp when tested in the presence or absence of mucus (ad-
dressed in section 3.2), but there was no significant variation between
the different mucus volumes/thicknesses. Therefore, even though the
calculated mucus layer thickness for 50 μL of mucin suspension ex-
ceeded the physiological range, it was considered the best volume to
use. This volume assured that the whole surface area of the barriers will
be fully covered with mucus and thus reduced any deviations in the
application volume.
3.2. Permeability of drugs in solution using the mucus-PVPA
Four different model drugs (naproxen, indomethacin, ibuprofen and
atenolol) were used both to evaluate whether the additional mucus
layer would affect their permeability and to further highlight whether
different mucin concentrations (10, 20 and 40mg/mL) would have an
effect on drug permeability. The drugs were chosen to cover a range of
relevant physicochemical properties (Table 1)
Fig. 4 shows that for all drugs there was a significant decrease
(p < 0.05) in permeation with the addition of the mucus layer. This
behaviour was to be expected especially for the more lipophilic drugs
(naproxen, indomethacin and ibuprofen), whereas a decrease in per-
meability was not expected for the more hydrophilic atenolol. However,
Boegh and colleagues (2014) have previously reported a significant
decrease in permeability of the hydrophilic drug mannitol in the pre-
sence of a biosimilar mucus layer on Caco-2 cell monolayer, high-
lighting the fact that mucus can represent a barrier to both hydrophilic
and lipophilic drugs. In fact, it has to be taken into account that there
Fig. 2. Mucin viscosity of three mucin concentrations (10, 20 and 40mg/mL).
Fig. 3. Naproxen Papp (left axis) in the presence of a mucus layer with varying thicknesses
(right axis, shaded area), and compared to the physiological mucus layer thickness (),
dependent on the volume of mucus (mucin 10mg/mL) added to the PVPA. The results are
indicated as mean ± SD (n=3). Statistical significance (p < 0.05) was investigated
with one-way ANOVA using the Bonferroni post hoc test.
*Statistically significant difference in drugs’ Papp in the presence of different mucus vo-
lumes compared to its absence.
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are multiple mechanisms taking place during diffusion of drugs through
the mucus layer before the permeation process, and that especially
mucins’ properties can influence mucus’ barrier characteristics. Mucins
are formed by a polypeptide backbone to which oligosaccharide side
chains are attached, resembling the structure of a bottle-brush. These
two different regions provide mucins with both a hydrophobic (protein
backbone) and hydrophilic (glycosylated regions) nature, which can
affect the diffusion of various types of drugs and formulations (Peppas
and Huang, 2004). Moreover, in Olmsted et al. (2001) it is suggested
that there are two major mechanisms hindering compounds from dif-
fusing through this layer: i) the interaction filtering, dependant on the
electrostatic, hydrophobic forces, hydrogen bonds and specific binding
interactions, and ii) the size filtering properties of the mucin mesh.
However, the overall hydrophilicity of the mucin gel mostly affects li-
pophilic compounds, whereas hydrophilic ones tend to be freer to pe-
netrate through (Boegh and Nielsen, 2015). It has been demonstrated
how lipophilic drugs are able to interact with the non-glycosylated
regions of the mucin macromolecule (naked protein region), which
provide an area for a hydrophobic interaction with the drug. Therefore,
the interaction between a lipophilic drug and mucin’s hydrophobic
region can slow down its diffusion through the mucus layer (Khanvilkar
et al., 2001). On the other hand, for the hydrophilic compounds, their
ionization can be the driving force of the diffusion through the mucus
(Shaw et al., 2005).
In conclusion, the use of differently viscous mucus layers (mucin
concentration of 10, 20 or 40mg/mL) did not lead to differences in
permeability of all of the tested drugs (Fig. 4), even though an increase
in viscosity could suggest a slowed-down diffusion through mucus and a
lower permeability through the barrier. Therefore, since no direct
correlation was found between the concentration of mucin in the mucus
layer and the drugs’ permeability, mucin 10mg/mL was chosen as the
preferred suspension since it was the easiest to handle from a practical
point of view.
Fig. 5 shows the permeabilities of different compounds in the pre-
sence and absence of mucus (no mucin or 10mg/mL mucin suspension,
respectively) at room temperature (23–25 °C) and at the physiological
temperature (37 °C). The permeability of the fluorescent marker calcein
was measured at both temperatures to assure that the barriers would
maintain their integrity in both conditions. In all experiments, the
electrical resistance was found to be in the range reported for the
barriers with maintained integrity (Flaten et al., 2008). The different
Papps of the tested drugs confirmed the ability of the barriers to dis-
criminate between compounds with different chemical structures and
properties (Table 1) both for the original PVPA barriers and for the
novel mucus-PVPA ones. Although some of the chosen drugs had
similar chemical properties, the resulting permeability values were
found to be compound-dependent, confirming that multiple forces are
responsible for the diffusion and permeation of drugs, and that an in
vitro screening model should be able to highlight different character-
istics, especially in relation to mucus-drug interaction. The permeability
of all the tested drugs further increased at 37 °C, most probably due to a
more fluid lipid layer of the barriers and potentially a lower viscosity
connected to the higher temperature. In general, the addition of mucus
on top of the PVPA barriers led to a significant decrease in permeability
at both temperatures as earlier discussed and as expected due to the
intrinsic characteristic of mucus (Sigurdsson et al., 2013).
However, if all drugs/marker would have behaved identically in
presence of the mucus layer compared to its absence, one could con-
clude that the rate-limiting factor could be the different diffusive
pathway length between the original PVPA barriers and the mucus-
PVPA model. Nevertheless, what we have found in our study was that
the permeabilities were linked to the chemical structure and physio-
chemical properties of the drug/marker and to the possible interactions
with the mucus layer. For this reason, we believe that the interaction
with this layer, rather than the longer diffusive pathway, is the im-
portant factor influencing the permeability of the compounds analysed
in this study.
Permeability experiments were also carried out on filters covered
with mucus only (without the phospholipid vesicle barrier), in order to
assess the contribution of the sole mucus layer on the permeability of
the drugs. However, it was found that the filters were not able to hold
the mucus in the donor compartment (58.82 ± 2.57% of the total
amount of mucus that was placed on top of the filters was found in the
acceptor medium after 5 h). Due to this, it was not possible to assess the
contribution of the mucus layer alone and compare it to the PVPA or
mucus-PVPA model.
A correlation between permeability coefficients of model drugs
obtained with the PVPA model, other well known models (such as Caco-
2 and PAMPA) and the fraction absorbed in humans after oral admin-
istration was already assessed in previous studies (Flaten et al., 2006b;
Naderkhani et al., 2014b). The novel mucus-PVPA model was still able
to correctly classify the different model drugs in the same way the
original model did (poorly, moderately and excellently absorbed
drugs), even though Papp values significantly changed with the addition
of mucus compared to its absence.
3.3. Permeability of liposome-associated drugs using the mucus-PVPA
Concerning mucosal administration, nanoparticulate mucoadhesive
and mucopenetrating formulations have demonstrated great efficacy in
Fig. 4. Drug permeability in the presence and ab-
sence of different mucin concentrations (0, 10, 20,
40mg/mL). The results are indicated as mean ± SD
(n=3). Statistical significance (p < 0.05) was in-
vestigated with one-way ANOVA using the
Bonferroni post hoc test.
*Statistically significant difference in drugs’ Papp in
the presence of mucus with different mucin con-
centrations compared to its absence.
M. Falavigna et al. International Journal of Pharmaceutics 537 (2018) 213–222
218
multiple in vitro and in vivo studies, for both local and systemic drug
delivery, confirming their innovative contribution to the pharmaceu-
tical development (Netsomboom and Bernkop-Schnürch, 2016). In
particular, liposomes have been established as promising carriers to
improve the absorption of poorly absorbed drugs and several liposomal
products are already on the market (Allen and Cullis, 2013). Mu-
coadhesive formulations (e.g. chitosan-coated liposomes) can actively
interact with the mucus layer, extending the resident time in the ap-
plication site and increasing the local concentration of the drug con-
tained in the delivery systems (Boegh and Nielsen, 2015). On the other
hand, mucopenetrating formulations (e.g. PEGylated liposomes) are
able to avoid the interaction with the mucus layer, accessing the un-
derlying epithelia in a more effective manner (das Neves et al., 2011;
Lai et al., 2011; Mahmood et al., 2017).
The optimal formulation should be able to assure a high drug con-
centration at the administration site and consequently a concentration
gradient, allowing a passive diffusion across the mucus layer. In this
study, plain, chitosan-coated and PEGylated liposomes have been
chosen as model drug delivery systems to get their diffusive properties
be tested on the novel mucus-PVPA model. We have already tested
mucoadhesive and plain liposomes on the original PVPA (Naderkhani
et al., 2014a). However, we realized the importance of the presence of
mucus to optimize the estimation of the penetration potential of na-
nosystems.
3.3.1. The effect of the delivery system on drug permeability in the mucus-
PVPA
The degree of interaction with mucus largely depends on the size
and surface properties of the delivery system. It has been reported that
by increasing the particle size of a delivery system from 124 to 560 nm
the amount transported in time through the mucus layer significantly
decreases due to a stronger steric impediment (Sanders et al., 2000).
Moreover, Takeuchi et al. (2001) have found that 100 nm liposomes are
able to diffuse through the mucus layer to a higher extent compared to
bigger ones. However, the surface properties of the delivery system
could also dictate its interaction with mucus, making the size the sec-
ondary diffusion driving force. It has been demonstrated that nano-
systems bearing a positive charge are able to actively interact with the
negatively charged mucus layer, producing a mucoadhesion effect (e.g.
chitosan-coated particles) (Mackie et al., 2017), whereas slightly ne-
gatively charged and neutral systems would favour a higher diffusion
ability thanks to their lack of interaction with such layer (e.g. PEGy-
lated particles) (Griffiths et al., 2010; Jøraholmen et al., 2017; Lieleg
et al., 2010). However, the particles that are strongly attracted to
mucus would be completely immobilized, whereas excessively nega-
tively charged particles would be repulsed and unable to diffuse
through such a layer (Groo and Lagarce, 2014; Lieleg et al., 2010).
Lieleg and colleagues have confirmed that particles’ mobility through
the mucus layer is particularly influenced by their surface charge. They
suggested that charged particles can interact via electrostatic interac-
tion with mucin, slowing down their diffusion through the mucus layer
(Lieleg et al., 2010). The authors have compared the diffusion through
mucus of differently functionalised particles at different pHs, and found
out that at neutral pH the diffusion of charged particles was not majorly
hindered compared to that of neutral particles, whereas at pH 3 there
was a significant difference in the diffusion of neutral and charged
formulations. Moreover, according to the results from Lieleg et al., the
zeta potential of the PEGyalted particles changed with the different pH
conditions (neutral surface potential at pH 3 and negative at pH 7,
Lieleg et al., 2010).
Fig. 5. Permeability of different compounds in the
presence and absence of mucin (10mg/mL) at room
temperature (23–25 °C) and at 37 °C. The results are
indicated as mean ± SD (n=3). Statistical sig-
nificance (p < 0.05) was investigated with one-way
ANOVA using the Bonferroni post hoc test.
*Statistically significant difference in drugs’ Papp in
the presence of mucus compared to its absence.
Table 2
Liposomal characteristics. The results are expressed as mean ± SD (n=3).
Formulationa Vesicle size (nm) PI Zeta potential (mV) Entrapment (%)
Plain liposomes containing NPR 146.30 ± 13.15 (100%) 0.28 −2.32 ± 1.20 26.15 ± 2.19
Coated liposomes containing NPR 138.10 ± 4.38 (95.2%) 0.38 0.19 ± 0.50 37.43 ± 5.79
PEGylated liposomes containing NPR 128.00 ± 6.36 (99.8%) 0.18 −10.89 ± 2.13 23.58 ± 0.31
Plain liposomes containing IND 140.85 ± 5.87 (97.6%) 0.27 −24.75 ± 0.35 83.30 ± 3.88
Coated liposomes containing IND 134.15 ± 18.74 (96.5%) 0.30 −18.68 ± 1.53 73.87 ± 4.03
PEGylated liposomes containing IND 96.22 ± 5.11 (98.3%) 0.23 −10.60 ± 0.34 77.81b
Plain liposomes containing MTR 202.52 ± 2.24 (70.1%) 0.52 −2.13 ± 1.34 2.82 ± 0.14
Coated liposomes containing MTR 162.27 ± 8.44 (68.9%) 0.63 1.91 ± 0.24 2.78 ± 0.01
PEGylated liposomes containing MTR 105.40 ± 5.11 (98.6%) 0.20 −4.38 ± 0.519 2.58 ± 0.20
a Naproxen (NPR), indomethacin (IND) and metronidazole (MTR).
b Only one batch was prepared.
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In our study, plain, chitosan-coated and PEGylated liposomes were
prepared incorporating three different drugs, respectively (Table 2).
The size of the liposomes ranged between 100 and 200 nm and the li-
posome dispersions exhibited a bimodal size distribution with varying
polydispersity indexes (PI), depending on the formulation. The zeta
potential varied between the different formulations and was dependant
on the incorporated drug. However, the coating process led to an in-
crease in zeta potential for the chitosan-coated formulations, as ex-
pected (Berginc et al., 2014). It has to be highlighted that the PEGylated
formulations exhibited a negative zeta potential for all the drugs in-
corporated and this characteristic could be of a key importance re-
garding the mucus-penetrating properties (Groo and Lagarce, 2014).
The fact that negatively charged nanocarriers have the characteristics
of being mucopenetrating is also supported by the results from Chen
et al. (Chen et al., 2013). Moreover, the surface potential of PEGylated
liposomes obtained by Jøraholmen and colleagues, confirms the fact
that PEG grafting can produce negatively charged liposomes
(Jøraholmen et al., 2017). The entrapment of the three model drugs
varied depending on their chemical properties. All formulations were
prepared according to the methods reported by Jøraholmen and col-
leagues (Jøraholmen et al., 2014; Jøraholmen et al., 2015; Jøraholmen
et al., 2017). The liposomes prepared in our study exhibited compar-
able characteristics to the ones described in the above-mentioned pa-
pers. In particular, the authors found that PEGylated formulations ex-
hibited a reduced binding efficacy compared to plain and chitosan-
coated ones, whereas chitosan-coated liposomes were binding mucin
significantly more compared to plain ones (Jøraholmen et al., 2017).
As previously stated, the interaction of liposomal formulations with
the mucus layer can be affected by numerous factors, such as the pH of
the physiological environment, pH of the specific formulation and pKa
and related degree of ionization of the associated drug (Groo and
Lagarce, 2014; Jøraholmen et al., 2017; Lieleg et al., 2010; Shaw et al.,
2005). In this study, chitosan-coated formulations were prepared at
acidic pH and were then adjusted to pH 7.40. This process was carried
out to ensure the same pH environment of the liposome-associated drug
for all formulations (plain, chitosan-coated, PEGylated liposomes). This
pH was selected as a model pH, however the next step would be to
adjust it to the targeted mucosal site (e.g. around pH 6 depending on
which part of the intestine or 4.5 for the vaginal site).
The permeability of metronidazole, indomethacin and naproxen
from different liposome formulations (Fig. 6) indicated decreased per-
meability for liposomally-associated drugs compared to drugs in solu-
tion, confirming that liposomes assured a sustained release of the as-
sociated drugs. This is a very important feature considering prolonged
release of drugs at the administration site, e.g. vaginal site (Jøraholmen
et al., 2014).
For metronidazole-containing liposomes, the drug permeability did
not vary between the different formulations in the absence of mucus,
suggesting that the chitosan coating and PEGylation processes had a
negligible effect on drug release from the liposomes compared to the
plain ones, evidence supported by the results obtained by Chen et al.
(2013). However, in the presence of the mucus layer, metronidazole’s
permeability changed according to the type of liposome formulation. In
fact, chitosan-coated liposomes displayed a lower permeability of the
drug compared to the plain ones, suggesting that the potential inter-
action between mucus and the chitosan-coating could slow down the
permeation process of metronidazole, whereas PEGylated liposomes
could easily penetrate through the mucus layer, contributing to a higher
permeability. These results can be also explained by the different zeta
potentials of the three formulations. Chitosan-coated liposomes,
bearing a slightly positive zeta potential, could interact with the ne-
gatively charged mucus leading to a mucoadhesive effect, whereas the
PEGylated liposomes, having a slightly negative zeta potential, could
more freely diffuse through the mucus layer. These results are sup-
ported by the findings of Chen and colleagues (2013), who clearly de-
picted the different mucus penetration potentials of plain phosphati-
dylcholine, chitosan-coated and Pluronic®-modified liposomes in ex vivo
penetration studies. Their in vivo pharmacokinetic study further de-
monstrated that the Pluronic®-modified formulation (bearing a zeta
potential of −4mV) could provide the best oral absorption profile for
the chosen drug, indicating that the ex vivo data correlate well with the
in vivo data.
The indomethacin- and naproxen-containing liposomes, exhibited a
different penetration behaviour; indomethacin-containing plain, chit-
osan-coated and PEGylated liposomes were all found to be negatively
charged (−25, −19 and −10mV, respectively), a feature that could
lead to a lack of significant differences in the diffusion potential of the
formulation and permeability of the drug. On the other hand, for the
naproxen-containing liposomes, the PEGylation lead to an increase in
permeability in the absence of mucus, suggesting an intrinsic penetra-
tion behaviour of the formulation. These deviations from the trends
described above for the metronidazole-containing liposomes can be
ascribed to the complexity of the physicochemical characteristics of the
specific liposomal formulation, highlighting the problem/challenge of
generalization when studying mucus diffusion properties and perme-
ability potentials of different types of formulations (Fabiano et al.,
2017; Netsomboon and Bernkop-Schnürch, 2016). Moreover, we found
that the zeta potential of the liposomes prepared varied according to
the drug incorporated. Therefore, the mucopenetrating or mucoadhe-
sive behaviour could mainly be linked to the specific zeta potential of
the formulation. The permeability of the drugs depends on numerous
factors including the penetration potential of the liposome formulation
through the mucus layer and the interaction with it, the vesicle surface
properties and size, but also the release of the drug from the delivery
system, the chemical and structural properties of the specific compound
and the drug equilibrium between the different layers. This confirms
the high importance and need to have reliable in vitro permeability
models able to predict the effect of mucus on the permeability of both
drugs in solutions and in more complicated formulations.
Fig. 6. Permeability of metronidazole, indomethacin
and naproxen from different liposomal formulations
in the presence and absence of mucin (10 mg/mL).
The results are indicated as mean ± SD (n=3).
Statistical significance (p < 0.05) was investigated
with one-way ANOVA using the Bonferroni post hoc
test.
*Statistically significant difference in drugs’ Papp
between the highlighted bar and all the others or
between 2 different bars.
M. Falavigna et al. International Journal of Pharmaceutics 537 (2018) 213–222
220
4. Conclusions
The novel mucus-PVPA model was developed and exploited to
better mimic the in vivo environment of mucosal tissues by adding a
mucus-simulating layer on top of the PVPA barriers. The reliability of
this upgraded version of the original PVPA model was proven in terms
of the barrier tightness and functionality, and the barriers demonstrated
maintained integrity under the chosen conditions. As expected, the
mucus layer proved to be an additional barrier to the permeation of the
selected drugs. The permeability varied depending on the different
chemical structures and properties of the tested drugs. Moreover, the
mucus-PVPA barriers showed potential towards being able to dis-
criminate between different types of nanodelivery systems. The mucus-
PVPA model was proven as a reliable tool in drug/active compound
screening and can serve in the development and optimization of for-
mulations destined for transmucosal delivery.
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Confocal laser scanning microscopy 
Methods 
Confocal laser scanning microscopy (CLSM) was used to assess possible interactions between the 
mucin suspensions and the PVPA barriers. The barriers were prepared as described in section 2.2 with 
the only exception that 0.2 mol% of the Lipoid E80 was replaced by 1,2-dioleoyl-sn-glycero-3-
phophoethanolamine-N-(Lissamine rhodamine B sulfonyl) (ammonium salt) rhodamine (purchased 
from Avanti Polar Lipids, Inc., Alabama, USA) to visualise the lipids composing the barriers. Calcein 
solution (1.65 mg/mL) was used to produce two suspensions with different mucin concentrations (10 
mg/mL and 40 mg/mL). Before the experiment, 50 µL of either calcein solution or mucin suspensions 
(10 mg/mL and 40 mg/mL) were added to the donor compartment and the system was left to soak for 
three hours in the acceptor wells containing 600 µL of PBS pH 7.4 to visualise possible aqueous 
channels throughout the barriers’ thickness caused by the mucus layer . After soaking, the donor fluids 
were removed and the filters carefully detached from the inserts. The CLSM analysis was performed 
on a Leica TCS SP5 microscope (Leica Microsystems CMS GmbH, Mannheim, Germany) equipped with 
an Argon laser for calcein and a DPSS 561 laser for rhodamine. Laser lines of 488 and 568 nm were 
used to excite calcein and rhodamine, respectively. For calcein, fluorescence was detected in the 
spectral range of 500-550 nm, while rhodamine was detected at 570-610 nm (Ternullo et al., 2017). 
Images were acquired with a 10x0.4 objective taking z-section micrographs (z-step size of 0.25 µm). To 
make sure the defects were not present throughout the whole thickness of the barriers, 420 z-sections 
were analysed for each barrier. The gain, off-set and zoom were kept as constant as possible to 
maintain the same setup for all the micrographs. The micrographs were superimposed using Volocity® 
v.6.3 software (PerkinElmer, MA, USA). 
 
Results 
In a previous study, Flaten and colleagues have analysed via confocal electron scanning microscopy 
the filters composing the PVPA barriers without the addition of the liposomes (Flaten et al., 2006a) 
and used it as a control in order to visualise how aqueous channels look like in the absence of the lipid 
component. By comparing this control to confocal images of the PVPA barriers, they were able to see 
that no significant aqueous channels were present throughout the thickness of the PVPA barriers. In 
our study, we wanted to visualise if the addition of mucus would cause the formation of aqueous 
channels in the PVPA barriers, especially since the high permeability of molecules (in or case the highly 
hydrophilic marker calcein) can be traced back to a significant number or defects and aqueous channels 
in the barriers (Richter et al., 2016). 
Confocal images are shown in Fig. S1 (calcein solution in the donor), Fig. S2 (10 mg/mL mucin 
suspended in calcein solution the donor) and Fig. S3 (40 mg/mL mucin suspended in calcein solution 
in the donor). 
 
Fig. S1. Confocal laser scanning microscopy of the PVPA barrier labelled with rhodamine (red) after soaking for 3 
hours in calcein solution (green). The two micrographs were taken from two different positions in the barrier. 
The white lines mark the placement of the cross-sections a and b shown at the top and bottom, respectively. 
 
Fig. S1 displays the PVPA barrier after exposure to the calcein solution, showing a dominant red 
fluorescence representing the rhodamine-associated PVPA barrier and a green fluorescence of the 
hydrophilic calcein solution. The cross-sections a and b taken in different positions confirm lack of 
aqueous channels through the barrier, suggesting the maintenance of the barrier’s integrity in the 
given condition. This is in agreement with previous CLSM studies of the original PVPA barriers (Flaten 
et al. 2006a). 
 
 
Fig. S2. Confocal laser scanning microscopy of the PVPA barrier labelled with rhodamine (red) after soaking for 3 
hours in mucin 10 mg/mL marked with calcein (green). The two micrographs were taken from two different 
positions in the barrier. The white lines mark the placement of the cross-sections a and b shown at the top and 
bottom, respectively. 
 
Fig. S2 indicates that no aqueous channels were present after the exposure to the lowest concentration 
of mucus suspension.  
 
Fig. S3. Confocal laser scanning microscopy of the PVPA barrier labelled with rhodamine (red) after soaking for 3 
hours in mucin 40 mg/mL marked with calcein (green). The two micrographs were taken from two different 
positions in the barrier. The white lines mark the placement of the cross-sections a and b shown at the top and 
bottom, respectively. 
 
As it can be observed from Fig. S3, calcein was more abundant as compared to previous results (Fig. 
S1 and S2). The first cross-section (a) indicates a barrier similar to the one when PVPA barrier was 
exposed to calcein solution (Fig. S1 and S2). In the second micrograph and cross-section (b) calcein was 
visible in a higher concentration in the donor side of the barrier. However, no significant breaches in 
the barrier were observed, suggesting that the barrier’s integrity was maintained also in the presence 
of the highest concentration of mucus suspension. 
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A B S T R A C T
Intestinal drug absorption following oral administration can be influenced by regional conditions (absorbing
surface area, bacterial flora, motility, pH, mucus thickness) and food intake, all of which affect drug solubility
and permeability. Therefore, it is crucial to assess the impact of these conditions on the drugability of drugs and
formulations. In this study, the ability of the liposome-based mucus-PVPA in vitro permeability model to handle
relevant intestinal pH conditions was evaluated, together with the investigation on the pH-dependent solubility
and permeability profiles of five model drugs. This study additionally evaluated the impact of all commercially
available versions of the fasted and fed state simulated intestinal fluids (SIFs) on the integrity of the barriers, and
the permeabilities of one hydrophilic and one lipophilic compound were examined under these conditions. The
model was found to be well-functioning in all tested pH conditions, and a pH-dependent trend was found for
both solubility and permeability profiles for acidic and basic compounds, according to their degree of ionization.
Moreover, the mucus layer and its pH-dependent viscosity particularly influenced the permeation of more li-
pophilic compounds. The PVPA barriers primarily maintained their functionality in the presence of the fed state
SIFs, and the permeability of the two tested compounds showed to be influenced by their hydrophilicity/lipo-
philicity, their degree of interaction with mucus and by the bile salts and phospholipids content in the SIFs.
Overall, the obtained results highlight the relevance of studying the effect that pH, mucus and SIFs have on
intestinal drug absorption, and suggest the suitability of the mucus-PVPA model for such investigations.
1. Introduction
The small intestine forms the largest part of the gastrointestinal (GI)
tract promoting the absorption of orally administered drugs (Billat
et al., 2017). Its three segments (namely, duodenum, jejunum and
ileum) are characterized by differences in length, absorbing surface
area, bacterial flora, motility, pH and mucus thickness (Billat et al.,
2017). The different regional characteristics can influence the solubility
and permeability of drugs, and thereby their absorption after oral ad-
ministration. For instance, the changes in pH through the length of the
GI tract can influence the ionization of the drugs and thus their in-
testinal absorption, as suggested by the pH partition hypothesis (Shore
et al., 1957). Changes in pH can also affect the hydrophilic mucus layer,
which lines, lubricates and protects the GI tract. This layer is the first
barrier that drugs need to overcome in order to explicate their effect
(Johansson et al., 2013), and changes in pH can affect its structure and
rheology, consequently impacting the diffusion properties of the drugs
through it (Cao et al., 1999; Lieleg et al., 2010).
In addition to the regional physiological changes in the GI tract, the
characteristics and composition of the intestinal fluids vary widely ac-
cording to the pre- or post- prandial state (Clarysse et al., 2009;
Riethorst et al., 2016; Riethorst et al., 2018). In this regard, it has been
demonstrated that bile salts and phospholipids in the human intestinal
fluids can affect drug solubilization, and thus influence permeability
through the intestinal walls (Riethorst et al., 2018). These regional and
nutritional differences can also have an effect on drug absorption in a
different manner according to the intrinsic characteristics of the drug in
consideration and to its formulation features (Augustijns et al., 2014). A
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conspicuous effort has thus been put into simulating the human in-
testinal fluids, and as a result different versions of fasted and fed state
simulated intestinal fluids (FaSSIF and FeSSIF) have been proposed
(Galia et al., 1998; Jantratid et al., 2008).
Since all these variables can affect the absorption of drugs and
formulations, understanding their impact is crucial, especially as oral
drug administration is still regarded as the leading route for drug de-
livery due to its accessibility, great patient compliance and cost-effec-
tiveness (Berben et al., 2018a). To assess the impact of these variables
on drugability (i.e. the ability of a drug to be used as a satisfactory
candidate for oral administration) while avoiding ethical, time- and
cost-consuming issues related to human and animal testing, numerous
in vitro permeability screening models have been proposed (Caco-2
model, Artusson et al., 2001; PAMPA model, Kansy et al., 1998; PVPA
model, Flaten et al., 2006b; Permeapad™, di Cagno et al., 2015; AMI-
system, Berben et al., 2018b). Studies combining different in vitro
permeability models with simulated intestinal fluids (SIFs) have been
carried out by several research groups, and a special focus has been put
on the impact that SIF-driven drug solubilization and permeation have
on drug absorption (Berben et al., 2018b; Bibi et al., 2015; Fischer
et al., 2012; Naderkhani et al., 2015). Other studies have focused on the
impact that pH variations in the intestine have on drug solubility and
permeability, and on the interplay that occurs between the two (Sieger
et al., 2017). The effect of the mucus layer on the permeability of drugs
and formulations has been investigated both with respect to their dif-
fusion through this layer alone (Fabiano et al., 2017; Shaw et al., 2005),
as well as through in vitro barriers in the presence of this hydrophilic
layer (Falavigna et al., 2018; Keemink and Bergström, 2018; Stappaerts
et al., 2018).
In the present study, we aimed to combine all the investigations
discussed above. In particular, we utilised our previously developed
modification of the PVPA (Phospholipid Vesicle-Based Permeation
Assay) barrier comprising mucus (namely, mucus-PVPA, Falavigna
et al., 2018) as a model for the intestinal membrane to move one step
further toward closer mimicking the in vivo environment by studying
the impact that pH and fasted/fed state SIFs have on drug permeability,
as well as their interplay with mucus. The integrity of these liposome-
based barriers was assessed in terms of permeability of a hydrophilic
fluorescent marker and of the electrical resistance across the barriers at
different pH and in the presence of different fasted and fed state SIFs.
Subsequently, the solubility and permeability profiles of five model
acidic/basic compounds were evaluated together with the investigation
on the rheological behaviour of mucus at different pH conditions.
Lastly, the permeability of a hydrophilic marker and a lipophilic BCS
class II drug was examined in the presence of all commercially available
versions of fasted and fed state SIFs.
Overall, the results collected in this study highlight the importance
of assessing the impact that pH, mucus and fasted/fed SIFs have on drug
permeability, and suggest the mucus-PVPA to be a promising tool for
such purpose.
2. Materials and methods
2.1. Materials
Ammonium molybdate, calcein (CAL), chloroform, ethanol (96%, v/
v), Fiske-Subbarow reducer, glacial acetic acid (≥99.8%), hydrochloric
acid, ibuprofen (IBP), indomethacin (IND), maleic acid, methanol
CHROMASOLV®, metoprolol (MTP), metronidazole (MTR), mucin from
porcine stomach type III (bound sialic acid 0.5–1.5%, partially pur-
ified), naproxen (NPR), phosphorus standard solution, potassium
phosphate monobasic, sodium chloride, sodium hydroxide, sodium
phosphate dibasic dodecahydrate, sodium phosphate monobasic
monohydrate and Triton X-100 were products of Sigma-Aldrich Chemie
GmbH (Steinheim, Germany). E80 lipoid egg-phospholipids (80%
phosphatidylcholine) were obtained from Lipoid GmbH (Ludwigshafen,
Germany). Acetonitrile for HPLC (gradient grade) was a product of
VWR chemicals (Fontenay-sous-Bois, France) and sulphuric acid was
purchased from May&Baker LTD (Dagenham, England). Hydrogen
peroxide 30% and Titriplex® III were obtained from Merck KGaA
(Darmstadt, Germany). FaSSIF/FeSSIF/FaSSGF, FaSSIF-V2 and FeSSIF-
V2 powders were purchased from biorelevant.com (Croydon, UK). All
chemicals employed were of analytical grade.
For the preparation of the PVPA barriers, nucleopore track-etch
membrane filters (0.4 and 0.8 μm pore size) were purchased from
Whatman (part of GE Healthcare, Oslo, Norway) and the nitrocellulose
membrane filters (0.65 μm DAWP) were obtained from Millipore
(Billerica, Massachusetts, USA). Transwell filter inserts and plates
(d=6.5mm) were products of Corning Inc. (Corning, New York, USA).
2.2. Drugs pH-dependent solubility studies
The solubility of different drugs (IBP, IND, MTP, MTR, NPR) was
investigated at pH 5.5, 6.2 and 7.4 at room temperature (23–25 °C),
following the method described by Berthelsen et al. (2014).
Briefly, phosphate buffer saline (PBS) was prepared in order to
obtain three buffers with different final pH (5.5, 6.2 and 7.4). 15mg of
drug were dispersed in 15mL of PBS in a 15mL tube, and left to rotate
on a Labinco test-tube rotor (Breda, The Netherlands) for a total of 24 h.
After 1, 4 and 24 h, the tubes were centrifuged for 10min at 4500 rpm
on a Biofuge Stratos thermostated centrifuge (Heraeus Instruments
GmbH, Hanau, Germany), where the temperature was kept between 23
and 25 °C to avoid sample heating and further drug solubilization. 1 mL
of the supernatant solution was further centrifuged for 10min at
13000 rpm on a Biofuge pico centrifuge (Heraeus Instruments GmbH,
Hanau, Germany), in order to provide an additional separation of the
possible undissolved drug, thus making sure that the amount of drug
quantified at the end of the experiment would only be the fraction
dissolved in the aqueous media. The supernatant was diluted and the
amount of drug dissolved was quantified spectrophotometrically on
SpectraMax 190 Microplate reader (Molecular Devices Corporation,
California, USA). The 15mL tubes were vortexed and put back on the
rotor. For each drug and each pH, 2 samples were prepared and ana-
lysed to assess changes in solubility.
IBP, IND, MTP, MTR and NPR were quantified spectro-
photometrically on SpectraMax 190 Microplate reader (Molecular
Devices Corporation, California, USA) at wavelengths of 220, 254, 274,
320 and 270 nm, respectively.
2.3. PVPA barrier preparation
The PVPA barriers were prepared according to the method pre-
viously described by Naderkhani et al. (2014a). Briefly, egg-phospho-
lipids (E80) liposomes were obtained by the film hydration technique
and extruded to obtain liposomes with two different size populations by
means of 0.8 and 0.4 μm pore size filters. The liposomes were then
deposited by centrifugation on top of cellulose ester filters (0.65 μm
pore size), followed by a freeze-thaw cycle to immobilize and fuse the
liposomes to the filter support.
2.3.1. Mucus-PVPA barrier preparation
To assess the impact of the mucus layer on drug permeability, 50 μL
of mucin dispersion were added on top of the PVPA barriers according
to the method previously described by us (Falavigna et al., 2018).
Briefly, mucin from porcine stomach type III was hydrated with PBS
pH 7.4 in order to achieve a final concentration of 10mg/mL or 40mg/
mL. The dispersion was directly pipetted on top of the PVPA barriers
and was left to incubate for 5min prior to the addition of the drug/
marker solution. When the impact of different pH on drug permeability
was investigated, the mucin dispersion was adjusted to the investigated
pH with the use of HCl or NaOH solutions before its addition on top of
the barriers.
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2.3.2. Mucus rheology
Rheology measurements of the mucus prepared with different con-
centrations of mucin (10 and 40mg/mL) as well as at different pH (5.5,
6.2 and 7.4) were performed on a Discovery HR-2 hybrid rheometer
(TA instruments, New Castle, USA) equipped with a Peltier plate en-
vironmental system, a cross hatched 40mm parallel plate geometry,
and a cross hatched lower plate. The sample was placed on the lower
plate, the geometry was lowered to the measuring gap of 1000 μm, and
the system was let equilibrate for 180 s at 25 °C (the same temperature
at which the permeability experiments were performed). The viscosity
of the different mucus simulating dispersions and the stress applied
were measured using a logarithmic flow sweep with steady state sen-
sing, where the shear rate was increased incrementally with 30 points
per decade from 2 to 200 1/s. For each mucin concentration and each
pH, three samples were prepared and measured.
2.4. Simulated intestinal fluids preparation
To study the effect of simulated intestinal fluids (SIFs) on the in-
tegrity of the PVPA barriers and on drug permeability, fasted (Fa-) and
fed (Fe-) state SIFs were prepared according to the standardised pro-
tocol provided by the supplier (biorelevant.com). In this study, two
versions (V1 and V2) of the simulated intestinal powders were used.
Briefly, FaSSIF/FeSSIF/FaSSGF (producing FaSSIF-V1 or FeSSIF-V1),
FaSSIF-V2 or FeSSIF-V2 powder was dissolved in the corresponding
fasted (FaB-V1 or V2) or fed (FeB-V1 or V2) buffer. The compositions of
the different media are depicted in Table 1.
2.5. In vitro permeability studies
The (mucus-)PVPA barriers were used to study the permeability of
different drugs/marker at room temperature (23–25 °C) following the
procedure previously described (Falavigna et al., 2018), in the presence
and absence of a mucus layer at different pH conditions and using
different dissolution media. When the experiment was carried out in the
presence of mucus, 50 μL of mucin dispersion were added on top of the
PVPA barriers and let to incubate for 5min prior to the addition of the
drug/marker in solution. After the drug/marker solution (100 μL) was
added on top of the PVPA barriers/mucus layer, the inserts were placed
in an acceptor compartment containing 600 μL of PBS pH 7.4, simu-
lating the in vivo blood circulation. The inserts were moved to fresh
acceptor compartments after 1, 2, 3, 3.5, 4, 4.5 and 5 h in order to
maintain sink conditions. After 5 h, the samples were collected from the
acceptor compartment prior to their quantification, and the electrical
resistances of the barriers were measured to examine the integrity of
the barriers.
IBP, MTP, MTR and NPR were spectrophotometrically quantified as
described in 2.2. IND was quantified by HPLC-UV at a wavelength of
254 nm (retention time 3.05min; injection volume: 20 μL) using a
Waters X-select™ CSH ™ C18 (2.5 μm, 3.0×75mm) XP column (guard
cartridge: Waters X-select™ CSH ™ C18 3.5 μm, 3.0× 20mm) on a
Waters e2795 Separation Module connected to a Waters 2489 UV/
Visible Detector (Waters, Milford, Massachusetts, USA). The flow rate
was adjusted to 0.5 mL/min and the mobile phase consisted of acet-
onitrile and MilliQ water with 0.1% glacial acetic acid (60:40, v/v).
CAL was quantified spectrofluorometrically at excitation and emission
wavelengths of 485 and 520 nm, respectively, using a POLARstar
Galaxy fluorometer (Fluostar, BMG Labtechnologies, Offenburg,
Germany). Validation parameters, LOD and LOQ for the quantification
of all compounds can be found in the Supplementary Material.
The apparent permeability coefficient (Papp) was calculated with the













where dQ/dt expresses the slope at the steady-state conditions (nmol/s),
A is the surface area of the barriers (cm2) and Cd represents the con-
centration of the drug/marker in the donor compartment (nmol/mL).
To ensure sink conditions, the drug/marker concentrations added in
the donor compartment were selected in order to achieve a value below
the solubility limit (< 10% of the donor concentration) in the acceptor
compartment (Flaten et al., 2006a, 2006b).
For each drug/marker in each condition, the permeability study was
carried out at least in triplicate (6 PVPA barriers tested for each one of
the three parallels).
2.5.1. The effect of pH on barrier integrity and drug permeability
To assess changes in Papp due to different pH conditions of the so-
lution in the donor compartment, several drugs/marker (i.e. CAL, IBP,
IND, MTP, MTR and NPR) were dissolved in PBS pH 5.5, 6.2 or 7.4. In
the case of the permeability experiment in the presence of mucus,
mucin 10mg/mL was prepared according to the pH of the drug/marker
solution.
In particular, as an increase in the permeability of the fluorescent
marker CAL would indicate possible disruption of the barriers (Flaten
et al., 2006b; Naderkhani et al., 2015), its permeability was quantified
to investigate the impact of changes in pH on the integrity of the bar-
riers.
2.5.2. The effect of simulated intestinal media on barrier integrity and drug
permeability
To investigate the impact of the SIFs on the integrity of the barrier
and on the permeability of drugs, CAL and IBP were dissolved in FaB,
FeB, FeSSIF or FaSSIF (V1 and V2), and their Papp was evaluated in the
presence and absence of mucus (mucin 10mg/mL). The mucus layer
was prepared in accordance with the pH of the media.
As the Papp of CAL dissolved in the fasted media was exceeding the
standard range (Flaten et al., 2006b), the influence of mucin 40mg/mL
Table 1
Composition of the fasted (Fa-) and fed (Fe-) state simulated intestinal blank buffers (FaB, FeB) and media (FaSSIF, FeSSIF) for both version 1 and version 2 (V1, V2),
as described by the provider (biorelevant.com).
FaB-V1 FaSSIF-V1 FaB-V2 FaSSIF-V2 FeB-V1 FeSSIF-V1 FeB- V2 FeSSIF- V2
Sodium taurocholate (mM) – 3.00 – 3.00 – 15.00 – 10.00
Lecithin (mM) – 0.75 – 0.20 – 3.75 – 2.00
Glycerol monooleate (mM) – – – – – – – 5.00
Sodium oleate (mM) – – – – – – – 0.80
Maleic acid (mM) – – 19.10 19.10 – – 55.00 55.00
Monobasic sodium phosphate monohydrate (mM) 28.40 28.40 – – – – – –
Sodium chloride (mM) 106 106 68.60 68.60 203 203 126 126
Sodium hydroxide (mM) 8.70 8.70 101 101 101 101 82.00 82.00
Glacial acetic acid (mM) – – – – 144 144 – –
pH 6.5 6.5 6.5 6.5 5.0 5.0 5.8 5.8
Osmolarity (mOsm/kg) 270 180 670 390
Buffer capacity (mM/dpH) 12 10 76 25
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on the permeability of CAL was investigated to examine its potential to
act as a further protective layer for the PVPA barriers.
Moreover, the same conditions studied by Fischer et al. (2012) were
investigated in this study. Briefly, the PVPA barriers were incubated for
1 h in FaB (V1 or V2) prior to the addition of the CAL solution in the
fasted buffers/media (FaB, FaSSIF V1 and V2), and the permeability of
CAL was quantified for a total of 4 h following the procedure described
in Section 2.5.
2.6. Phospholipid quantification
The amount of phospholipids lost from the PVPA barriers in the
presence of fasted and fed state buffers/media was quantified using the
modified phosphorus assay (Bartlett, 1959), following the method
previously described by Naderkhani and colleagues (2015). Briefly, the
PVPA barriers were placed in an acceptor compartment containing
600 μL of PBS pH 7.4 and the donor compartment was loaded with FaB,
FeB, FaSSIF or FeSSIF (V1 and V2) (100 μL). The barriers were in-
cubated for 5 h. The incubations in PBS pH 7.4 and 0.5% Triton X-100
were used as negative and positive control, respectively. Samples
(50 μL) were withdrawn from the donor compartment after 5 h, diluted
with 50 μL of distilled water and treated following the phosphorus
assay. Blanks (PBS pH 7.4, 0.5% Triton X-100, FaB, FeB, FaSSIF, FeSSIF,
V1 or V2) were treated in the same manner. Three PVPA barriers for
each condition were tested.
2.7. Statistical analysis
The statistical evaluation of all results was carried out using
GraphPad Prism 7.0 software. When significant difference between two
sets of data was to be highlighted, Student t-test was employed
(p < 0.05). One-way ANOVA was used to compare three or more sets
of data and the Bonferroni post hoc test was employed to detect sig-
nificant differences (p < 0.05).
3. Results and discussion
3.1. The pH environment of the intestinal tract
Drug solubility and permeability in the intestinal tract are regarded
as the two major factors affecting oral drug absorption, especially with
regards to poorly soluble compounds. As the pH environment of the
intestine varies widely through its length (5.6–7.8, Bergström et al.,
2014), it is of key importance to investigate its effect on solubility and
permeability. In order to infer if a pH-dependent solubility/perme-
ability trend could be observed for drugs with different physicochem-
ical characteristics, we studied the impact that a shift in pH could have
on the solubility and permeability of five different drugs. Moreover, as
drug permeability was assessed both in the presence and absence of a
mucus layer at pH 5.5, 6.2 and 7.4, the investigation on the integrity of
the PVPA barriers and the rheological characterization of mucus in such
pH conditions were carried out.
3.1.1. Barrier integrity and mucus characterization
To guarantee the optimal functionality of the (mucus-)PVPA bar-
riers, their integrity was investigated at pH 5.5, 6.2 and 7.4. CAL was
chosen as a marker to detect changes in barrier integrity at the selected
pH conditions both in the presence and absence of the mucus layer.
Fig. 3a (shaded area) shows that no significant increase in CAL per-
meability was found compared to the reference value (0.06 * 10−6 cm/
s; Flaten et al., 2006b; Flaten et al., 2008), suggesting that the in-
vestigated conditions did not cause any barrier impairment. The elec-
trical resistance across the barriers was measured after 5 h, and the
results (data not shown) also indicated intact barriers (electrical re-
sistance>290 Ohm*cm2, Naderkhani et al., 2015).
Since drug permeability in the intestinal environment could be af-
fected by the rheology of the mucus layer, and as it has been demon-
strated that mucus can undergo a conformational change induced by a
shift in pH (Lieleg et al., 2010), rheology measurements of the mucus
placed on top of the PVPA barriers were carried out at different pH
conditions and mucin concentrations.
As it can be observed in Fig. 1, the general Newtonian behaviour of
the mucus at pH 6.2 (10mg/mL) and 7.4 (10 and 40mg/mL) confirmed
previous findings regarding mucus rheology (Falavigna et al., 2018;
Mackie et al., 2017). However, when decreasing the pH of the mucin
hydration media to 5.5, a non-Newtonian (shear-thinning) behaviour
was observed (Fig. 1), correlating with what other research groups have
found in the in vivo mucus layer (Boegh et al., 2014; Lai et al., 2009).
These findings show how the rheology of mucus could be affected by
the change in environmental pH. In fact, Cao et al. (1999) have sug-
gested that a sol-gel transition could result from a pH-induced con-
formational change when decreasing the pH from 6 to 7 to a more
acidic one. Lieleg et al. (2010) have also proposed that, at lower pH, the
mucus layer tends to generate a stronger barrier toward particle mo-
bility compared to a neutral pH environment. With regards to mucus
viscosity, Fig. 1 shows that a decrease in pH or an increase in mucin
concentration, causes an increase in apparent viscosity, as previously
observed in other studies (Cao et al., 1999; Park et al., 2007).
The results obtained in this study prove that mucus can undergo
relevant rheology changes, which should be carefully taken into ac-
count when assessing the behaviour of a drug in such environment.
These considerations are especially relevant when investigating the
diffusion of drugs and formulations through the mucus layer and their
subsequent permeation through the intestinal mucosa.
3.1.2. Drugs pH-solubility profiles
The pH-dependent permeability profiles of five model drugs were
evaluated using the mucus-PVPA model. The selection of the drugs was
carried out to cover both acidic (IBP, IND, MTR and NPR) and basic
(MTP) compounds as well as compounds with different degree of li-
pophilicity (Table 2). Since the pH-dependent solubility of a drug is
important when investigating its ability to permeate the GI barrier,
solubility studies of the five model drugs were performed at pH con-
ditions simulating different parts of the intestinal tract.
As it can be observed from Fig. 2 and Table 2, the equilibrium so-
lubility of the investigated drugs at the different pH conditions was
dependent on their acidity constant (pKa), the pH of the medium in
which the drugs were solubilized and their intrinsic hydrophilicity/li-
pophilicity. In particular, for IBP, IND and NPR (acidic and lipophilic
drugs with pKa≈ 4 and LogP>3), the solubility significantly in-
creased (p < 0.05) from pH 5.5 to 7.4, as their degree of ionization
increases at pH higher than their isoelectric point. In the case of the
basic drug MTP (pKa 9.56, LogP 1.88), a non-significant decrease in



















Mucin 10 mg/mL pH 5.5
Mucin 10 mg/mL pH 6.2
Mucin 10 mg/mL pH 7.4
Mucin 40 mg/mL pH 7.4
Fig. 1. Viscosity of mucus at different pH conditions (5.5, 6.2 and 7.4) and
mucin concentrations (10mg/mL and 40mg/mL).
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likely related to the fact that the pH conditions at which the experi-
ments have been performed were far below the isoelectric point of MTP,
thus not significantly differentiating the solubilities at pH 5.5, 6.2 and
7.4. For MTR (pKa 2.62, LogP −0.02), a significant increase was only
observed when comparing the solubility at pH 5.5 with the other two
pH conditions. Again, this is most likely due to the fact that solubility
changes are only observable when comparing pH closer to the iso-
electric point. Moreover, the hydrophilicity/lipophilicity of the ex-
amined drugs highly influenced their solubility. The more hydrophilic
compounds such as MTP and MTR were found to be more soluble
compared to more lipophilic IBP, IND and NPR, as expected.
These findings are in accordance with previous pH-dependent
investigations carried out both in vitro and in silico (Bergström et al.,
2004; Shoghi et al., 2013; Völgyi et al., 2010; Varma et al., 2012).
Nonetheless, it has to be noted that the solubility profiles are sub-
stance-specific and that not only the pH, but also the ionic strength and
the buffer capacity of the environment simulating the intestinal media
should be carefully considered (Bergström et al., 2014; Hamed et al.,
2016; Madsen et al., 2018).
3.1.3. Drugs pH-permeability profiles
The Papp of the same five model drugs was examined in the presence
and absence of mucus layer at different pH conditions (5.5, 6.2 and 7.4)
to investigate their possible pH-dependent permeability.
In general, the permeability of the investigated compounds in the
absence of the mucus layer was found to be highly affected by their
degree of ionization (Fig. 3), in accordance with the pH partition hy-
pothesis (Shore et al., 1957). It has previously been shown that an in-
crease in the fraction of drug in its unionized form directly increases the
permeability of the drug (Flaten et al., 2008; Shore et al., 1957). In
particular, in our study it was found that, for the BCS class II acidic
drugs IBP and NPR, the permeability significantly decreased
(p < 0.05) with increasing pH of the donor compartment, as the io-
nized form became the predominant one. Correspondingly, the per-
meability of the BCS class I basic drug MTP exhibited an increase in Papp
when the pH was increasing from 5.5 to 7.4. For the BCS class II IND,
the decrease in Papp with increasing pH was less visible, probably due to
the highly lipophilic nature of the compound, which can cause a re-
tention of the drug into the barriers and thereby causing a low recovery
at the end of the experiment (Naderkhani et al., 2015). With regards to
BCS class I MTR, no change in permeability was found at different pH
conditions. This was most likely due to the fact that the pH conditions
of the experiments were significantly above the isoelectric point for this
acidic compound, in accordance with the solubility results discussed in
Section 3.1.2. Furthermore, it has to be noted that more lipophilic
compounds such as IBP and NPR (LogP> 3) are able to permeate the
lipophilic PVPA barriers to a higher degree compared to more hydro-
philic ones such as MTP and MTR due to their intrinsic nature.
The (mucus)-PVPA has previously shown to correlate well with in
vivo data on the fraction absorbed in humans (Flaten et al., 2006b;
Naderkhani et al., 2014b; Falavigna et al., 2018). Furthermore,
Table 2
Chemical properties and solubility of calcein (CAL), ibuprofen (IBP), indomethacin (IND), metoprolol (MTP), metronidazole (MTR) and naproxen (NPR).









IBP 4.45c 3.97d II 206.29 220 pH 5.5: 0.37
pH 6.2: 1.06
pH 7.4: 1.72
IND 4.42c 4.27d II 357.79 254 pH 5.5: 0.03
pH 6.2: 0.09
pH 7.4: 0.71
MTP 9.56c 1.88d I 267.36 274 pH 5.5: 1.01
pH 6.2: 1.07
pH 7.4: 0.99
MTR 2.62e -0.02d I 171.15 320 pH 5.5: 1.02
pH 6.2: 1.09
pH 7.4: 1.07
NPR 4.18c 3.18d II 230.26 270 pH 5.5: 0.15
pH 6.2: 0.56
pH 7.4: 1.37
a Flaten et al., 2006b.
b Naderkhani et al., 2014a.
c Avdeef, 2003.
d Benet et al., 2011.
e Rediguieri et al., 2011.









































Fig. 2. Solubility of metronidazole (MTR), metoprolol (MTP), naproxen (NPR),
ibuprofen (IBP) and indomethacin (IND) at pH 5.5, 6.2 and 7.4. The results are
indicated as mean ± SD (n=6). Statistical significance (p < 0.05) was in-
vestigated with one-way ANOVA using the Bonferroni post hoc test.
*statistically significant difference in solubility between pH 5.5 and 6.2/7.4.
**statistically significant difference in solubility between pH 6.2 and 5.5/7.4.
***statistically significant difference in solubility between pH 7.4 and 5.5/6.2.
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satisfactory correlations were found between the results obtained in this
study at the different pH conditions (7.4, 6.2 and 5.5) and data where
drug permeability was assessed at comparable pH (6.83) using a mucus-
comprising Caco-2 cell model (Fig. 2S and 3S, Supplementary Material).
Especially in the case of the (mucus)-PVPA data at pH 7.4, which was
the pH closest to the one used in the Caco-2 cell experiments, R2 of 0.96
and 0.97 were identified in the presence and absence of mucus re-
spectively.
As the intestinal walls are lined with a mucus layer that differs in pH
according to the specific location (Lieleg et al., 2010), the permeability
of the same compounds was tested in the presence of mucin 10mg/mL
to assess the impact of this additional layer at different pH conditions.
With regards to mucus-drug interaction, it has to be noted that there are
multiple mechanisms which could take place when different drugs are
in contact with this layer. In particular, Olmsted and colleagues
(Olmsted et al., 2001) suggested interaction filtering (depending on
specific binding interactions, electrostatic and hydrophobic forces and
hydrogen bonds) and size filtering as the two main driving forces for the
diffusion of drugs through the hydrophilic mucus layer. This empha-
sizes the fact that more lipophilic compounds might decrease their rate
of diffusion through mucus to a higher extent compared to hydrophilic
ones, and that their ionization might further be the driving force ac-
cording to the pH environment (Khanvilkar et al., 2001; Shaw et al.,
2005).
When the hydrophilic mucus layer was added on top of the PVPA
barriers, the permeability of the different drugs was generally decreased
compared to its absence, and the pH effect was also less evident (Fig. 3).
As the isoelectric point of mucin is estimated to be between 2 and 3 (Lee
et al., 2005), its ionization would increase with the increase in pH.
When the same occurs for ionizable drugs, this could cause an elec-
trostatic repulsion or interaction (according to the nature of the drug)
that would translate into a decrease in the Papp of the drug (Shaw et al.,
2005).
Moreover, the lipophilicity of the drug might also affect its degree of
interaction with the mucus layer. In particular, the permeability of the
more lipophilic compounds IBP and NPR significantly decreased
(p < 0.05) in the presence of the mucus layer compared to its absence
in all tested pH conditions.
Additionally, changes in the rheological characteristics of mucus,
usually occurring with a shift in environmental pH, could affect the
diffusion/permeability behaviour of drugs at different pH conditions. In
fact, as it can be observed in Fig. 3 for IBP and NPR, the higher viscosity
of the mucus at pH 5.5 (Fig. 1) could be a contributing factor to the
greater decrease in permeability compared to the results at pH 6.2 and
7.4. The findings obtained in this study highlight how the inclusion of
the mucus layer is of key importance when investigating pH-dependent
permeability, and emphasize the mucus-PVPA model as a suitable tool
to study drug permeation in the intestinal environment.
The permeability-solubility interplay was studied by plotting the
permeability and the solubility of the different drugs previously in-
vestigated against the pH in the absence of mucus (Fig. 4). A similar
trend would be visible by plotting the results in the presence of the
mucus layer. As it can be observed, for acidic drugs with pKa around 4
(IBP, NPR and IND; Fig. 4A, B, C) the permeability was higher at more
acidic pH, whereas their solubility showed the opposite pH-dependent
trend. On the other hand, a pH-driven variation in solubility and per-
meability was not noticeable for MTR (Fig. 4D), as expected from its
physicochemical characteristics (Table 2). For the basic drug MTP
(Fig. 4E), the tendency of higher permeability at decreasing degree of
ionization was observed, but a significant decrease in solubility was not
visible.
The trends observed can be explained by the pH partition hypoth-
esis, which highlights the fact that ionizable drugs tend to permeate
lipidic membranes when in their undissociated form (Shore et al.,
1957), whereas their solubility is higher when the dissociated form is
the predominant one. Moreover, these findings are in agreement with
previous investigations on the pH-dependent permeability-solubility
interplay for ionizable compounds (Sieger et al., 2017).
Since previous findings have emphasized that the solubility-per-
meability trade-off should be carefully considered when aiming to de-
sign optimal formulations (Dahan and Miller, 2012; Porat and Dahan,
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Fig. 3. Apparent permeability (Papp) of metronidazole (MTR), metoprolol (MTP), naproxen (NPR), ibuprofen (IBP) and indomethacin (IND) in the presence and
absence of mucus at pH 5.5, 6.2 and 7.4. Papp of calcein (CAL) (shaded area) was quantified to investigate the integrity of the PVPA barriers at the chosen pH
conditions. The results are indicated as mean ± SD (n=18). Statistical significance (p < 0.05) was investigated with one-way ANOVA using the Bonferroni post
hoc test.
* statistically significant difference in Papp between different pH conditions in the absence of mucus.
** statistically significant difference in Papp between different pH conditions in the presence of mucus.
° statistically significant difference in Papp between the presence and absence mucus.
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to elucidate this interplay. The PVPA model used in this study, together
with pH-dependent solubility experiments, proved the relevance of this
kind of investigation and showed to be appropriate for such purpose.
3.2. The intestinal media environment
Together with the variations in environmental pH, the intestine is
also characterized by intraluminal fluids that can vary in composition
according to the fasted or fed state (Clarysse et al., 2009).
In particular, bile salts and lecithin have shown to form colloidal
structures which can provide the entrapment of drug molecules and
their subsequent increased solubilisation, especially with regards to li-
pophilic drugs (Augustijns et al., 2014; Jantratid et al., 2008; Dahan
and Miller, 2012). The fraction of the drug solubilized by these struc-
tures is not readily able to permeate the intestinal walls (Miller et al.,
2011) and, for this reason, it is important to assess the impact that
intestinal fluids have on drug permeation. The commercially available
FaSSIF and FeSSIF have previously been proved to mimic the compo-
sition of the human intestinal fluids (Jantratid et al., 2008) and have
been extensively used in the past decade in numerous solubility and
permeability studies using artificial cell-free permeability models
(Berben et al., 2018b; Bibi et al., 2015; Fischer et al., 2012; Naderkhani
et al., 2015). Therefore, in this study we evaluated the impact that these
SIFs have on the PVPA barriers, as well as on the permeability of dif-
ferent compounds.
3.2.1. PVPA barriers in the presence of simulated intestinal media
The PVPA barriers used in this study have previously been shown to
be stable in the presence of FaSSIF V1 by another research group
(Fischer et al., 2012). However, as the components in the different SIFs
could potentially interact with the PVPA lipids and affect the integrity
of the barriers, we wanted to investigate this further. For the first time,
in this study the PVPA and mucus-PVPA barriers were evaluated in
terms of their compatibility with both the fed and fasted state SIFs
(namely, FeSSIF and FaSSIF, V1 and 2, composition found in Table 1).
To the best of our knowledge, this is the first attempt in studying the
impact that all the commercially available media versions (version 1,
V1; version 2, V2) have on the functionality of the PVPA barriers; we
believe that this investigation is crucial in order to design the best in-
testinal-resembling in vitro permeability model.
The permeability of the fluorescent marker CAL was used to eval-
uate if the addition of the fed or fasted state SIFs would induce changes
in the integrity of the PVPA barriers.
As previously mentioned, an increase in the reference calcein Papp
value (0.06 * 10−6 cm/s) and decrease in barrier electrical resistance
(< 290 Ohm*cm2) would suggest a potential change in barrier integrity
(Flaten et al., 2006b; Flaten et al., 2008; Naderkhani et al., 2015).
As it can be observed in Fig. 5, with the fed state buffers/media
(Fig. 5A) the permeability of CAL did not increase compared to the
control (PBS pH 5.5, Fig. 5A shaded area), suggesting that their pre-
sence did not influence the functionality of the barriers, both in the
presence and absence of the mucus layer. On the other hand, a general
increase in Papp and decrease in electrical resistance was observed when
experiments with CAL dissolved in the fasted state buffer/media were
performed (Fig. 5B). However, permeability of CAL was lower in the
presence of buffers compared to the fasted state media, suggesting that
the components found in the media (namely sodium taurocholate, le-
cithin, glycerol monooleate and sodium oleate; Table 1) could be
causing changes in the integrity of the barriers.
The presence of mucin 10mg/mL seemed to shield the barriers from
the effect of FaSSIF V1, which was the medium causing the most sig-






















































































































































































Fig. 4. pH-dependent permeability-solubility interplay in the absence of mucus, depicted as apparent permeability (Papp, black dotted line) and solubility (grey
dotted line) plots of ibuprofen (4A, IBP), naproxen (4B, NPR), indomethacin (4C, IND), metronidazole (4D, MTR) and metoprolol (4E, MTP).
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higher mucin concentration would provide additional protection of the
barriers, mucin 40mg/mL was also tested. As it can be seen from
Fig. 5B, in general this setup led to a decrease in CAL Papp, especially in
the case of the fasted state media, suggesting a higher degree of pro-
tection from the more concentrated mucus layer. However, CAL per-
meability was still significantly higher compared to the control and the
electrical resistance measured in this condition was still below the op-
timal range (< 290 Ohm*cm2; Naderkhani et al., 2015).
As mentioned above, Fischer and colleagues (Fischer et al., 2012)
concluded that the integrity of the barriers appeared to be maintained
in the presence of the fasted state medium (V1) since the results ob-
tained using FaB and FaSSIF (V1) were not statistically different. In this
study, PBS pH 7.4 was not included as control. The permeability ex-
periments performed by Fisher and colleagues were carried out in a
different manner compared to the present study. In particular, the
barriers were hydrated for 1 h in FaB V1 and the following permeability
assay was 4 h long. For this reason, we decided to investigate the per-
meability of CAL in these conditions. As it can be observed in Fig. 5B, a
significant decrease in calcein Papp was found with the hydrated-bar-
riers setup, especially with the V1 fasted state medium. These findings,
together with the differences in surface area and donor volume, as well
as lab-to-lab variations, could be the reasons for the differences be-
tween the results obtained in the current study and the ones from
Fischer and colleagues (Fischer et al., 2012).
Moreover, in previous studies performed in our research group
(Naderkhani et al., 2015) a modification of the original PVPA model
(namely, PVPAbiomimetic) was used to assess the impact of the fasted and
fed state SIFs (V2). In accordance with our findings (Fig. 5), a higher
CAL permeability and lower electrical resistance was observed in the
presence of fasted state medium compared to the fed one (Naderkhani
et al., 2015). However, with the PVPAbiomimetic the fasted medium (V2)
was found to be much less aggressive to the barriers and thus more
compatible with the model compared to the original PVPA (Naderkhani
et al., 2015). The PVPAbiomimetic barriers have also shown to be more
robust against the presence of co-solvents and tensides compared to the
original PVPA (Naderkhani et al., 2014b), and are thus a good alter-
native when permeability studies with conditions that might affect the
original PVPA barriers have to be performed.
However, as the Papp of drugs/compounds can be differently af-
fected according to their physicochemical characteristics, we wanted to
investigate how the permeability of one more lipophilic compound
would be affected in the presence of the SIFs. Therefore, the perme-
ability of the BCS class II drug IBP was evaluated in the presence of fed
and fasted state SIFs with and without the presence of the mucus layer,
to see if the variation in the permeability of IBP would follow the same
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Fig. 5. Apparent permeability (Papp) of calcein (CAL; 5A, B) and ibuprofen (IBP; 5C, D), and electrical resistance of the PVPA barriers in the presence of fed (A, C) or
fasted (B, D) state media (FeSSIF and FaSSIF, respectively) and corresponding buffers (FeB and FaB, respectively) for both versions 1 and 2 (V1, V2) in the presence
and absence of mucus (10 and 40mg/mL) and with hydrated barriers. Papp and electrical resistance in the presence of PBS (pH 5.5 or 6.2) are used as controls (shaded
area). The results are indicated as mean ± SD (n=18). Statistical significance (p < 0.05) was investigated with one-way ANOVA using the Bonferroni post hoc test.
+ statistically significant difference in Papp between the absence of mucus and the other 3 conditions (mucus 10mg/mL, mucus 40mg/mL and hydrated barriers).
* statistically significant difference in Papp between PBS and all other SIFs without mucus.
** statistically significant difference in Papp between PBS and all other SIFs with mucus.
° statistically significant difference in Papp between the presence and absence of mucus.
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As it can be seen in Fig. 5D, the permeability of IBP dissolved in the
fasted state media in the absence of mucus significantly increased
(p < 0.05) only in the case of FaSSIF V2, when compared to the one
where the drug was dissolved in PBS pH 6.2 (Fig. 5D, shaded area). In
the presence of the mucus layer, the corresponding buffer (FaB V2) also
caused a significant increase in Papp. The electrical resistance across the
PVPA barriers followed the trend seen in Fig. 5B, suggesting potential
barrier impairment in the presence of the fasted state media. However,
the permeability of this lipophilic compound was not affected by the
presence of this media to the same extent as CAL, suggesting that the
changes in the PVPA structure may be related to an increase in aqueous
pores through the barriers and not to variations in their lipidic part. In
fact, events that affect the structure of the PVPA barriers can cause an
increase in aqueous pathways, resulting in a higher permeability
especially for hydrophilic compounds (Flaten et al., 2006b).
Fig. 5C shows the apparent permeability of IBP dissolved in the fed
state (SIFs). In general, minor changes were found when comparing the
Papp of the drug dissolved in PBS pH 5.5 (control, shaded area) with the
one in the fed state buffers/media in the presence and absence of the
mucus layer. These findings could be related to the different solubili-
zation that the drug can exhibit in these different environments, which
again can translate into a change in permeability (Dahan and Miller,
2012; Porat and Dahan, 2018). Moreover, in all tested fed conditions,
the Papp of IBP was found to be lower in the presence of mucus. On the
contrary, as it can be seen in Fig. 5A, the permeability of the hydro-
philic marker CAL did not significantly change between the presence
and absence of mucus. In fact, the presence of the mucus layer can
particularly hinder the diffusion of lipophilic drugs because of its hy-
drophilic nature and of the possible interaction of the drugs with its
hydrophobic regions (Khanvilkar et al., 2001). These results were able
to prove this concept, and stressed the necessity of a permeability in
vitro model comprising mucus to properly assess its impact on oral drug
absorption.
As previously mentioned, lecithin and bile salts have shown to en-
trap drug molecules in vesicular structures, thus increasing drug
solubilization and lowering the amount of free drug able to permeate
through the intestinal walls (Augustijns et al., 2014; Miller et al., 2011).
This effect should be particularly evident with the fed state media,
where the concentration of the above-mentioned components is higher
compared to the fasted state one. As a proof of this concept, Fig. 5C
shows a significant decrease (p < 0.05) in permeability when com-
paring the Papp of IBP dissolved in FeB V2 with the one in FeSSIF V2,
both in the presence and absence of mucus. In fact, the presence of
sodium taurocholate, lecithin and other lipolysis products in FeSSIF V2
can provide the formation of micelles, otherwise not present in the fed
state buffer (FeB V2), thus influencing drug solubilization and perme-
ability. A similar trend was found with FeB V1 and FeSSIF V1, but not to
the same extent. This could be due to the different composition of the
two media (Table 1), stressing the significant impact on drug permea-
tion of the presence of FeSSIF V2, which has a higher bile salt-lecithin
ratio and additional lipolysis products (sodium oleate and glycerol
monooleate). Regarding this matter, it has been previously shown that
the complex composition of the fed intestinal fluids could contribute to
larger colloidal vesicles (Riethorst et al., 2016) and therefore affect
drug absorption to a higher extent. Moreover, according to the bile salt-
lecithin ratio, the vesicles could change in dimension and tend either to
a bilayered structure or to the one of mixed micelles, as previously
discussed (Riethorst et al., 2018). The same trend was not observed for
CAL (Fig. 5A), emphasizing that this study was able to highlight the fact
that the FeSSIF composition did not affect the permeability of hydro-
philic compounds in the same manner as lipophilic ones.
In the presence of mucus, a significant decrease in IBP permeability
(p < 0.05) was only found between FeB and FeSSIF V2 and not be-
tween FeB and FeSSIF V1 (Fig. 5C). This could again be traced back to
the different composition of the two media, as well as to the potential
interaction of the drug with the mucus. Moreover, the reduction in drug
diffusion through native mucus has previously been found to be related
to sodium taurocholate, competing with mucins in binding the drug
diffusing through this layer (Legen and Kristl, 2001).
All these considerations underline the impact that the different SIFs
have on the permeation of different compounds through the PVPA
barriers, but also on the diffusion of drugs through the mucus layer.
These findings are especially relevant as the need of predictive in vitro
models simulating the GI tract is further increasing (Berben et al.,
2018a; Billat et al., 2017; Riethorst et al., 2018).
3.2.1.1. Loss of lipids from the PVPA barriers in the presence of simulated
intestinal media. To further investigate the mechanism behind the
possible change in barrier integrity suggested by the increased CAL
permeability discussed in Section 3.2.1, the potential loss of lipids from
the PVPA barriers in the donor compartment was investigated in the
presence of the different SIFs.
Fig. 6 shows how the loss of phospholipids in all tested conditions
was significantly lower (p < 0.05) than the one caused by the presence
of Triton X-100 0.5% (positive control), which is certainly causing
barrier disintegration as proved by other authors (Fischer et al., 2011;
Naderkhani et al., 2015). However, an increase in amount of phos-
pholipids released from the barrier was observed with some of the SIFs
compared to the presence of PBS pH 7.4 (negative control). In parti-
cular, a significant increase in phospholipid loss compared to the ne-
gative control was observed in the presence of FaB V1, FaSSIF V1 and
FaSSIF V2. Moreover, a significant difference in lipid loss was found
between the buffer and the medium for the fasted state V2 and the fed
state V1.
These trends could explain part of the permeability results shown in
Fig. 5B and add more information regarding the effects of the SIFs on
the tightness of the PVPA barriers. In particular, a higher loss of lipids is
suggested in the presence of the fasted state media, compared to the fed
ones, in accordance with the results discussed in Section 3.2.1.
Moreover, the results in Fig. 6 are in the same range as the ones
previously observed by Fischer and colleagues (Fischer et al., 2012).
Fig. 6. Amount of phospholipids released to the donor compartment of the
PVPA barriers after 5 h of incubation with PBS pH 7.4, fasted (Fa-) and fed (Fe-)
state buffers (FaB and FeB) and media (FaSSIF and FeSSIF) (both version V1 and
V2) and Triton X-100 0.5%. The results are indicated as mean ± SD (n= 6).
Statistical significance (p < 0.05) was investigated with one-way ANOVA
using the Bonferroni post hoc test.
* statistically significant difference in phospholipids loss compared to PBS
pH 7.4.
** statistically significant difference in phospholipids loss between the buffer
and the media fluids.
° statistically significant difference in phospholipids loss between the presence
of Triton 0.5% and all other conditions.
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However, they did not compare the loss of phospholipids caused by the
fasted state media with the one in the presence of PBS pH 7.4, therefore
a negative control as the one discussed in our study was not accessible.
Naderkhani et al. (2015) observed that a lower lipid loss was found
with the PVPAbiomimetic barriers both in the presence of fasted and fed
state media and of Triton X-100 0.5% compared to the original PVPA,
highlighting the difference in barrier integrity and further supporting
the permeability results discussed in Section 3.2.1.
In the present study, the loss of phospholipids caused by the fed and
fasted state buffer/media in the presence of the mucus layer was also
investigated. However, the collection process of the samples from the
donor compartment led to variations in the amount of mucus present in
each sample. As mucus was prepared in phosphorus-containing buffer
(PBS), the amount of phosphorus quantified in each sample varied ac-
cording to the amount of mucus withdrawn from the donor compart-
ment, thus leading to compromised sensitivity of the assay and the
results could therefore not be trusted in the presence of this layer.
The different results observed using the FaSSIF and FeSSIF media
could be ascribed to their different composition (Table 1), which is not
only related to the different amounts of bile salts, lecithin and other
lipolysis products, but also to their different buffer composition. In fact,
as it can be observed in Figs. 5 and 6, in some cases the buffers
themselves seemed to potentially affect the barrier integrity.
Moreover, since it has been reported that the concentration of bile
salts and lecithin in fasted state human intestinal fluid is much lower
compared to the fed one (Clarysse et al., 2009) and since the SIFs have
shown to mimic the human intestinal fluids (Jantratid et al., 2008), the
resulting vesicular structures would be different according to FaSSIF or
FeSSIF media, thus possibly affecting the PVPA barrier structure in a
different manner.
Overall, the results obtained suggest the PVPA barriers to be espe-
cially stable in the presence of the fed state media, whereas the ones
found with the fasted state media suggest a certain potential of barrier
impairment, and precautions should be taken when interpreting results
obtained in presence this media. However, as the PVPAbiomimetic bar-
riers have shown to be more robust compared to the original ones
(Naderkhani et al., 2014b), they could be the best model to use when
fasted state SIFs have to be employed to assess drug permeability.
Moreover, the findings discussed in Section 3.2.1 highlight the fact
that different media can result in a different impact on the PVPA barrier
integrity as well as on the permeability of the model compounds. This
emphasizes the relevance of the investigation on both media and both
versions carried out in this study.
4. Conclusions
In this study, the impact of regional and nutritional intestinal dif-
ferences has been successfully investigated using the mucus-PVPA in
vitromodel. The pH-dependent drug permeability and solubility profiles
showed trends in agreement with the pH partition hypothesis. An in-
crease in mucus viscosity at lower pH conditions was also observed.
Moreover, the impact of bile salts and phospholipids on drug permea-
tion was evident, and the different SIFs showed to influence the per-
meability to various extents according to the hydrophilicity/lipophili-
city of the drugs. Further, the presence of mucus particularly affected
the permeability of the more lipophilic compounds. The results ob-
tained in this work thus suggest the suitability of the mucus-PVPA
model for investigations on the impact that pH and SIFs, as well as their
interplay with mucus, have on intestinal drug absorption.
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1. Quantification methods: drug permeated in the acceptor compartment 
The quantification of the amount of drug found in the acceptor compartment at the end of the 
permeability study was carried out with different quantification methods according to the 
specific compound. Previous studies by us have assessed the possibility of interference of lipids 
from the PVPA barrier in the quantification process, and have concluded that no lipids were 
found in the acceptor compartment (Flaten et al., 2007). UV-Vis spectrophotometry was 
sensitive enough for the quantification of IBP, MTP, MTR and NPR in the permeation studies, 
as the absorbance of each specific drug found in the acceptor compartment was inside the 
specific standard curve range and above the LOD and LOQ values (Table 1S). However, for 
the quantification on IND, HPLC-UV was needed since the absorbance in the acceptor 
compartment was not appreciable enough by the UV-Vis spectrophotometry quantification 
method. 
Table 1S: Parameters for the quantification of CAL, IBP, IND, MTP, MTR and NPR. 











5.5 0.10-2.20 0.9999 0.05 0.16 
6.2 0.10-2.20 0.9998 0.07 0.22 
7.4 0.02-2.20 0.9995 0.09 0.27 
 
IBP 
5.5 8.00-150.00 0.9994 6.70 20.29 
6.2 8.00-150.00 0.9994 6.70 20.29 
7.4 8.00-150.00 0.9999 2.99 9.06 
 
IND UV 
5.5 12.00-120.00 1 1.16 3.53 
6.2 12.00-120.00 1 0.82 2.49 
7.4 12.00-120.00 0.9992 7.86 23.82 
IND HPLC 7.4 0.015-30.00 0.9998 0.56 1.70 
 
MTP 
5.5 1.00-30.00 0.9991 1.86 5.65 
6.2 1.00-30.00 0.9997 1.09 3.31 
7.4 1.00-30.00 0.9992 2.08 6.32 
 
MTR 
5.5 18.00-366.00 0.9997 14.00 42.42 
6.2 18.00-366.00 0.9999 8.75 26.50 
7.4 18.00-366.00 0.9998 6.50 19.70 
 
NPR 
5.5 50.00-250.00 0.9989 20.07 60.82 
6.2 50.00-250.00 0.9993 16.72 50.67 
7.4 50.00-250.00 0.9991 18.77 56.89 
 
For the validation of the HPLC-UV quantification method of IND, different parameters have 
been assessed. First, the evaluation of the right column type, mobile phase, time run and flow 
was carried out by injecting a standard IND solution (in PBS pH 7.4) and by monitoring the 
separation profile at 254 nm. The retention time of IND obtained with a Waters X-select™ CSH 
™ C18 (2.5 μm, 3.0 × 75 mm) XP column, a flow rate of 0.5 mL/min and a mobile phase of 
acetonitrile and MilliQ water with 0.1% glacial acetic acid (60:40, v/v) was found to be 3.05 
during a total run time of 5.5 minutes, while the retention time of the solvent front was found 
to be 1.07 minutes (Fig. 1S). The IND standard was injected at increasing concentrations (9 
dilutions; 3 replicates for each dilution; 0.015-30 nmol/mL) in order to obtain a satisfactory 
calibration curve (R2 = 0.9998; LOD = 0.56 nmol/mL; LOQ = 1.70 nmol/mL). The retention 
3 
 
capacity factor k was also evaluated and found to be acceptable (k = 1.87), together with the 
peak asymmetry factor (As = 1.22) and efficiency (N = 674). As both the standard IND solution 
and the samples obtained from the permeability study were only containing IND, the assessment 
of the selectivity and resolution was not possible. 
 
 
Fig. 1S: Chromatogram of IND standard. 
 
The spectrofluorometric determination of CAL was carried out following the method described 
by Flaten and colleagues (2006b). The excitation and emission wavelengths (485 and 520 nm, 
respectively) were chosen to accurately quantify the compound and to avoid a crosstalk between 
excitation and emission curves. A CAL standard solution (in PBS pH 7.4) was prepared at 
increasing concentrations (9 dilutions; 3 replicates for each dilution; 0.02-2.2 nmol/mL) in order 
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2. Correlation between the (mucus)-PVPA and the Caco-2 model 
A correlation between permeabilities obtained using a mucus-comprising Caco-2 model 
(Berben et al., 2018b) with the permeability of four different drugs (IBP, IND, NPR, MTP) 
obtained using the PVPA barriers both in the absence and presence of mucus was carried out. 
The Caco-2 data used for these correlations was obtained from a study where mucus was added 
on top of Caco-2 cells prior to the addition of the drug in solution, which was dissolved in 
FaHIF (fasted state human intestinal fluids) at pH 6.83 (Berben et al., 2018b). The correlations 
are the following: 
 
Fig. 2S: Correlation between the Papp obtained using the Caco-2 model (data from: Berben et 
al., 2018b) and the PVPA model. 
 
Fig. 3S: Correlation between the Papp obtained using the Caco-2 model (data from: Berben et 
al., 2018b) and the mucus-PVPA model. 

































Correlation: Caco-2 vs. PVPA
PVPA pH 7.4 PVPA pH 6.2 PVPA pH 5.5
Linear (PVPA pH 7.4) Linear (PVPA pH 6.2) Linear (PVPA pH 5.5)

































Correlation: Caco-2 vs. mucus-PVPA
m-PVPA pH 7.4 m-PVPA pH 6.2 m-PVPA pH 5.5
Linear (m-PVPA pH 7.4) Linear (m-PVPA pH 6.2) Linear (m-PVPA pH 5.5)
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As it can be observed in Fig. 2S and 3S, a satisfactory correlation for all pH conditions between 
the permeability data obtained using the Caco-2 model and the (mucus)-PVPA model has been 
obtained. This was especially evident in the case of (mucus)-PVPA data at pH 7.4, most likely 
due to the fact that the Caco-2 data was exclusively collected at pH 6.83. These correlations 
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The aim of this work was to develop a new in vitro lipolysis-permeation model to predict the in vivo
absorption of fenofibrate in self-nanoemulsifying drug delivery systems (SNEDDSs). More specifically, the
in vitro intestinal lipolysis model was combined with the mucus-PVPA (Phospholipid Vesicle-based
Permeation Assay) in vitro permeability model. Biosimilar mucus (BM) was added to the surface of the
PVPA barriers to closer simulate the intestinal mucosa. SNEDDSs for which pharmacokinetic data after
oral dosing to rats was available in the literature were prepared, and the ability of the SNEDDSs to
maintain fenofibrate solubilized during in vitro lipolysis was determined, followed by the assessment of
drug permeation across the mucus-PVPA barriers. The amount of drug solubilized over time during
in vitro lipolysis did not correlate with the AUC (area under the curve) of the plasma drug concentration
curve. However, the AUC of the drug permeated after in vitro lipolysis displayed a good correlation with
the in vivo AUC (R2 > 0.9). Thus, it was concluded that the in vitro lipolysisemucus-PVPA permeation
model, simulating the physiological digestion and absorption processes, was able to predict in vivo ab-
sorption data, exhibiting great potential for further prediction of in vivo performance of SNEDDSs.
© 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.Introduction
In the past decades, lipid-based drug delivery systems (LbDDSs)
have attracted increasing attention due to their ability to improve
the bioavailability of poorly water-soluble drugs1 via solubilization
enhancement, supersaturation,2,3 permeation enhancement and
lymphatic transport.4 Among LbDDSs, self-nanoemulsifying drug
delivery systems (SNEDDSs; mixture of oil, surfactant, co-
surfactant and co-solvent) have especially been studied because
of their ability to spontaneously form nanoemulsions after disper-
sion in an aqueous environment. Once entered into the gastroin-
testinal (GI) tract, these formulations are dispersed in the gastric
and intestinal fluids and are concomitantly affected by digestive
enzymes. These physiological processes result in the formation of a
wide range of colloidal structures able to affect the solubilization of
the administered drug, and thus impacting its absorption.5®. Published by Elsevier Inc. All riAlthough several studies have been carried out regarding the po-
tential of LbDDSs as oral drug delivery systems3,6e8 and several
LbDDSs have reached the market,9 the development of an optimal
LbDDS is still regarded as a challenging process.1 The main reason
for this is that numerous excipients can be used for LbDDSs, and the
selection of the appropriate excipients is a demanding procedure
due to e.g. insufficient methods currently able to estimate the
in vivo absorption profile.5,8 In this regard, the UNGAP (Under-
standing Gastrointestinal Absorption-related Processes) European
COST Action Network has recently stressed the problems related to
a poor comprehension of GI drug absorption, and has highlighted
the current approaches and further developments needed in this
field.10 For instance, the in vitro intestinal lipolysis model has been
developed to investigate the performance of LbDDSs prior to in vivo
testing.11 Even though the model provides valuable information on
the lipolysis rate of a LbDDS, as well as drug solubilization during
lipolysis of a LbDDS, recent studies have shown that the in vitro
model does to not always predict the in vivo performance of LbDDSs
in terms of drug absorption.3,8,12 For instance, in the study by
Michaelsen et al.12 the amount of fenofibrate found in the aqueousghts reserved.
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SNEDDS75, super-SNEDDS solution150 and super-SNEDDS suspen-
sion150) failed to correlate with in vivo drug absorption in rats, and
it has been proposed that the lack of an absorption step in the
in vitro lipolysis model could be the reason for the low correlation
with in vivo data.13 In parallel, numerous in vitro permeability
models have been validated to mimic the intestinal mucosa and to
assess drug absorption from different drug delivery systems (e.g.
the Caco-2 model14; the PAMPA model15; the PVPA model16; the
Permeapad™17; and the AMI system18). The PVPA (Phospholipid
Vesicle-based Permeation Assay) in vitro barriers, composed of li-
posomes immobilized in and on top of nitrocellulose filters, have
been established in the past decade and have proved to simulate
the intestinal mucosa.16 However, all the above-mentioned
permeation models were developed without considering the GI
digestion affecting LbDDSs. Since neither the in vitro lipolysis
models nor the in vitro permeationmodels alone are able to provide
a full picture of the physiological processes driving GI drug ab-
sorption from LbDDSs, they have recently been combined to allow
the concomitant study of lipolysis and permeation. For instance, a
cell-free artificial membrane, the Permeapad™, has been combined
with the in vitro intestinal lipolysis model using porcine pancreatin
as source of digestive enzymes.6,13 Moreover, a cell-based system,
the Caco-2 cell model, has been combined with the in vitro intes-
tinal lipolysis utilizing immobilized microbial lipase as the diges-
tive enzyme.7,19,20 Several of these combined studies led to
improved prediction of in vivo absorption data compared to the
in vitro lipolysis models or in vitro permeation models alone.13
Besides Keemink and Bergstrom,19 where mucin from porcine
stomach type III was used as a mean to protect the Caco-2 cell layer,
all other models were designedwithout simulating themucus layer
covering the intestinal wall, thus not fully mimicking the physio-
logical environment of the intestinal mucosa.21 In fact, the mucus
layer is the first barrier that a drug gets in contact with after
entering the lumen, and the drug partition between the intestinal
luminal fluids, the mucus layer and the intestinal epithelium can
affect the extent of drug permeation.21 Moreover, mucus has shown
to affect the absorption of drugs, lipids and nutrients, and lipid
digestion products can conversely modulate the properties of this
barrier.22e24 Therefore, it is of key importance to include the mucus
layer in such in vitro models, in order to be able to consider its
impact on drug absorption. Thus, efforts have been made to
simulate the mucus layer covering the GI tract and, as a result of
this, an artificial biosimilar mucus (BM) has been developed,25 and
proved to resemble both the composition and the rheological
properties of porcine intestinal mucus.25,26
In light of the importance of including mucus in combined
in vitro lipolysis-permeation models, as described above, the pre-
sent study aimed at evaluating if the PVPA in vitro permeability
model covered with biosimilar mucus would be compatible with a
digesting environment. Moreover, the model was tested in terms of
its ability to predict the in vivo plasma exposure of fenofibrate
(poorly water-soluble drug; LogP 5.827) from SNEDDS75, super-
SNEDDS solution150 and super-SNEDDS suspension150 previously




Bovine bile, bovine serum albumin (BSA), 4-bromophenyl-
boronic acid (BBBA), calcein, cholesterol, fenofibrate, maleic acid,
MES hydrate, magnesium sulphate, mucin from porcine stomach
type II, pancreatin from porcine pancreas, soybean oil (long-chain(LC) glycerides), tris-(hydroxymethyl)aminomethane (Tris) were
products of Sigma Aldrich (St. Luis, MO, USA). Acetonitrile (High-
Performance Liquid Chromatography, HPLC, grade), dimethyl sulf-
oxide (DMSO), ethanol (EtOH; Ph. Eur. Grade), methanol (MeOH;
HPLC grade) sodium chloride (NaCl) were purchased from VWR
(Herlev, Denmark). Calcium chloride dihydrate, sodium hydroxide
were obtained from Merck (Darmstadt, Germany), whereas poly-
sorbate 80 (Tween 80) and polysorbate 20 (Tween 20) were ob-
tained from Fluka Chemie AG (Buchs, Switzerland). Maisine 35e1
was kindly donated by Gattefosse (St. Priest, France) and Kolliphor
RH-40 was kindly received from BASF (Ludwigshafen, Germany).
Polyacrylic acid (Carbopol® 974P NF) was purchased from Lubrizol
(Brussels, Belgium). E80 lipoid egg-phospholipids (80% phospha-
tidylcholine) and soy phospholipids (S-PC) were obtained from




Biosimilar mucus (BM) was prepared following the method
described by Boegh et al.25 Briefly, Carbopol® was dissolved in a
hypo-tonic buffer (10 mM MES buffer with 1.0 mM MgSO4 and
1.3 mM CaCl2; pH 6.5) and mucin type II from porcine stomach was
added. A lipidmixturewas separately prepared in an isotonic buffer
(10 mMMES buffer with 1.0 mMMgSO4, 1.3 mM CaCl2 and 137 mM
NaCl; pH 6.5) by mixing SPC, cholesterol and polysorbate 80.
Finally, BSA and the lipid mixture were added to the Carbopol®-
mucin mixture, in order to obtain the final concentrations: Carbo-
pol® (0.9% w/v), mucin type II from porcine stomach (5% w/v), S-PC
(0.18%w/v), cholesterol (0.36%w/v), polysorbate 80 (0.16%w/v) and
BSA (3.1% w/v). The pH was carefully adjusted to 6.5 and the BM
was stored at 4 C overnight before its use.
PVPA Barrier Preparation
The PVPA barriers were prepared as previously described by
Falavigna et al.28,29 Briefly, liposomes with two different size dis-
tributions (0.4 and 0.8 mm) were obtained using the thin-film hy-
dration technique followed by extrusion. In order to provide
immobilization and fusion of the liposomes, they were centrifuged
and freeze-thawed on top of nitrocellulose membrane filters fused
to Transwell inserts (surface area 0.33 cm2) (Corning Inc., New York,
USA).
Preparation of SNEDDSs
SNEDDS composed of soybean oil (27.5% w/w), Maisine 35e1
(27.5% w/w), Kolliphor RH-40 (35% w/w) and absolute ethanol (10%
w/w) were prepared following the method previously described by
Michaelsen et al.12 Firstly, soybean oil, Maisine 35e1 and Kolliphor
RH-40 were heated at 50 C, and subsequently Maisine 35e1 and
soybean oil were mixed in a 1:1 (w/w) ratio; Kolliphor RH-40 was
then added to the mixture, which was left to stir until cooled down
to room temperature. Lastly, absolute ethanol was added, and the
SNEDDS pre-concentrate was stirred until homogeneity was
reached.
Three fenofibrate-loaded SNEDDSs were prepared by adding
different amounts of the drug to the pre-concentrate. The equilib-
rium solubility (Seq) of fenofibrate in the pre-concentrate was
previously reported to be 88.5 mg/g8. SNEDDS75 was prepared by
adding drug corresponding to 75% of the fenofibrate Seq to the pre-
concentrate (Table 1) and leaving it to stir at room temperature
(23e25 C) to aid the dissolution process until use. The super-
SNEDDS suspension150 was prepared in the same way as the
SNEDDS75, but 150% of the Seq was added to the pre-concentrate.
The super-SNEDDS solution150 was prepared by adding drug
Table 1
Fenofibrate Loading and form in the Prepared SNEDDSs.
Name Drug Concentration
(% of Drug Seq in the
Pre-Concentrate)
Drug State
SNEDDS75 75 In solution
Super-SNEDDS solution150 150 In solution
Super-SNEDDS suspension150 150 In suspension
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(Table 1), which was then bath-sonicated for 30 min, heated for 3 h
at 60 C, and finally left to cool to 37 C overnight.Solubility Studies to Select Acceptor Medium for Permeation
Experiment
The solubility of fenofibrate in different aqueous media was
tested in order to select a good acceptor medium for the perme-
ation experiments. The method employed followed the procedure
described by Berthelsen et al.30 Briefly, 10 mg of fenofibrate were
suspended in 15mL of either PBS pH 7.4; Tween 20 5mg/mL; DMSO
10 mg/mL; DMSO 40 mg/mL; BSA 4% (w/v) or BSA 1% (w/v) (all
media were prepared in PBS pH 7.4) and the suspensions were left
to rotate at 37 C for a total of 48 h. The tubes containing the sus-
pensions were centrifuged after 1, 4, 24 and 48 h of incubation for
10 min at 6500g, and samples (1 mL) from the supernatant were
withdrawn and centrifuged for 10 min at 19,000g. The superna-
tant was finally diluted with MeOH prior to the quantification of
fenofibrate solubilized in the chosen medium. Difference inFig. 1. A) PVPA barrier integrity expressed as apparent permeability (Papp) of calcein (5.5 mM
n ¼ 12). B) Setups tested in terms of PVPA barrier compatibility with and without BM. PBSfenofibrate solubility in one specific medium below 5% between
two consequent time points was considered enough to state that
the solubility was reached. The quantification of fenofibrate was
carried out by HPLC (Dionex UltiMate 3000 pump, ASI 100 auto-
mated sample injector, Dionex Ultimate 3000 detector; all from
Thermo Fischer, Waltham, MA, USA), using a Phenomenex Kinetix
5u XB-C18 100A column (100  4.6 mm; Phenomenex, Torrance,
CA, USA). Fenofibrate was detected at a wavelength of 288 nm, with
a retention time of approximately 2.5 min. The mobile phase was
composed of 20% purified water and 80% of MeOH and the flowwas
set to 1 mL/min. In the case of BSA (1 and 4% w/v) as acceptor
medium, acetonitrile was added to the samples in order to pre-
cipitate the BSA prior to the quantification via HPLC. The solubility
in each medium was tested in triplicate (n ¼ 3).
Compatibility of the PVPA Barriers with Donor and Acceptor Media
Before the assessment of fenofibrate permeation from
SNEDDSs, the permeation of calcein (5.5 mM) was tested to assess
the compatibility of the PVPA barriers with the different donor
media (Fig. 1B) using PBS pH 7.4 as the acceptor medium. Once
the donor media had been evaluated, the compatibility of the
PVPA barriers with different acceptor media (see Section
Solubility Studies to Select Acceptor Medium for Permeation
Experiment) was studied. All experiments were performed at
37 C. For the experiment being performed in the presence of BM,
the mucus layer (50 mL) was carefully pipetted on top of the PVPA
barriers and left to incubate for 10 min prior to the addition of the
donor medium (Fig. 1B). The donor samples (100 mL; Fig. 1B) were
directly pipetted on top of the barriers (with or without BM). The) and electrical resistance across the PVPA barriers with different setups (Mean ± SD;
pH 7.4 was used as the acceptor medium.
M. Falavigna et al. / Journal of Pharmaceutical Sciences 110 (2021) 208-216 211barriers were then placed into an acceptor Transwell well con-
taining the acceptor medium (600 mL) and were moved into new
wells with the same medium after 2, 4, 5 and 6 h to uphold sink
conditions. At the end of the permeation experiment, calcein Papp
was calculated and the electrical resistance across the PVPA bar-
riers was measured using a Millicell-ERS volt-ohmmeter (Milli-
cell-ERS, Millipore, USA). The measured electrical resistance was
then subtracted with the electrical resistance of the nitrocellulose
filter (119 Ohm), and the resulting value was normalized with the
surface area of the PVPA barriers (0.33 cm2). The quantification of
calcein was carried out using a Tecan Infinite M200 fluorimeter/
spectrophotometer (Salzburg, Austria; Software: Magellan) at
excitation wavelength of 485 nm and emission of 520 nm (gain:
70). For each condition tested, 12 PVPA barriers were used
(n ¼ 12). Values of calcein Papp below 0.06 $ 106 cm/s and
electrical resistance above 290 Ohm $ cm2 indicate that the
integrity of the barriers was maintained.29In Vitro Lipolysis of Fenofibrate-Loaded SNEDDSs
The lipolysis of the SNEDDSs under fasted state conditions using
the in vitro intestinal lipolysis model was carried out following the
method described by Michaelsen et al.12 with minor adjustments.
In particular, the SNEDDSs were weighed into a thermostated
vessel (37 C), and subsequently 26 mL of fasted state intestinal
medium was added (bile bovine 2.95 mM, calcium chloride
1.40 mM, calcein 5.50 mM, maleic acid 2.00 mM, sodium chloride
146.80 mM, S-PC 0.26 mM, tris 2.00 mM; pH 6.50).
The amount of SNEDDS added into the vessel was adjusted to
obtain a final fenofibrate concentration of 480 mg/mL in all exper-
iments, following the procedure described by Michaelsen et al.12
The pancreatic lipase solution was prepared by mixing the crude
lipase extract with 5 mL of intestinal medium in the absence of
calcein, centrifuging the mixture for 7 min at 6500g, and col-
lecting the supernatant. Lipolysis was initiated by adding 4 mL of
pancreatic lipase solution to the thermostated reaction vessel (final
activity of 550 USP/mL). The decrease in pH due to the release of
free fatty acids from the digested SNEDDSwas countered by the use
of an automated pH-stat (Metrohm Titrino 744, Tiamo version 1.3,
Herisau, Switzerland) with automated addition of NaOH (0.4 M) in
order to keep the pH constant at 6.5. The calcium chloride present
in the intestinal medium allowed for a continued lipolysis by
removing the free fatty acids by precipitation, and thereby avoiding
inhibition of the lipase activity.
Samples (1 mL) were taken from the vessel after dispersion
(i.e. before lipase addition; 0 min) and after 30 min of lipolysis,
both to be used for the analysis of fenofibrate distribution be-
tween the aqueous and pellet phase, and for permeability ex-
periments. Lipolysis in the samples used for the investigation of
the fenofibrate distribution was inhibited by the addition of 5 mL
BBBA (1 M in MeOH). The inhibited samples (time point 0 and
30 min) were centrifuged for phase separation (19,000g for
10 min), and the concentration of fenofibrate in the aqueous
phase was quantified by HPLC after appropriate dilution in MeOH
following the method described in Section Solubility Studies to
Select Acceptor Medium for Permeation Experiment. To quantify
the total amount and determine the recovery of fenofibrate in the
lipolysis vessel, samples were taken before centrifugation and
analysed by HPLC. The lipolysis was carried out four times for
each SNEDDS (n ¼ 4). The permeability samples were directly
pipetted (100 mL) on top of the mucus-PVPA barriers to study the
permeation of fenofibrate (see Section Fenofibrate Permeation
Using the Mucus-PVPA Model). The lipolysis of the SNEDDSs
was not inhibited for the permeation samples after 30 min of
lipolysis.Fenofibrate Permeation Using the Mucus-PVPA Model
Once the preferred donor and acceptor media for the perme-
ation experiment had been selected (Section Compatibility of the
PVPA Barriers with Donor and Acceptor Media), the permeation
of fenofibrate from SNEDDS (i.e. SNEDDS75, super-SNEDDS solu-
tion150, super-SNEDDS suspension150) was tested using the mucus-
PVPA barriers. Calcein was added to all donor media, in order to
enable an in-line assessment of the mucus-PVPA barrier integrity
(data not shown). As described above (Section Compatibility of the
PVPA Barriers with Donor and Acceptor Media), BM was pipetted
(50 mL) on top of the PVPA barriers 10 min prior to the addition of
the donor sample (100 mL). The donor sample was either obtained
after dispersion of SNEDDSs in the intestinal medium (i.e. sample
before lipolysis; time point 0 min), or after 30 min of lipolysis (i.e.
digesting SNEDDSs in intestinal medium; no lipolysis inhibition).
The barriers were then placed into an acceptor Transwell well
containing the acceptor medium (600 mL) and were moved into
new wells with the same medium after 2, 4, 5 and 6 h to uphold
sink conditions. The electrical resistance across the PVPA barriers
was measured after 6 h to test if the integrity of the barriers was
maintained, as discussed above (Section Compatibility of the PVPA
Barriers with Donor and Acceptor Media). The quantification of
calcein and fenofibrate in the acceptor compartment was carried
out using a Tecan Infinite M200 fluorimeter/spectrophotometer
(Salzburg, Austria; Software: Magellan) at excitation wavelength of
485 nm and emission of 520 nm (gain: 70) for calcein and 288 nm
for fenofibrate. For each condition tested, six PVPA barriers were
used (n ¼ 6).
Calculations











Where dQ/dt expresses the flux at the steady state (nmol/s), A is the
surface area of the PVPA barriers (0.33 cm2) and Cd the initial
fenofibrate/calcein concentration in the donor compartment
(nmol/mL).
The area under the curve (AUC) was calculated using GraphPad
Prism 7.03 (GraphPad Software, San Diego, CA, USA), which
employed a linear trapezoidal model from t ¼ 0 to t ¼ 6 h.
Statistical Analysis
GraphPad Prism 7.03 was employed for the statistical analysis of
the presented results (GraphPad Software, San Diego, CA, USA). The
data was analysed using one-way ANOVA followed by Sidak post
hoc test to detect significant differences (p < 0.05) when comparing
three or more sets of data. If a comparison between two sets of data
was made, student t-test was employed (p < 0.05).
Results and Discussion
In this study, the development and validation of the in vitro
lipolysis e mucus-PVPA permeation model was carried out. Bio-
similar mucus (BM) was added on top of the PVPA barriers, leading
to a better simulation of the intestinal mucosa, which also contains
a mucus layer.
The integrity of the PVPA barriers was evaluated in the presence
of BM, simulated intestinal medium, undigested and digesting
SNEDDSs. The lipolysis of fenofibrate-loaded SNEDDSs was studied
using the in vitro intestinal lipolysis model, followed by the drug
permeation assessment using the mucus-PVPA barriers. Finally, the
correlation of in vitro lipolysis and lipolysis-permeation data with
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of IVIVC assessed in this study can be referred to as a Level D cor-
relation, and it is considered a qualitative correlation which can be
used in the development of new formulations.31Lipolysis-Permeation Model Setup
Donor Medium Selection
The compatibility of the PVPA barriers, with and withoutmucus,
with the donor medium compositions in Fig.1B, using PBS pH 7.4 as
acceptor medium, was evaluated by assessing the permeation of
the hydrophilic marker calcein, and the electrical resistance across
the barriers at the end of the permeation assay (see Section
Compatibility of the PVPA Barriers with Donor and Acceptor
Media).
As it can be observed in Fig. 1, the PVPA barriers were able to
maintain their functionality in all the tested donor media in the
presence of BM. In the absence of BM, the mediumwith undigested
SNEDDS75 (Fig. 1, Setup 5) led to barrier impairment; calcein Papp
was 0.29 $ 106 cm/s and the electrical resistance was 208 Ohm $
cm2, which were both values outside the limits set for intact bar-
riers (i.e. calcein Papp above 0.06 $ 106 cm/s and electrical resis-
tance below 290 Ohm $ cm2 indicate loss of barrier integrity28).
However, the digested SNEDDS75 in the donor compartment
showed to be compatible with the barrier also in the absence of
mucus (Fig. 1, Setup 7). The difference in barrier compatibility be-
tween the undigested and digested SNEDDS75 might be due to the
colloidal structures that are generated during the lipolysis of
SNEDDSs. SNEDDS75 before lipolysis display a very distinct struc-
ture characterized by nano-emulsion droplets, while during lipol-
ysis their lipid fractions result in the formation of different colloidal
structures, such as vesicles andmicelles, composed of both lipolysis
products and components present in the simulated intestinal
medium.12
BM, fasted state simulated intestinal medium, undigested
SNEDDS75 (in the presence of BM) and digested SNEDDS75 (both
with uninhibited and inhibited pancreatin) were compatible with
the barriers (Fig. 1). As the presence of BM maintained barrier
integrity with undigested SNEDDS75 (Fig. 1, Setup 6), BM was
applied on top of the barriers during the assessment of the
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Acceptor Medium Selection
The solubility of fenofibrate was determined in the acceptor
medium for the permeation study described in Section Solubility
Studies to Select Acceptor Medium for Permeation Experiment.
Higher solubility of the lipophilic drug in the acceptor compart-
ment of the PVPA model would enable a larger amount of drug to
permeate, thereby easing the quantification of the amount of
permeated drug. As can be observed in Table 2, the highestTable 2
Equilibrium Solubility of Fenofibrate in Different Aqueous Media Prepared in PBS pH
7.4 (Mean ± SD; n ¼ 3).
Acceptor Medium Equilibrium Solubility (nmol/mL)
PBS pH 7.4 0.48 ± 0.03
DMSO 10 mg/mL 0.59 ± 0.08
DMSO 40 mg/mL 0.82 ± 0.01a
BSA 1% w/v 14.19 ± 0.13a
BSA 4% w/v 58.02 ± 0.49a
Tween 20 5 mg/mL 116.71 ± 5.73a
a Statistically significant difference in fenofibrate equilibrium solubility compared
to PBS pH 7.4 (p < 0.05).solubility of fenofibrate was in Tween 20 5 mg/mL and BSA 4% w/v.
Moreover, DMSO significantly increased the solubility of fenofi-
brate at a concentration of 40 mg/mL, but not at 10 mg/mL, when
compared to PBS pH 7.4 (Table 2).
Only DMSO (1e40 mg/mL) has previously been investigated
regarding its compatibility with the PVPA barriers,32 and showed
not to impair the integrity of the barriers up to a concentration of
40 mg/mL. Thus, to select the best acceptor medium, the func-
tionality of the barriers in the presence of each acceptor medium
was investigated before performing permeation experiments,
while using calcein solution (in PBS pH 6.5; 5.5 mM) on the donor
side. As can be seen in Fig. 2 the barriers maintained their integrity
in the presence of PBS pH 7.4 and DMSO (10 and 40 mg/mL). In
contrast, BSA (1 and 4% w/v) and Tween 20 5 mg/mL caused barrier
impairment, as demonstrated by an increased calcein Papp and
decreased electrical resistance. Based on the effect on PVPA barrier
integrity and the solubility of fenofibrate, DMSO 40 mg/mL was
chosen as the acceptor medium in the fenofibrate permeation
studies.
In Vitro Lipolysis of Fenofibrate-Loaded SNEDDSs
Three SNEDDSs (SNEDDS75, super-SNEDDS solution150 and
super-SNEDDS suspension150) were analysed in terms of their
capability of solubilizing fenofibrate after 30 min of in vitro lipol-
ysis. Fig. 3 depicts the distribution of fenofibrate in the aqueous and
the pellet phase before (0 min) and after (30 min) lipolysis. For
SNEDDS75, little to no precipitation was observed both before
(0 min) and after (30 min) lipolysis, while for the super-SNEDDS
solution150, precipitation of fenofibrate was observed at the start
of lipolysis and after 30 min. In the case of the super-SNEDDS
suspension150, the presence of drug precipite was pronounced
both after dispersion (0 min) and after lipolysis (30 min), and a
significant increase over time (p < 0.05) was observed when
comparing the amount of precipitate before and after lipolysis
(Fig. 3). The differences between the SNEDDSs can be due to that
twice as much SNEDDS75 was added, compared to the super-
SNEDDS solution150 and the super-SNEDDS suspension150, in or-
der to keep the fenofibrate concentration constant in the lipolysis
vessel. This lower amount of lipid caused a decrease in drug solu-
bilization and an increase in drug precipitation.
When comparing the two super-SNEDDSs, containing the same






























Fig. 2. PVPA barrier integrity expressed as apparent permeability (Papp) of calcein
(5.5 mM) and electrical resistance across the barriers with different media in the
acceptor compartment, and calcein 5.5 mM in the donor compartment (in PBS pH 6.5).


























FF in aqueous phase
FF in pellet phase
*
*  Statistical difference between
    0 and 30 min of lipolysis
Fig. 3. Relative amount of fenofibrate present in the aqueous phase (grey) and pellet phase (black) during in vitro intestinal lipolysis of SNEDDS75, super-SNEDDS solution150 and
super-SNEDDS suspension150. (Mean ± SD; n ¼ 4). * Statistical difference between the percentages of fenofibrate in solution after 0 min compared to 30 min of lipolysis.
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This is due to the nature of the super-SNEDDS suspension150 where
the drug is only partially dissolved, whereas the drug is completely
dissolved in the super-SNEDDS solution150.
Michaelsen et al.,12 studied the same fenofibrate-containing
SNEDDSs, and the impact of fenofibrate load and SNEDDSs lipol-
ysis on drug solubilization and absorption was evaluated via an
in vivo pharmacokinetic study in rats and in vitro lipolysis. The re-
sults depicted in Fig. 3 are in accordance with the in vitro lipolysis
data obtained by Michaelsen et al.12 Even though the ranking in
terms of drug precipitation of the three SNEDDSs was the same as
the findings in the present study, the percentage of drug precipi-
tated during lipolysis was higher in the results presented by
Michaelsen et al.12 The difference in drug precipitation between the
two studies can be explained by the different experimental setups
of the in vitro lipolysis applied in the two studies: in the present
study, calciumwas added to the simulated intestinal medium prior
to lipolysis (initial/bolus addition of calcium) to simplify the
experimental setup, whereas in the study by Michaelsen et al.12
calcium was continuously added during lipolysis to control the
rate of lipolysis (dynamic addition of calcium). It has previously
been demonstrated that initial and continuous addition of calcium
can lead to differences in terms of drug precipitation during lipol-
ysis of LbDDSs, and that the calcium concentration can also have an
effect on the extent of lipolysis.33In Vivo Absorption-In Vitro Lipolysis Correlation
In the study by Michaelsen et al.,12 the super-SNEDDS solu-
tion150 had a superior in vivo performance after oral dosing to ratsTable 3
Area Under the Curve (AUC) Resulting From Fenofibrate Absorption During In Vivo Studi
30 min of In Vitro Lipolysis, and AUC Resulting from the Mass Transfer of Fenofibrate Pe
(30 min) In Vitro Lipolysis From Super-SNEDDS Solution150, SNEDDS75 and Super-SNEDD
AUC0e30h, in vivo (mg$h/mL) in vivo rats*
Fenofibrate (%) in the aqueous phase after 30 min of in vitro lipolysis
AUC0e6h, perm (nmol$h) in vitro mucus-PVPA: f
enofibrate permeation before lipolysis
AUC0e6h, perm (nmol$h) in vitro mucus-PVPA:
fenofibrate permeation after 30 min in vitro lipolysis
Values labelled with the same letter are significantly different. (Mean ± SEM; n ¼ 6).(i.e. higher AUC0e30h, in vivo and Cmax) compared to SNEDDS75 and
super-SNEDDS suspension150 (Table 3). This was not correlating
with the observed drug solubilization during in vitro lipolysis,
where SNEDDS75 led to a higher drug solubilization. Thus,
Michaelsen et al.12 were not able to find a correlation between the
in vivo absorption and the drug solubilization during in vitro
lipolysis.
In accordance with the findings from Michaelsen et al.,12 the
present study did not find a correlation between the drug solubi-
lized during in vitro lipolysis (Section In vitro lipolysis of
fenofibrate-loaded SNEDDSs) and the in vivo plasma data
(R2 ¼ 0.397; Fig. 4, Table 3), highlighting the fact that in vitro sol-
ubilization alone cannot predict the in vivo absorption of fenofi-
brate from the SNEDDS analysed in this study. Even though it is
generally assumed that the SNEDDS able to maintain the most drug
in solution during lipolysis leads to the highest bioavailability,34 it
should be noted that the amount of fenofibrate in the aqueous
phase during in vitro lipolysis is in a dynamic equilibrium between
free drug and drug solubilized in vesicles and other colloidal
structures resulting from the lipolysis products (e.g. free fatty acids
and monoglycerides) and their interaction with bile salts and
phospholipid in the medium.13 Only the free drug is available for
absorption, and therefore it is of interest to quantify this, by adding
a permeation step to the in vitro lipolysis.In Vitro Permeation
The permeation of fenofibrate across the mucus-PVPA barriers
following administration of three different SNEDDSs was evaluated
before (0 min) and after (30 min) in vitro lipolysis. This allowed thees in Rats (*12, AUC0e30h, in vivo), % of Fenofibrate Found in the Aqueous Phase After
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Fig. 4. Fenofibrate (%) found in the aqueous phase (AP) after 30 min of in vitro lipolysis
as a function of the AUC 0e30h, in vivo from the plasma curve after oral dosing in rats
(Michaelsen et al., 201912) of super-SNEDDS solution150 (grey circle), SNEDDS75 (black
square) and super-SNEDDS suspension150 (white triangle).
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i) SNEDDSs composition and ii) lipolysis of the SNEDDSs. The in-
line assessment of the mucus-PVPA barrier integrity carried out
by measuring the permeation of calcein confirmed the correct
functionality of the mucus-PVPA barriers (data not shown), and
confirmed that the componenets present in the donor compart-
ment of the permeation barriers did not affect the mucus-PVPA
barriers integrity.
As can be observed from Fig. 5, both before and after lipolysis,
the super-SNEDDS solution150 allowed the highest permeation of
fenofibrate, followed by the SNEDDS75 and the super-SNEDDS
suspension150. Even though the ranking of the three SNEDDSs
was the same before (Fig. 5A) and after lipolysis (Fig. 5B), differ-
ences in the permeation profiles in the two conditions led to dif-
ferences in AUC0e6h, perm (Table 3). The AUC0e6h, perm for the
undigested super-SNEDDS solution150 was significantly higher than
for the super-SNEDDS suspension150, but not the SNEDDS75. After
30 min of in vitro lipolysis, the AUC0e6h, perm for the super-SNEDDS
solution150 was significantly higher than the AUC0e6h, perm for both
the super-SNEDDS suspension150 and the SNEDDS75 (Table 3). This
is in accordance with the in vivo data presented by Michaelsen
et al.12 where the ranking of the in vivo AUC0e30h, in vivo was: super-
SNEDDS solution150 > SNEDDS75 > super-SNEDDS suspension150
(Table 3). The difference between the AUC0e6h, perm before and after
lipolysis can be explained by a change in drug concentration in the
aqueous phase upon lipolysis. The nanoemulsion droplets of
SNEDDS formed after dispersion in the intestinal medium (i.e.



























Fig. 5. Cumulative amount of fenofibrate permeated across the mucus-PVPA barriers from
suspension150 (white triangle) A) before (0 min) and B) after (30 min) lipolysis. (Mean ± SDsolubilization compared to the colloidal structures formed during
lipolysis. This will especially impact the equilibrium between the
amount of drug free in solution and the one associated with
colloidal structures, and thus the amount of drug available for
permeation across the PVPA barriers.
The results discussed thus far demonstrate that, even though
the total drug concentration in the donor compartment was the
same (480 mg/mL) for all the analysed SNEDDSs, the amount of
fenofibrate permeating through the barriers was affected by the
SNEDDS in the donor compartment. Moreover, even though the
in vitro lipolysis showed that the SNEDDS75 resulted in the highest
amount of drug solubilized in the aqueous phase (Fig. 3), the super-
SNEDDS solution150 exhibited the highest permeation (Fig. 5).
Thomas et al.35 have demonstrated that drug precipitation
following lipolysis of super-SNEDDS solutions does not necessarily
translate to lower in vivo drug absorption. The difference in drug
permeation between the super-SNEDDS solution150 and SNEDDS75
can be due to the partitioning of the drug between being free in
solution and in the colloidal structures, formed upon dispersion/
lipolysis of the SNEDDS on top of the permeation barriers. For
SNEDDS75, the lipid content is higher, and more drug can be asso-
ciated to the colloidal structures, thus not being able to permeate.
In contrast, for super-SNEDDS solution150, the lower lipid content
can lead to a higher amount of drug being free in solution, and thus
able to permeate through the mucus-PVPA barriers, as demon-
strated in Fig. 5.In Vivo Absorption-In Vitro Permeation Correlation
To assess the correlation between in vitro and in vivo data, the
in vitro AUC0e6h, perm from the fenofibrate permeationwas depicted
as a function of the in vivo AUC0e30h, in vivo (Table 3,12) in Fig. 6. The
correlation of the permeation data after 30 min of in vitro lipolysis
was better (Fig. 6B, R2 ¼ 0.9952) compared to the permeation of
fenofibrate from undigested SNEDDSs (Fig. 6A, R2 ¼ 0.9255),
highlighting the positive impact of the presence of lipolysis on the
IVIVC. Comparing these findings to Fig. 4, it is clear that for the
investigated SNEDDSs, the amount of drug solubilized during
in vitro lipolysis studies alone cannot predict the in vivo absorption
of fenofibrate, while an additional permeation step can enable a
prediction of the performance of SNEDDS in vivo.
In the present study, the presence of the BM layer on top of the
absorptive PVPA barriers permitted the development of a perme-
ation model able to withstand a digesting environment (Fig. 1).
Moreover, the addition of BM on top of the PVPA barriers allowed
for a better simulation of the intestinal mucosa, and possibly


























super-SNEDDS solution150 (grey circle), SNEDDS75 (black square) and super-SNEDDS
; n ¼ 6).




























































Before lipolysis After lipolysis
a b
Fig. 6. In-vivo-in-vitro correlation (IVIVC) of in vivo plasma exposure (Michaelsen et al., 201912) and in vitro fenofibrate permeation across the mucus-PVPA barriers A) before (0 min)
and B) after (30 min) lipolysis from super-SNEDDS solution150 (grey circle), SNEDDS75 (black square) and super-SNEDDS suspension150 (white triangle).
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permeation experiments were performed in the presence of mucus,
the comparison in terms of drug permeation between the presence
and absence of the mucus layer could not be assessed. The hydro-
philic mucus barrier in the mucus-PVPA model has previously
shown to affect drug permeation depending on the physicochem-
ical properties of the investigated drug, drug formulation and the
simulated physiological conditions,28,29,36 and it is thus regarded as
an essential part of the artificial absorption barrier. The presence of
mucus is also important as it has been shown that SNEDDSs can
rapidly permeate across this layer thanks to the low interaction of
their hydrophobic surface with the hydrophilic regions of mucus
and thanks to their low droplet size, consequently enabling higher
drug absorption.37,38 Thus, the inclusion of mucus on top of an
in vitro permeation membrane is crucial to simulate the environ-
ment that SNEDDSs would be presented to in vivo, and allows these
drug delivery systems to explicate the positive effect on drug ab-
sorption related to their high mucus permeation.Conclusion
In the present study, the in vitro lipolysis e mucus-PVPA
permeation model was developed. The model allowed the combi-
nation of the assessment of drug distribution during lipolysis for
fenofibrate-loaded SNEDDSs typical of the in vitro intestinal lipol-
ysis model with the quantification of the fenofibrate permeation
through an artificial membrane mimicking the intestinal epithe-
lium (i.e. mucus-PVPA barrier). The barriers used in this work were
more stable when lined with a mucus layer, thus being able to
closely mimic the physiology of the intestinal mucosa and to
improve the relevance of the model for oral absorption studies. The
investigated SNEDDSs had different abilities to keep fenofibrate
solubilized in the aqueous phase during in vitro lipolysis, and led to
different drug permeation profiles. No correlation was found be-
tween already published in vivo absorption and drug solubilization
during in vitro lipolysis (R2 < 0.4), whereas a satisfactory correlation
was found between the same in vivo data with in vitro permeation
data both before and after in vitro lipolysis (R2 > 0.9), highlighting
the importance of the permeation step following lipolysis in the
prediction of in vivo drug absorption. The combination of in vitro
lipolysis with in vitro permeation led to a better correlation
(R2 ¼ 0.9952) compared to absence of lipolysis (R2 ¼ 0.9255).
However, the satisfactory correlation in the absence of lipolysis
suggests that this step might not be necessary. In order to validate
this statement, further studies with other types of SNEDDSs need to
be carried out.By applying the in vitro lipolysis e mucus-PVPA permeation
model, it was possible to mimic physiological processes (i.e. lipol-
ysis and permeation) and to correlate the amount of fenofibrate
permeated in vitro with the AUC after oral dosing of the applied
SNEDDSs in rats.
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A B S T R A C T   
The prediction of the in vivo performance of self-nanoemulsifying drug delivery systems (SNEDDSs) is currently 
gaining increasing attention. Therefore, the need for reliable in vitro models able to assess the drug solubilization 
capacity of such formulations upon in vitro lipolysis, as well as to concomitantly evaluate in vitro drug perme-
ation, has become ever so evident. In the current study, the high-throughput in vitro intestinal lipolysis model was 
combined with the mucus-PVPA in vitro permeation model to study the solubilization capacity of SNEDDSs for 
the poorly water-soluble drug fenofibrate and to study the consequent drug permeation. Moreover, drug solu-
bilization and permeation were evaluated both in the presence and absence of lipolysis. The results obtained 
demonstrated that the presence of in vitro lipolysis significantly impacted the solubilization and permeation 
profiles of fenofibrate compared to its absence. The results were in accordance with already published in vivo 
data regarding the same fenofibrate-loaded SNEDDSs. Additionally, the correlation between the in vitro 
permeation data and in vivo plasma concentration in rats was found to be excellent both in the presence and 
absence of lipolysis (R2 > 0.98), highlighting the ability of the developed combined in vitro model to predict in 
vivo drug absorption.   
1. Introduction 
The complexity of the physiological processes and characteristics of 
the gastrointestinal (GI) tract have shown to greatly affect the thera-
peutic outcome of oral drug-delivery systems (Lin and Wong, 2017). For 
instance, drug absorption can be largely influenced by the pH condition 
of the specific GI compartment, the presence and activity of metabolic 
enzymes and by the presence and composition of the food components 
possibly present along the GI tract (Vertzoni et al., 2019). These factors 
can have different effects on drug absorption according to the specific 
administered drug and its physicochemical characteristics. In particular, 
as up to 70% of new drug entities have been shown to be poorly water- 
soluble, increasing focus has been put on developing formulations able 
to overcome the low bioavailability connected to this type of drugs, and 
to understand the physiological processes affecting the performance of 
such formulations (Berben et al., 2018). In particular, lipid-based for-
mulations such as self-nanoemulsifying drug delivery systems 
(SNEDDSs) have shown to improve the bioavailability of poorly water- 
soluble drugs (PWSD) thanks to enhancement of solubilization and 
permeation, lymphatic transport and stimulation of supersaturation 
(Gao and Morozowich, 2006; Porter et al., 2007; Siqueira et al., 2017; 
Trevaskis et al., 2008). The dispersion of these formulations into the 
gastric and intestinal fluids and the digestion processes initiated by 
digestive enzymes are two of the key factors affecting the performance of 
SNEDDSs and the related drug absorption (Feeney et al., 2016). Even 
though several SNEDDSs have already reached the market, their opti-
mization is still regarded as challenging due to the complex array of 
processes (i.e. equilibrium between SNEDDSs digestion, drug supersat-
uration, precipitation and absorption) that can affect their performance 
(Savla et al., 2017). Due to the challenges related to predicting the 
behavior of these lipid-based formulations, the need for in vitro models 
able to evaluate the in vivo performance of SNEDDSs has become ever so 
evident. Consequently, several research efforts initially focused on 
producing in vitro models able to either study the effect of digestive 
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enzymes on the in vitro drug solubilization capacity of SNEDDSs (i.e. the 
in vitro intestinal lipolysis model (Zangenberg et al., 2001)), or on 
evaluating the in vitro permeation of PWSDs with the use of permeation 
barriers (i.e. the Caco-2 model (Artursson et al., 2001); the PAMPA 
model (Kansy et al., 1998); the PVPA model (Flaten et al., 2006); the 
Permeapad™ (di Cagno et al., 2015); and the AMI system (Berben et al., 
2018)). However, the separate evaluation of in vitro lipolysis and in vitro 
drug permeation did not lead to a complete overview of the physiolog-
ical processes affecting oral drug absorption. In fact, it has been shown 
that the evaluation of drug solubilization upon in vitro lipolysis of lipid- 
based formulations in the absence of an absorptive sink overestimates 
drug supersaturation and precipitation and underestimates drug ab-
sorption, while the addition of a permeation step leads to a more 
representative prediction of oral drug absorption in vivo (Bevernage 
et al., 2012; Stillhart et al., 2014). As a result of this, these two processes 
have been pooled together to produce combined in vitro lipolysis- 
permeation models (Alskär et al., 2019; Berthelsen et al., 2019; Bibi 
et al., 2017; Hedge and Bergström, 2020; Ille et al., 2020; Keemink et al., 
2019; Keemink and Bergström, 2018; O’Dwyer et al., 2020). These 
combined models proved to predict the in vivo drug absorption from 
SNEDDSs to a higher extent compared to in vitro lipolysis or in vitro 
permeation alone. However, all of the mentioned models except one 
(Keemink and Bergström, 2018) lack the presence of a mucus layer on 
top of the permeation barriers, thus not being able to closely mimic the 
physiology of the GI mucosa (Falavigna et al., 2020a; Lechanteur et al., 
2018). Notably, it has been shown that the presence of the mucus layer 
can stabilize supersaturation of PWSDs after in vitro lipolysis of lipid- 
based formulations, and it has been proposed that this could be one of 
the intrinsic mechanisms of action of these formulations (Yeap et al., 
2013, 2019). Further, several studies have pointed at the influence that 
mucus has on the diffusion and permeation of PWSDs, thus further 
emphasizing the importance of taking this additional barrier into ac-
count (Falavigna et al., 2020b; Miyazaki et al., 2019). To account for the 
need of mucus in a combined in vitro lipolysis-permeation model, a 
biosimilar mucus layer was added on top of the PVPA (Phospholipid 
Vesicle-based Permeation Assay) barriers (i.e. mucus-PVPA barriers) 
(Falavigna et al., 2020a). The mucus-PVPA barriers were used in com-
bination with the in vitro intestinal lipolysis model equipped with a pH- 
stat-titration apparatus (Falavigna et al., 2020a), and it was found that 
the combined in vitro lipolysis-permeation model was able to predict the 
in vivo oral absorption of fenofibrate from SNEDDSs for which in vivo 
data was available in the literature (Falavigna et al., 2020a; Michaelsen 
et al., 2019). However, while the above-mentioned combined models 
provided insightful information in the prediction of in vivo absorption 
data, for the most part they share the dependence from a pH-stat- 
titration apparatus to conduct the in vitro lipolysis step, thus limiting 
them to the availability of such laboratory equipment. 
In light of the limitations connected to the already available com-
bined in vitro models, the current study utilized the pH-stat-titration 
independent in vitro lipolysis model (i.e. the high-throughput (HTP) in-
testinal lipolysis model) developed by Mosgaard et al. (2015), in com-
bination with the mucus-PVPA in vitro permeation model to study the 
performance of three fenofibrate-loaded SNEDDSs. Specifically, the HTP 
in vitro intestinal lipolysis model has previously shown to predict drug 
distribution between aqueous, oil and pellet phase during lipolysis of 
SNEDDSs in the same manner as the in vitro intestinal lipolysis model, 
while not being tied to a pH-stat-titration apparatus (Mosgaard et al., 
2015, 2017). In fact, the high buffer capacity of the HTP intestinal 
medium is able to prevent the pH drop usually occurring after the 
release of free fatty acids from the digested SNEDDSs (Mosgaard et al., 
2015), thus leading to a constant pH and eliminating the need for the 
pH-stat titrator. The mucus-PVPA barriers were chosen as the in vitro 
permeation model because of their ability to provide the combination of 
a biosimilar mucus layer with a permeation barrier, and as these barriers 
have previously proven to mimic the intestinal mucosa physiology 
(Falavigna et al., 2018, 2019). More specifically, the mucus-PVPA 
barriers allow the assessment of passive drug diffusion from their 
donor to the acceptor compartment similarly to other cell-free in vitro 
permeation tools used to assess intestinal drug permeation (i.e. PAMPA 
model (Kansy et al., 1998); Permeapad™ (di Cagno et al., 2015); AMI 
system (Berben et al., 2018)). The mentioned cell-free tools are not able 
to take into account the active and carrier-mediated transport occurring 
when a drug is being absorbed in vivo. However, even though an un-
derestimation of active and carrier-mediated transport is a consequence 
of the mentioned tools, they provide a good estimation of in vivo passive 
drug diffusion, which is thought to be the predominant transport 
mechanism especially for lipophilic drugs (Dahlgren and Lennernäs, 
2019). 
The results obtained were compared to in vivo absorption data ob-
tained by Michaelsen et al. (2019), where the same fenofibrate-loaded 
SNEDDSs were administered to rats, and for which no in vivo-in vitro 
correlation (IVIVC) was found when comparing the in vivo absorption 
data with in vitro lipolysis data. To evaluate if the model developed in 
the present study would predict the in vivo data collected by Michaelsen 
et al. (2019), the correlation between these in vivo data and the in vitro 
data obtained in the present study was evaluated. 
2. Materials and methods 
2.1. Materials 
Acetonitrile CHROMANORM® (High-Performance Liquid Chroma-
tography, HPLC, grade), ethanol NORMAPUR® 96%, v/v (HPLC grade), 
methanol CHROMANORM® (HPLC grade) were purchased from VWR 
(Radnor, PA, USA). Bile bovine, Bis-Tris, bovine serum albumin (BSA), 
4-bromophenylboronic acid (BBBA), calcein, calcium chloride dihydrate 
(CaCl2 ⋅ 2H2O), chloroform, cholesterol, dimethyl sulfoxide (DMSO), 
fenofibrate, hydrochloric acid (HCl), magnesium sulfate (MgSO4), ma-
leic acid, MES hydrate, mucin from porcine stomach type II, pancreatin 
from porcine pancreas, potassium phosphate monobasic, sodium chlo-
ride (NaCl), sodium hydroxide (NaOH), sodium phosphate dibasic 
dodecahydrate, soybean oil, Tween® 80, Trizma® base were products of 
Sigma-Aldrich (St. Louis, MO, USA). Ethanol 99.9% (v/v) was purchased 
from Arcus AS (Oslo, Norway). Kolliphor RH-40 was purchased from 
BASF (Ludwigshafen, Germany). Lipoid egg phospholipids E80 (80% 
phosphatidylcholine, PC) and Lipoid soybean lecithin S100 (>94% PC 
S100) were kindly gifted from Lipoid GmbH (Ludwigshafen, Germany), 
while Maisine CC was kindly donated from Gattefossé (St. Priest, 
France). Polyacrylic acid (Carbopol® 974 PNF, PAA) was obtained from 
Lubrizol (Brussels, Belgium). All chemicals employed were of analytical 
grade. 
2.2. Methods 
In this study, the mucus-PVPA barriers were used to assess the in vitro 
permeation of fenofibrate from three different SNEDDSs (i.e. super- 
SNEDDS solution150, SNEDDS75 and super-SNEDDS suspension150) in 
the absence or presence of in vitro lipolysis utilizing the HTP in vitro 
intestinal lipolysis model. The results obtained from the in vitro lipolysis 
and permeation experiments were compared to in vivo plasma concen-
tration of fenofibrate in rats after administration of the same SNEDDSs to 
assess the IVIVC between these sets of data. 
2.2.1. Preparation of the mucus-PVPA barriers 
2.2.1.1. Biosimilar mucus. Biosimilar mucus (BM) was prepared ac-
cording to the method described by Boegh et al. (2014) and as described 
in Table 1. Specifically, PAA was dissolved in non-isotonic buffer (10 
mM MES, 1.3 mM CaCl2, 1.0 mM MgSO4) and mucin was added and 
stirred until homogeneously dispersed. In parallel, a lipid mixture was 
prepared by mixing PC S100 lipids, cholesterol and Tween® 80 in 
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isotonic buffer (10 mM MES, 1.3 mM CaCl2, 1.0 mM MgSO4, 137 mM 
NaCl). Finally, the lipid mixture and BSA were added to the PAA 
mixture, and stirred until homogeneity was reached. The pH of the final 
mixture (BM) was adjusted to 6.5. 
2.2.1.2. Mucus-PVPA barriers. The PVPA barriers were prepared 
following the method previously described (Falavigna et al., 2018, 
2019). Briefly, liposomes with two different size distributions (0.4 and 
0.8 µm) were immobilized by series of centrifugation and freeze-thawing 
on top of membrane filters (nitrocellulose, pore size 0.65 µm) fused on 
Transwell inserts (Corning Inc., New York, USA). 
To produce the mucus-PVPA barriers, BM (50 µL) was deposited on 
top of the PVPA barriers 10 min prior to the start of the permeation 
experiment. 
2.2.2. Preparation of high-throughput intestinal medium 
The HTP intestinal medium was prepared according to the method 
described by Mosgaard et al. (2015), as illustrated in Table 2. Briefly, the 
HTP intestinal medium was prepared by weighing the components listed 
in Table 2 and dissolving them in MilliQ water. Finally, the pH of the 
HTP intestinal medium was adjusted to 6.5. Calcein (5 mM) was added 
to the HTP intestinal medium to determine its permeability across the 
mucus-PVPA barriers, and thus to assess their integrity (see Section 
2.2.4.2). 
2.2.3. Preparation of fenofibrate-loaded SNEDDSs 
The fenofibrate-loaded SNEDDSs were prepared starting from a 
SNEDDS pre-concentrate according to the method described by 
Michaelsen et al. (2019). Briefly, the SNEDDS pre-concentrate was ob-
tained by heating soybean oil, Maisine CC and Kolliphor RH-40 at 50 ◦C, 
and by mixing them in the following ratio: soybean oil-Maisine CC (1:1 
w/w) 55% (w/w), Kolliphor RH-40 35% (w/w). Ethanol 99.9% (v/v) 
was added (10% (w/w)) once the mixture reached room temperature. 
The pre-concentrate was stirred until homogeneous at room tempera-
ture (23–25 ◦C). 
Fenofibrate was added to the pre-concentrate to yield three different 
fenofibrate-loaded SNEDDSs, namely super-SNEDDS solution150, 
SNEDDS75 and super-SNEDDS suspension150. SNEDDS75 and super- 
SNEDDS suspension150 were obtained by adding to the SNEDDS pre- 
concentrate an amount of fenofibrate corresponding to 75% and 150% 
of its equilibrium solubility, respectively (fenofibrate equilibrium solu-
bility in the SNEDDS pre-concentrate: 88.5 mg/g (Thomas et al., 2014)). 
SNEDDS75 and super-SNEDDS suspension150 were left to stir at room 
temperature (23–25 ◦C) until homogeneity was reached. Fenofibrate 
was completely dissolved in the SNEDDS75 (concentration lower than 
the equilibrium solubility), whereas for super-SNEDDS suspension150 
the drug was found both solubilized and in suspension (concentration 
higher than the equilibrium solubility). The super-SNEDDS solution150 
was obtained by dissolving an amount of fenofibrate corresponding to 
150% of its equilibrium solubility to the SNEDDS pre-concentrate. To 
aid the complete solubilization of the drug in the pre-concentrate (i.e. 
avoid the formation of a suspension above the equilibrium solubility), 
the super-SNEDDS solution150 was bath-sonicated for 30 min, heated at 
60 ◦C for 3 h and then let cool down at 37 ◦C overnight. 
2.2.4. In vitro lipolysis-permeation experiment 
This study focused on the development of a model where in vitro 
lipolysis and permeation could occur in parallel. The concomitant 
evaluation of drug distribution between aqueous and pellet phase during 
in vitro lipolysis and the assessment of drug permeation using the mucus- 
PVPA barriers was enabled by the use of HTP intestinal medium, which 
allowed the study to be independent from the pH-stat-titration appa-
ratus typically used in the in vitro intestinal lipolysis model (Zangenberg 
et al., 2001). To account for the impact that lipolysis has on in vitro drug 
distribution and on in vitro drug permeation, fenofibrate distribution 
between the aqueous and pellet phase in the HTP intestinal medium and 
permeation across the mucus-PVPA barriers were evaluated both after 
dispersion of SNEDDSs in the HTP intestinal medium (i.e. absence of 
lipolysis) and after commencement of in vitro lipolysis. This evaluation 
allowed the comparison of the data obtained in the present study with 
the data obtained by Michaelsen et al. (2019), where in vivo absorption 
of fenofibrate was studied both while lipolysis had been inhibited by the 
co-administration of the pancreatic lipase inhibitor orlistat, and in the 
presence of lipolysis. 
2.2.4.1. In vitro lipolysis. The three fenofibrate-loaded SNEDDSs (i.e. 
super-SNEDDS solution150, SNEDDS75 and super-SNEDDS suspen-
sion150) were separately weighed in a beaker and dispersed in 26 mL of 
HTP intestinal medium (Table 2). The amount of SNEDDS (i.e. either 
super-SNEDDS solution150, SNEDDS75 or super-SNEDDS suspension150) 
added to the beaker was chosen in order to obtain a final fenofibrate 
concentration of 480 µg/mL for all SNEDDSs and to have the same drug 
concentration as the one utilized in the in vitro lipolysis experiments 
performed by Michaelsen et al. (2019). The mixture was stirred at 37 ◦C 
for 20 min prior to the addition of the pancreatic lipase solution (4 mL) 
in the case of the presence of lipolysis, or of HTP intestinal medium (4 
mL) in the case of sole dispersion (i.e. absence of lipolysis). To obtain the 
pancreatic lipase solution, the crude lipase extract was mixed with 5 mL 
of HTP intestinal medium in the absence of calcein, and the mixture was 
centrifuged for 7 min at 6500 × g. The supernatant (4 mL) was added to 
the beaker to initiate the lipolysis (final activity of 550 USP/mL). To 
simulate physiological temperature, the experiment was performed at 
37 ◦C. Samples (1 mL), either utilized for the assessment of fenofibrate 
distribution in the aqueous phase or used for the permeation study, were 
taken out of the beaker after initial dispersion, after 30 min of additional 
dispersion or after 30 min from the initiation of lipolysis. This allowed to 
study both how the presence or absence of lipolysis affects the distri-
bution of fenofibrate in the HTP intestinal medium on top of the mucus- 
PVPA barriers, and to evaluate the resulting drug permeation. 
To study the distribution of fenofibrate between the aqueous and 
pellet phase before the start of lipolysis (i.e. 0 min) and after 30 min of 
dispersion/lipolysis, 5 µL of BBBA (1 M in MeOH) were added to the 1 
mL sample to inhibit lipolysis. The inhibited samples (0 and 30 min) 
were exposed to centrifugation for 10 min at 19,000 × g to allow phase 
separation. The concentration of fenofibrate in the aqueous phase was 
quantified via HPLC after dilution in MeOH, and compared to the total 
amount of drug in the beaker. The quantification of fenofibrate was 
carried out via HPLC using a Waters 2690 Separation Module HPLC 
system, equipped with Waters 996 Photodiode Array Detector (Waters 
Corporation, Milford, MA, USA) and utilizing a Phenomenex Kinetix 5u 
XB-C18 100A column (100 × 4.6 mm; Phenomenex, Torrance, CA, 
USA). The drug was detected at a wavelength of 288 nm (retention time 
Table 1 
Composition of biosimilar mucus (BM).  




PC S100 0.18 
Tween® 80 0.16 
BSA 3.10  
Table 2 
Composition HTP intestinal medium.  
Components Concentration (mM) 
Bile bovine 2.96 
PC S100 0.26 
CaCl2⋅2 H2O 4.50 
Bis-Tris 200  
M. Falavigna et al.                                                                                                                                                                                                                              
International Journal of Pharmaceutics 596 (2021) 120258
4
~ 2.5 min) using a mobile phase composed of 20% MilliQ water and 
80% of MeOH (flow 1 mL/min). The study of fenofibrate distribution in 
the different phases upon lipolysis was carried out in triplicate for each 
SNEDDS. 
To confirm that the pH conditions were kept constant during 
dispersion/lipolysis by the buffering capacity of the HTP intestinal 
medium, the pH was monitored using a SensIONTM pH 31 pH meter 
(HACH, Dusseldorf, Germany). Moreover, the size of the SNEDDSs 
droplets after dispersion and after initiation of lipolysis was determined 
using a Malvern Zetasizer Nano ZS (Malvern, Oxford, UK). Samples were 
prepared by dispersing the SNEDDS pre-concentrate in HTP intestinal 
medium (concentration 1.45 mg/mL), and for the investigation on the 
effect of lipolysis on the droplet size, pancreatic lipase extract was added 
to the dispersion in order to obtain a final activity of 550 USP/mL. The 
operating conditions used for the size determination were the following: 
viscosity of the sample dispersant 0.8872 cP, temperature 25.0 ◦C, 
measurement angle 173 ◦ backscatter, cell type disposable cuvettes 
(DTS0012), number of measurements 3. 
2.2.4.2. In vitro permeation. To study the permeation of fenofibrate 
from the different SNEDDSs, samples (1 mL) were taken out of the 
beaker before the start of lipolysis (i.e. sole dispersion, absence of 
lipolysis) and right after initiation of lipolysis (i.e. after the addition of 
the pancreatic extract), and were transferred (100 µL) on top of the 
mucus-PVPA barriers. The samples where lipolysis was initiated (100 
µL) were transferred on top of the mucus-PVPA barriers without inhib-
iting lipolysis, thus allowing this process to continue on top of the bar-
riers. The mucus-PVPA barriers were then placed in acceptor Transwell 
wells containing 600 µL of acceptor medium and the permeation 
experiment was carried out at 37 ◦C for a total of 6 h. DMSO 40 mg/mL 
in phosphate buffered saline (PBS) pH 7.4 was chosen as the acceptor 
medium to both simulate the pH conditions of the systemic blood cir-
culation and to enable higher fenofibrate solubility compared to PBS pH 
7.4 (Falavigna et al., 2020a). Higher fenofibrate solubility in the 
acceptor medium resulting from the presence of DMSO allows a higher 
amount of drug to permeate and this aids in the quantification of the 
permeated drug (Falavigna et al., 2020a). The barriers were moved to 
wells containing fresh acceptor medium after 2, 4 and 6 h to maintain 
sink conditions. At the end of the permeation experiment, samples (200 
µL) from the acceptor compartments were taken out to quantify the 
amount of fenofibrate permeated over time. 
As the previous assessment of the compatibility of the PVPA barriers 
with the components in the donor compartment showed that the pres-
ence of BM was essential for the correct functionality of the barriers 
(Falavigna et al., 2020a), BM was placed on top of the PVPA barriers in 
all of the permeation experiments. Moreover, in the present study, to 
assure the correct functionality of the mucus-PVPA barriers during the 
permeation experiment, an in-line assessment of barrier integrity was 
carried out in parallel to the fenofibrate permeation study. This evalu-
ation was done by measuring the permeability of calcein contained in 
the HTP intestinal medium and the electrical resistance across the bar-
riers at the end of the permeation study. To this regard, it has been 
demonstrated that high calcein permeability (>0.06 * 10− 6 cm/s) and 
low electrical resistance (<290 Ohm * cm2) indicate barrier impairment 
(Falavigna et al., 2018, 2019). 
The quantification of fenofibrate was carried out at 288 nm using the 
spectrophotometer module of the Spark Multimode Microplate Reader 
(Tecan, Männendorf, Switzerland), while calcein was quantified using 
the spectrofluorometer module of the same apparatus at excitation 
wavelength of 485 nm and emission of 520 nm. 












where dQ/dt is the flux at the steady state (nmol/s), A expresses the 
surface area of the PVPA barriers (0.33 cm2) and Cd is the calcein con-
centration in the donor compartment at time zero (nmol/mL). 
All permeability experiments were conducted using a total of 12 
PVPA barriers. 
2.2.5. In vivo-in vitro correlation 
The areas under the curve (AUCs) resulting from the in vivo plasma 
concentration of fenofibrate in rats obtained by Michaelsen et al. (2019) 
for the three SNEDDSs (i.e. super-SNEDDS solution150, SNEDDS75 and 
super-SNEDDS suspension150) were compared to the AUC resulting from 
either i) the in vitro dispersion/lipolysis described in Section 2.2.4.1, or 
ii) the in vitro permeation data described in Section 2.2.4.2. The in vitro 
dispersion/lipolysis/permeation AUC was calculated using GraphPad 
Prism 8.4.1 (GraphPad Software, San Diego, CA, USA) by utilizing a 
linear trapezoidal model from t = 0 to t = 30 min/6h. For the calculation 
of the AUC resulting from in vitro dispersion/lipolysis, the amount of 
fenofibrate found in the aqueous phase upon lipolysis over time was 
utilized. The AUCs of the in vitro permeation study was obtained from 
the mass transfer of fenofibrate permeated across the mucus-PVPA 
barriers over time. This comparison allowed to determine the IVIVC 
between the above-mentioned sets of data, and to study if the in vitro 
dispersion/lipolysis or combined dispersion/lipolysis/permeation data 
could predict in vivo drug absorption for the investigated SNEDDSs. 
2.2.6. Statistical analysis 
GraphPad Prism 8.4.1 (GraphPad Software, San Diego, CA, USA) was 
used for the statistical analysis of the results obtained in this study. One- 
way ANOVA was used to compare three or more sets of data, followed by 
Šidák post hoc test to determine significant difference between results (p 
< 0.05). 
3. Results and discussion 
In the present study, the need for a combined in vitro lipolysis- 
permeation model able to predict in vivo drug absorption from 
SNEDDSs was met by the combination of the HTP in vitro lipolysis model 
with the mucus-PVPA in vitro permeation model. In particular, the HTP 
in vitro lipolysis model allowed a simple and pH-stat-titration- 
independent evaluation of fenofibrate distribution in the aqueous and 
pellet phase after dispersion or lipolysis of three SNEDDSs, whereas the 
mucus-PVPA model allowed the evaluation of fenofibrate permeation. 
Finally, in vitro drug solubilization and drug permeation data were 
separately compared to in vivo absorption data present in the literature 
(Michaelsen et al., 2019) to assess the prediction potential of the 
experimental setups utilized in this study. The Level D correlation be-
tween in vivo and in vitro data was therefore determined since it is 
considered as a useful qualitative correlation that can be utilized during 
formulation development (Schen and Burgess, 2015). 
3.1. Effect of in vitro lipolysis of SNEDDSs on fenofibrate distribution 
The distribution of fenofibrate between the aqueous and pellet phase 
was studied after addition of the three SNEDDSs to the HTP intestinal 
medium both in the absence (i.e. sole dispersion) and presence of in vitro 
lipolysis for a total of 30 min. This investigation was carried out to es-
timate i) how much of the drug would be found in the aqueous phase 
over time (i.e. amount of drug potentially available for absorption) ii) 
which SNEDDS would result in a better drug solubilization upon 
dispersion/lipolysis and iii) how the presence of lipolysis affects the 
drug distribution between the aqueous and pellet phase compared to the 
absence of lipolysis. Moreover, the pH in the presence of in vitro lipolysis 
was measured to assure that the optimal pH condition for the activity of 
the pancreatic lipase would be maintained (i.e. pH ~ 6.5). In fact, the 
activity of the pancreatic enzyme has shown to induce the release of 
fatty acids upon digestion of SNEDDS, resulting in a decrease in pH and 
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thus inhibition of the lipolysis process (Zangenberg et al., 2001). To this 
regard, the HTP intestinal medium proved to be able to keep the pH 
around 6.48 ± 0.03 thanks to its high buffer capacity throughout all in 
vitro lipolysis experiments, in accordance with the results from Mos-
gaard et al. (2015). This pH condition was also kept in the absence of 
lipolysis, thus enabling the comparison between the drug distribution in 
the presence and absence of lipolysis. 
As can be observed in Fig. 1, both in the absence (Fig. 1A) and 
presence (Fig. 1B) of lipolysis, SNEDDS75 was able to maintain most of 
the drug solubilized in the aqueous phase during 30 min of dispersion/ 
lipolysis. However, for both super-SNEDDS solution150 and super- 
SNEDDS suspension150 the absence and presence of lipolysis both 
caused precipitation of the drug, thus increasing the amount found in 
the pellet phase. The same trend has previously been observed, where 
super-SNEDDS solution150 caused higher fenofibrate precipitation over 
time than SNEDDS75 and lower precipitation than super-SNEDDS sus-
pension150 (Falavigna et al., 2020a). Notably, in the presence of lipolysis 
drug precipitation occurred to a greater extent from 0 to 30 min in the 
case of super-SNEDDS solution150 compared to super-SNEDDS suspen-
sion150 (Fig. 1B). In fact, a modest change in precipitation was observed 
for super-SNEDDS suspension150, while for super-SNEDDS solution150 
this change was more drastic, most likely due to the instability of the 
supersaturated system resulting from this formulation. 
While drug precipitation in the pellet phase significantly increased 
over time (p < 0.05) in the presence of lipolysis (Fig. 1B) for super- 
SNEDDS solution150 and super-SNEDDS suspension150, after 30 min of 
dispersion (i.e. absence of lipolysis) the amount of drug found in the 
pellet phase was the same as at the start of the experiment (Fig. 1A). This 
trend was also found in the study by Michaelsen et al. (2019), where 
fenofibrate distribution between the aqueous and pellet phase of the 
same SNEDDSs was evaluated in two conditions, i) inhibition of dynamic 
in vitro lipolysis by the use of the pancreatic lipase inhibitor orlistat and 
ii) the presence of dynamic in vitro intestinal lipolysis. Further, the 
precipitation of fenofibrate remained constant in the presence of the 
pancreatic lipase inhibitor, whereas in its absence (i.e. active lipolysis) 
drug precipitation increased over time for super-SNEDDS solution150 
and super-SNEDDS suspension150 (Michaelsen et al., 2019). The increase 
in drug precipitation upon in vitro lipolysis is to be expected as the 
addition of the pancreatic lipase can induce the formation of different 
colloidal structures (i.e. micelles and vesicles) which are able to solu-
bilize the incorporated drug to a different extent compared to the nano- 
emulsion droplets of the SNEDDSs obtained after dispersion in the HTP 
intestinal medium (Mosgaard et al., 2015). To this regard, the size of the 
SNEDDSs droplets was determined after dispersion and after initiation of 
lipolysis. The results showed that the SNEDDSs diameter after dispersion 
was around 50.89 ± 1.09 nm with a polydispersity index of 0.38, sug-
gesting a rather monodispersed size distribution, whereas after initiation 
of lipolysis it was not possible to determine the size of the SNEDDSs due 
to a highly polydispersed size population (polydispersity index > 0.8), 
suggesting the formation of structures with various sizes upon the 
initiation of lipolysis. The structural changes in the colloidal species 
formed after dispersion compared to after lipolysis could have an effect 
on drug precipitation, and could be the underlying cause for the dif-
ferences in drug solubilization shown in Fig. 1. 
The results discussed thus far confirm the correct functionality of the 
HTP intestinal medium in maintaining the desired pH condition for the 
in vitro lipolysis process, and highlight the similarity of the obtained 
results with already published data. The use of the HTP intestinal me-
dium eliminates the need for the pH-stat-titration typically used in the in 
vitro intestinal lipolysis method, resulting in a simpler and less 
apparatus-dependent model. 
3.2. In vitro permeation of fenofibrate 
The permeation of fenofibrate across the mucus-PVPA barriers was 
determined both in the absence (i.e. sole dispersion) and presence of 
lipolysis to determine i) which SNEDDS would enable the highest drug 
mass transfer across the barriers and ii) whether the presence of lipolysis 
would cause a change in mass transfer compared to its absence. In 
parallel to the estimation of fenofibrate mass transfer, an in-line 
assessment of barrier integrity was carried out by measuring the 
permeability of the highly hydrophilic marker calcein and by deter-
mining the electrical resistance across the mucus-PVPA barriers at the 
end of the permeation experiment. As can be observed in Table 3, the 
barriers maintained their integrity in all of the tested conditions, as 
values of calcein Papp and electrical resistance were within the limits 
previously associated to barrier integrity (i.e. calcein Papp < 0.06 ⋅ 10− 6 
cm/s and electrical resistance >290 Ohm ⋅ cm2 (Falavigna et al., 2018)) 
In terms of fenofibrate mass transfer across the mucus-PVPA barrier, 
both in the absence (Fig. 2A) and presence (Fig. 2B) of lipolysis, super- 
SNEDDS solution150 exhibited the highest fenofibrate mass transfer, 
suggesting that this formulation would lead to the highest bioavail-
ability in both cases. Instead, for SNEDDS75 and super-SNEDDS sus-
pension150 the ranking was different according to the absence or 
Fig. 1. Fenofibrate (%) present in the pellet (black) and aqueous phase (grey) over time A) in the absence of lipolysis (i.e. sole dispersion) and B) with lipolysis for 
SNEDDS75, super-SNEDDS solution150 and super-SNEDDS suspension150. (Mean ± SD; n = 3). * Statistically significant (p < 0.05) difference between the percentages 
of fenofibrate in the aqueous phase after 0 min compared to 30 min. 
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presence of lipolysis; in fact, super-SNEDDS suspension150 promoted a 
significantly higher mass transfer of fenofibrate in the absence of 
lipolysis compared to SNEDDS75, whereas in its presence SNEDDS75 and 
super-SNEDDS suspension150 led to a similar drug permeation across the 
mucus-PVPA barriers (Fig. 2). 
The change in ranking in terms of fenofibrate plasma concentration 
was also observed by Michaelsen et al. (2019), where the same SNEDDSs 
were administered to rats both in the presence of lipolysis and after this 
process was inhibited by the co-administration of the pancreatic lipase 
inhibitor orlistat. The authors found that the absorption of fenofibrate 
from super-SNEDDS suspension150 significantly increased when orlistat 
was present. Regarding this, it was suggested that when lipolysis is 
inhibited, the SNEDDS nano-emulsion droplets remain present in the GI 
tract, providing constant solubilization of the drug and aid in the drug 
absorption process while avoiding further precipitation (Michaelsen 
et al., 2019). The positive effect of the absence of lipolysis on drug 
solubilization can also be observed in Fig. 1A, where fenofibrate pre-
cipitation did not increase over time in the absence of lipolysis, whereas 
when this process was initiated, drug precipitation increased (Fig. 1B). 
Therefore, in the case of the super-SNEDDS suspension150 for both this 
study and the one from Michaelsen et al. (2019) the inhibition of 
lipolysis maintained fenofibrate solubilized for a longer time. However, 
it has to be noted that the drug found in the aqueous phase is present as 
both solubilized in the SNEDDS nano-emulsion droplets/in the colloidal 
structures formed upon lipolysis and free in solution. The ability to keep 
the drug free in solution promotes drug permeation, as only this fraction 
is able to cross the permeation barrier (Keemink and Bergström, 2018). 
In the current study, a difference in drug transfer between the absence 
and presence of lipolysis was also observed for SNEDDS75, where drug 
permeation was found to be higher in the presence of lipolysis. In 
contrast to the super-SNEDDS suspension150, where fenofibrate is pre-
sent both as a precipitate and solubilized in the SNEDDS, the SNEDDS75 
has all the drug completely solubilized in the nano-emulsion droplets. 
Thus, when SNEDDS75 is dispersed in the HTP intestinal medium most of 
the drug is possibly solubilized in the SNEDDS, rather than free in so-
lution. The formation of different colloidal structures upon in vitro 
lipolysis can shift the equilibrium of the drug towards the fraction free in 
solution, translating to higher fenofibrate permeation in the presence of 
lipolysis. The increase in fenofibrate permeation in the presence of 
lipolysis for SNEDDS75 was not observed in the previous study (Fala-
vigna et al., 2020a), as it was found that SNEDDS75 had similar fenofi-
brate permeation both in the absence and presence of lipolysis. 
Differences in fenofibrate permeation between published data and the 
results collected in the present study could be due to the different 
compositions of the utilized simulated intestinal fluids. In fact, in the 
case of HTP intestinal medium, the high concentration of Bis-Tris might 
affect i) the droplet size of the SNEDDSs and of the colloidal structures 
forming upon lipolysis, ii) the drug equilibrium between the fraction 
free in solution and the one solubilized by the SNEDDS and iii) the extent 
and nature of drug precipitate, thus possibly leading to a change in drug 
permeation. Moreover, it has to be noted that drug solubilization in 
SNEDDSs in the absence of drug supersaturation or precipitation can 
reduce the drug thermodynamic activity (Yeap et al., 2013), and it has 
been demonstrated that drug solubilization in SNEDDSs does not lead to 
higher drug absorption if the free drug concentration does not increase, 
despite the rise in total solubilized drug (Yeap et al., 2013). On the other 
hand, drug supersaturation can result in an increase in thermodynamic 
activity and instability, possibly resulting in drug precipitation (Tanaka 
et al., 2020), as suggested by the results described in Section 3.1 with 
regards to super-SNEDDS solution150 and super-SNEDDS suspension150 
(Fig. 1). However, drug precipitation caused by the thermodynamic 
instability of a supersaturated state does not necessarily translate to 
lower drug absorption, as the solid state of the precipitate could re- 
dissolve and thus lead to high absorption (Tanaka et al., 2020). How-
ever, to confirm the hypothesis that fenofibrate could re-dissolve from 
its precipitated state and to identify the mechanisms behind this process, 
further characterization of the drug and SNEDDSs would be needed. 
Table 3 
Calcein Papp and the electrical resistance across the mucus-PVPA barriers during 
dispersion/lipolysis-permeation experiments. (Mean ± SD; n = 12).   
SNEDDS Calcein Papp 










422 ± 22 
SNEDDS75 0.055 ±
0.002 





450 ± 3 




562 ± 37 
SNEDDS75 0.027 ±
0.001 





818 ± 112  
Fig. 2. Fenofibrate permeated across the mucus-PVPA barriers (cumulative amount) from super-SNEDDS solution150 (grey circle), SNEDDS75 (black square) and 
super-SNEDDS suspension150 (white triangle) A) in the absence of lipolysis and B) with lipolysis. (Mean ± SD; n = 12). *Statistically significant (p < 0.05) difference 
between the amount of fenofibrate permeated from super-SNEDDS solution150 and from super-SNEDDS suspension150 and SNEDDS75. **Statistically significant (p <
0.05) difference between the amount of fenofibrate permeated from super-SNEDDS suspension150 and SNEDDS75. 
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3.3. In vivo-in vitro correlation 
The results obtained in this study and described in Section 3.1 and 
3.2 were compared to the ones obtained by Michaelsen et al. (2019), 
where the same SNEDDSs were utilized to study fenofibrate absorption 
in rats. In particular, the AUCs resulting from the in vivo study, where 
lipolysis was either inhibited (− ) by presence of orlistat or taking place 
(+) (AUC in vivo, − /+ lipolysis), were compared to the AUCs resulting from 
the amount of drug found in the aqueous phase after in vitro dispersion 
(− ) or lipolysis (+) over time (AUC in vitro, − /+ lipolysis). The same in vivo 
data was also compared to the AUCs calculated from the fenofibrate 
mass transfer after in vitro permeation in the absence (− ) or presence (+) 
of lipolysis using the mucus-PVPA barriers (AUC in vitro permeation, − /+
lipolysis) (Table 4). Moreover, the statistical difference in AUC between 
absence and presence of lipolysis for both in vivo and in vitro results was 
evaluated (Table 4), and the IVIVC between these sets of data were 
determined (Fig. 3 and Fig. 4). 
3.3.1. Correlation with in vitro drug solubilization upon dispersion/lipolysis 
As can be observed in Fig. 3 and Table 4, the in vitro solubilization 
data (AUC 0–0.5h, − /+ lipolysis) failed to correlate with in vivo plasma 
concentration in rats both in the absence and presence of lipolysis. In 
fact, the prediction of drug absorption via the evaluation of drug found 
in the aqueous phase during dispersion/lipolysis does not take into ac-
count that the fenofibrate present in the aqueous phase is in a dynamic 
equilibrium between its fraction freely dissolved in the luminal contents 
and the fraction solubilized by the SNEDDS colloidal structures formed 
upon lipolysis. Therefore, the drug in the aqueous phase is an over-
estimation of the amount of drug freely solubilized and thus available 
for permeation (Michaelsen et al., 2019). This was clearly evident when 
SNEDDS75 was evaluated. In fact, according to the drug distribution in 
the aqueous and pellet phase after dispersion/lipolysis (AUC 0–0.5h, − /+
lipolysis), SNEDDS75 is the one where most of the drug is found in the 
aqueous phase (Fig. 1, Table 4), whereas in vivo the corresponding AUC 
is lower than for the super-SNEDDS solution150. The difference in the 
ranking between the in vitro dispersion/lipolysis and in vivo plasma 
concentration data can be ascribed to the above-mentioned lack of 
distinction between the freely solubilized drug and the drug in the 
colloidal structures, and also to the lack of an absorption step. In fact, 
Bevernage et al. (2012) have evaluated the influence of an absorption 
step on supersaturation and precipitation of a poorly water-soluble drug, 
and found that precipitation from a supersaturated system can be 
suppressed by the escape of the drug via the absorption sink, thus 
averting the system from reaching a critical degree of supersaturation 
and the start of precipitation. Thus, the results described in the study by 
Bevernage et al. (2012) suggest that precipitation kinetics change when 
supersaturated drugs have the chance of permeating instead of precip-
itating, and that the shift towards drug permeation instead of precipi-
tation increases with increasing degrees of supersaturation. 
3.3.2. Correlation with in vitro drug permeation 
The results depicted in Fig. 4, where the AUCs resulting from the in 
vitro permeation of fenofibrate (AUC0–6h permeation, − /+ lipolysis) were 
plotted against the in vivo drug absorption data (AUC0–30h, − /+ lipolysis), 
are proof of the importance of the absorption step in in vitro models 
evaluating lipid-based formulations, (Fig. 4). In fact, an excellent IVIVC 
(R2 > 0.98) was found when comparing the in vitro drug permeation in 
the absence or presence of lipolysis with in vivo data where lipolysis was 
either inhibited (i.e. use of orlistat) or taking place. The lack of IVIVC 
using in vitro drug distribution data from the dispersion/lipolysis ex-
periments alone (AUC 0–0.5h, − /+ lipolysis) (Fig. 3) compared to the good 
correlation obtained using the in vitro permeation data following 
dispersion/permeation (Fig. 4) suggests that the intrinsic solubilization 
of SNEDDSs does not dictate the degree of drug absorption, whereas the 
propensity of SNEDDSs to promote supersaturation seems to be more 
important (Yeap et al., 2013). 
Moreover, the presence of the mucus layer on top of the mucosa of 
the small intestine has been suggested to play an important role in sta-
bilizing drug supersaturation. In fact, it has been found that mucin and 
pig intestinal mucus were both able to delay precipitation during 
supersaturation-permeation experiments for two PWSD (Yeap et al., 
2019). It has been proposed that the mechanisms enabling the stabili-
zation of supersaturation exerted by the mucus layer were drug-specific. 
In particular, it has been shown that the presence of mucin and pig in-
testinal mucus delayed carvedilol and piroxicam precipitation, and that 
the absorption of carvedilol from a supersaturated solution was higher 
across mucus-producing co-culture of Caco-2 cell-layers compared to 
non-mucus-producing ones (Yeap et al., 2019). Therefore, the absence of 
biosimilar mucus in the HTP dispersion/lipolysis setup (Section 3.1) 
could be another reason why the in vitro lipolysis evaluation did not 
correlate with in vivo data, as the stabilization of drug supersaturation 
could not be carried out by the mucus layer. During the in vitro perme-
ation experiments, on the other hand, the biosimilar mucus layer lining 
the PVPA barriers possibly enabled the maintenance of fenofibrate su-
persaturation by delaying drug precipitation, and thus leading to higher 
mass transfer for those formulations providing a supersaturated fenofi-
brate concentration (i.e. super-SNEDDS solution150 and super-SNEDDS 
suspension150). The good IVIVC obtained using the mucus-PVPA 
model (Fig. 4) together with the results described by Yeap et al. 
(2019) highlight the importance of having a mucus layer lining the 
permeation barrier when studying the permeation of supersaturated 
PWSD. This is especially relevant as the supersaturation stabilization 
process could be seen as an intrinsic mechanism of action for lipid-based 
formulations, and it should thus be taken into consideration in the 
development of novel drug delivery systems. 
Overall, the results presented in this study underline the complexity 
of the processes affecting the performance of SNEDDSs in vivo, and 
emphasize that drug solubilization, supersaturation, precipitation and 
permeation all coexist in a dynamic equilibrium that drives drug ab-
sorption. This could be simulated with the use of an appropriate in vitro 
model as the one presented in this work. Further studies assessing a 
broader selection of drugs and formulations need to be performed to 
investigate the full potential of the combined in vitro model developed in 
this study. At this stage, this appears to be a very promising approach to 
estimate in vivo performance of lipid-based formulations, and as such a 
highly valuable tool in the development and optimization of this type of 
formulations. 
Table 4 
Area under the curve (AUC) resulting from fenofibrate absorption from in vivo 
studies in rats in the absence (− ) or presence (+) of lipolysis [26] (in vivo 
AUC0–30h, − /+ lipolysis), AUC from drug solubilization without (− ) and with (+) in 
vitro lipolysis (i.e. amount of drug found in the aqueous phase; in vitro AUC 0–0.5h, 
− /+ lipolysis) and mass transfer of fenofibrate permeated across the mucus-PVPA 
barriers without (− ) or with (+) lipolysis (in vitro AUC0–6h permeation, − /+ lipol-
ysis) from super-SNEDDS solution150, SNEDDS75 and super-SNEDDS suspen-





In vivo AUC0–30h, −
lipolysis (µg⋅h/mL) 
136.9 ± 27.5 66.3 ± 14.9 108.9 ± 39.5 
In vivo AUC0–30h, +
lipolysis (µg⋅h/mL) 
148.0 ± 47.5 88.3 ± 20.9 58.1 ± 16.9 
In vitro AUC 0–0.5h, −
lipolysis (min⋅%) 
2160.0 ± 235.8 2985.0 ±
105.4 
1800.0 ± 197.1 
In vitro AUC 0–0.5h, +
lipolysis (min⋅%) 
1965.0 ± 121.5 2835.0 ±
168.5 
1335.0 ± 46.1 
In vitro AUC0–6h 
permeation, − lipolysis 
(nmol⋅h) 
23.0 ± 1.4 13.0 ± 0.8 20.0 ± 2.2 
In vitro AUC0–6h 
permeation, + lipolysis 
(nmol⋅h) 
25.0 ± 2.0 19.0 ± 1.8 17.0 ± 2.3  
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4. Conclusion 
The obtained results demonstrate that the present study succeeded in 
the development of a combined in vitro lipolysis-permeation model able 
to predict in vivo drug absorption from the investigated SNEDDSs. The 
typical in vitro intestinal lipolysis model was substituted with the HTP in 
vitro lipolysis model to allow the use of a pH-stat-titration-independent 
system and permit the simultaneous investigation of in vitro lipolysis and 
permeation. While no correlation was found when comparing the 
amount of drug solubilized in the aqueous phase upon in vitro disper-
sion/lipolysis with the in vivo literature data (Michaelsen et al., 2019) 
(R2 < 0.58), the addition of an in vitro permeation step using the mucus- 
PVPA barriers led to excellent IVIVCs (R2 > 0.98). Also, the difference in 
fenofibrate in vivo absorption between the presence and absence of 
lipolysis could be accurately predicted by the combined in vitro model. 
Herewith, the evidence gathered in this study suggests that the evalua-
tion of in vitro drug distribution alone cannot predict drug plasma con-
centration in vivo, while the combination with in vitro drug permeation 
assessed with the use of the mucus-PVPA model is able to do so to a 
higher extent. The combined in vitro model presented in this study could 
thus be a highly valuable tool in the development and optimization of 
novel lipid-based formulations. 
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(+) lipolysis. 
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